

An Independent Licensee of the Blue Cross and Blue Shield Association.

Investigational Services and Procedures Corporate Medical Policy

File Name: Investigational Services and Procedures File Code: 10.01.VT204 Origination: 09/2016 Last Review: 06/01/2025 Next Review: 10/01/2025 Effective Date: 07/01/2025 & 08/01/2025

Description

Attachment (I) outlines current services and/or procedure(s) considered to be investigational by Blue Cross Blue Shield of Vermont (Blue Cross VT).

Definition of Investigational

"Experimental or Investigational Services" means health care items or services that are either not generally accepted by informed health care providers in the United States as effective in treating a condition, illness, or diagnosis for which their use is proposed, or are not proven by medical or scientific evidence to be effective in treating a condition, illness, or diagnosis.

Technologies are assessed using the following criteria. Any technology that fails to meet ALL the following criteria is considered to be "Investigational":

- 1. The technology must have final approval from the appropriate governmental regulatory bodies.
 - This criterion applies to drugs, biological products, devices and any other product or procedure that must have final approval to market from the U.S. Food and Drug Administration (FDA) or any other federal governmental body with authority to regulate the use of the technology.
 - Any approval that is granted as an interim step in the U.S. Food and Drug Administration's or any other federal governmental body's regulatory process is not sufficient.
 - The indications for which the technology is approved need not be the same as those which the (Blue Cross VT) Medical Policy Committee is evaluating.

- 2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes.
 - The evidence should consist of well-designed and well-conducted investigations published in peer- reviewed journals. The quality of the body of studies and the consistency of the results are considered in evaluating the evidence.
 - The evidence should demonstrate that the technology can measure or alter the physiological changes related to a disease, injury, illness, or condition. In addition, there should be evidence, or a convincing argument based on established medical facts that such measurement or alteration affects health outcomes.
- 3. The technology must improve the net health outcome.
 - The technology's beneficial effects on health outcomes should outweigh any harmful effects on health outcomes.
- 4. The technology must be as beneficial as any established alternatives.
 - The technology should improve the net health outcome as much as, or more than, established alternatives.
- 5. The improvement must be attainable outside the investigational settings.
 - When used under the usual conditions of medical practice, the technology should be reasonably expected to satisfy Criteria #3 and #4.

In reviewing the above criteria, the Blue Cross VT Medical Policy Committee will consider physician specialty society recommendations, the view of prudent medical practitioners practicing in relevant clinical areas and any other relevant factors.

Policy

The following is a list of current services and/or procedure(s) which are considered investigational.

Coding Information

Attachment I

Policy Implementation/Update information

	Policy new Format
10/2020	Coding Updates effective 10/01/2020 Medical Policy: Added codes: 0097U,
	0107U, 82239, 82272, 82274, 82542, 82656, 82710, 82715, 82725, 83520,
	83630, 83986, 83993, 84311, 87045, 87046, 87075, 87102, 87177, 87209,
	87328, 87329, 87336, 89160, 89161, 89240 ARE CONSIDERED
	INVESTIGATIONAL WITH THE FOLLOWING DIAGNOSES CODES: A04.8, A04.9,

	K58.0, K58.1, K58.2, K58.8, K58.9, K59.8, K63.9, K90.89.
	Coding Updates effective 10/01/2020 via Adaptive Maintenance Cycle:
	Added codes: 0016M, 0203U, 0204U, 0205U, 0206U, 0207U, 0208U,
	0209U, 0211U, 0216U, 0217U, 0218U, 0219U, 0220U, 0225U, K1006,
	K1007, K1010, K1011, K1012, Q4249, Q4250, Q4254, Q4255.
01/2021	Coding Updates effective 01/01/2021 Adaptive Maintenance Cycle:
01/2021	Changed effective date to 01/01/2021
	Removed Codes 38230, 83993, 90694
	Updated Codes 82172 & 84181 to Investigational for All diagnoses
	Updated Codes 64910, 64911, 64912, 64913 as Investigational with dx
	codes C61, N52.0-N52.9
	Added codes 0227U, 0228U, 0229U, 0620T, 0621T, 0622T, 0623T, 0624T,
	0625T, 0626T, 0627T, 0628T, 0629T, 0630T, 0631T, 0632T, 0633T, 0634T,
	0635T, 0636T, 0637T, 0638T, 0639T, 22869, 22870 30468, 55880, 57465,
	81514, 92229, C1825, C9771, C9772, C9773, C9774, C9775
	Deletéd codes 0400T, 0401T
	Removed codes 38206, 38230, 38241 codes require PA
04/2021	Coding Updates effective 04/01/2021 Adaptive Maintenance Cycle:
	Added codes: C9776, C9777, J3490, K1016, K1017, K1018, K1019,
	K1020, S1091, 0242Ú, 0243Ú, 0244Ú, 0247Ú. Removed codes: K1010,
	K1020, S1091, 0242Ú, 0243Ú, 0244Ú, 0247Ú. Remóved codes: K1010, K1011, K1012, 64451, 78803, 78830, 78831, 78832, 78835
05/2021	Coding Update effective 05/01/2021: Added codes 81518, 0045U,
	01530.
07/2021	Coding Updates effective 07/01/2021: 0248U, 0249U, 0250U, 0251U,
	0252U, 0253U, 0640T, 0641T, 0642T, 0643T, 0645T, 0646T, 0647T,
	0648T, 0649T, 0652T, 0653T, 0654T, 0655T, 0656T, 0657T, 0658T,
	0659T, 0660T, 0661T, 0664T, 0665T, 0666T, 0667T, 0668T, 0669T,
	0670T, A9593, A9594, G0327, 58674, 90626, 90627, 90671, 90677,
	90758, C1761
08/2021	Coding Updates effective 08/01/2021: Added codes E1700, E1701,
00 (2024	E1702
09/2021	Coding update effective 09/01/2021: Removed code 53854
10/2021	Coding update effective 10/01/2021: Added Codes 0255U, 0258U,
	0259U 0260U, 0261U, 0262U, 0263U, 0264U, 0266U, 0267U, 0279U,
	0280U, 0281Ú, 0282Ú, 0283Ú, 0284Ú, 0018M, Deleted code 0139U.
	Revised 0051U descriptor. Added HCPCS Codes: C1831, C9780,
11/2021	K1023, K1024, K1025, K1026, Q4251, Q4252, Q4253 Coding update effective 11/01/2021 (To Align Corporate
11/2021	Bioengineered Skin Medical Policy Table): Added codes C9354,
	C9356, C9358, C9360, C9363, C9364, Q4103, Q4104, Q4110, Q4111,
	Q4112, Q4113, Q4115, Q4117, Q4118, Q4121, Q4123, Q4124, Q4125,
	Q4126, Q4127, Q4130, Q4134, Q4135, Q4136, Q4141, Q4142, Q4143,
	Q4146, Q4147, Q4149, Q4152, Q4158, Q4161, Q4164, Q4165, Q4166,
	Q4167, Q4179, Q4182, Q4193, Q4196, Q4200, Q4202, Q4203, Q4222.
	Removed codes: Q4185, Q4189, Q4192, Q4249, Q4250, Q4254,
	Q4255.
12/2021	Coding update effective 12/01/2021: Added code G9143
12/2021	Coding Update Effective 01/01/2022 (Adaptive Maintenance Cycle):
	Deleted the following codes: 0548T, 0549T, 0550T, 0551T, C9752,
	C9753, 95943, 0208U
	Codes Added: 33370, 42975, 43497, 53451, 53452, 53453, 53454,
	61736, 61737, 64628, 64629, 81560, 90759. Added codes PLA: 0285U,
	02880, 02890, 02900, 02910, 02920, 02930, 02940, 02950, 02960,
	0297U, 0298U, 0299U, 0300U, 0303U, 0304U, 0305U. Added codes
	· · · · · · · · · · · · · · · · · · ·

	CAT III: 0672T, 0673T, 0674T, 0675T, 0676T, 0677T, 0678T, 0679T,
	0680T, 0681T, 0682T, 0683T, 0684T, 0685T, 0686T, 0687T, 0688T,
	0689T, 0690T, 0691T, 0693T, 0694T, 0695T, 0696T, 0697T, 0698T,
	0700T, 0701T, 0702T, 0703T, 0704T, 0705T, 0706T, 0707T, 0708T,
	0709T, 0710T, 0711T, 0712T, 0713T. Added the following HCPCS
	Codes: A2001, A2002, A2004, A2005, A2006, A2007, A2008, A2009,
	A2010, C1832, C1833, G0465, Q4199. Removed codes: 0030U, 0032U,
	0033U, 0173U, 0175U, 90677.
04/2022	
04/2022	Coding Update Effective 04/01/2022 (Adaptive Maintenance Cycle):
	A2003 deleted code never became effective 01/01/2021. (0)0970
	deleted. Added codes: 0306U, 0307U, 0308U, 0309U, 0310U, 0311U,
	0312U, 0313U, 0314U, 0315U, 0316U, 0317U, 0318U, 0319U, 0320U,
	0321U, 0322U. A2013, A9291, C9781, K1028, K1029, K1030, K1031,
	K1032, K1033. Removed code J3490 per Ketamine Medical Policy
	effective 04/01/2022.
05/2022	Coding Update Effective 05/01/2022 (Investigational Medical Policy
	Reconciliation): Codes removed: A4641, A4642, A9500, A9502,
	A9520, A9541, A9568, A9572, A9582 may be eligible for benefit
	approved by AIM or BCBSVT. Codes removed: J9035, 15788, 15789,
	15792, 15793, 17000, 17003, 17004, 30520, 17106, 17107, 17108,
	82656, 83630, 90677 effective: 01/01/2022), 97032 may be eligible
	for services based on current standards of care. Codes removed:
	G0259, L8603*, L8605*, L8606*, L8684, S8080, 0026U, 0097U, 0107U,
	0278T, 15824, 15826, 30130, 30140, 31626, 34701, 34702, 34703,
	34704, 34705, 34706, 34707, 34708, 36012, 37241, 38242, 43201,
	43210, 43212, 43257, 51715, 64590, 64595, 64632, 64640, 64716,
	64722, 64771, 64772, 64910, 64911, 64912, 64913, 76940, 78195,
	78800, 78801, 78802, 78804, 82239, 82272, 82274, 82397, 82542,
	82652, 82710, 82715, 82725, 83520, 83698, 83986, 84311, 86141,
	86304, 87045, 87046, 87075, 87102, 87177, 87209, 87328, 87329,
	87336, 89160, 89240, 92229, 93895, 95812, 95813, 95816, 95819,
	95921, 95922, 95923, 95924, 96904 codes require prior approval.
	Removed codes: E0748, E0749, J3490, L8680, L8681, L8682, L8683,
	L8685, L8686, L8687, L8688, L8689, Q4168, Q4185, Q4189, Q4192,
	S3852, 0029U, 0156U, 0173U, 0175U, 0278U, 0394T, 15780, 15781,
	15782, 15783, 20974, 20975, 61885, 61886, 64553, 64568, 64569,
	64570, 67900, 75571, 81226, 81291, 81313, 81400, 81401, 81403,
	81406, 81407, 81415, 81416, 81417, 81439, 81490, 81493, 81500,
	81406, 81407, 81415, 81416, 81417, 81439, 81490, 81495, 81500, 81500, 81503, 81504, 81535, 81536, 81538, 81540, 81595, 95980, 95981,
	95982 codes always required prior approval. Changed the following
	codes to be investigational for all diagnoses: A9584, E0740, E0761,
	E0769, G0166, G0295, G0329, G9147, S3722, 0003U, 0101T, 0102T,
	0207T,0278T, 0330T, 0332T, 0338T, 0339T, 0397T, 0421T, 0424T,
	0425T, 0426T, 0441T, 0563T, 28890, 33548, 43206, 43252, 43284,
	43285, 43647, 43648, 43881, 43882, 46707, 47371, 47381, 47383,
	62263, 62264, 64505, 77085, 77086, 82523, 83006, 83695, 84080,
	85384, 86352, 88375, 95957, 97610, 98922. Added new codes: C1825,
	C9359, C9362, E0746, G9143, S8130, S8131, 0651T, 64575
	investigational for all diagnoses. Removed codes: G0281, G0282,
	V5095, 90876, 97014 codes are considered non-covered. Removed
	code S2080 code considered not medically necessary. Removed codes
	31627 & 57465 not medically necessary per payment policy CPP_04.
	Added codes to as investigation but have been investigational per
	applicable medical policy: E0762, E0764, M0076, P9020, S8040,
	0232T, 0355T, 41512, 64585, 83937, 91111, 92548, 92145, 92572,
	92576, 93701, 95803, 96000, 96001, 96002, 96003, 96004, 97799.
	/23/0, 73/01, 73003, 70000, 70001, 70002, 70003, 7000 4 , 7/779.

	Codes deleted: A9599, C9750, 0355T, 0399T, 0406T, 0407T, 30660,
	30661, 61632, 98922.
06/2022	Removed codes 0116U & 0117U Effective: 06/01/2022
	Added code P2031 Effective: 06/01/2022, Added COVID-19
	Monoclonal Antibodies & Administration codes: M0240, M0241, M0243, M0244, M0245, M0246, Q0240, Q0243, Q0244, Q0245
	Effective:01/24/2022. Added COVID-19 Monoclonal Antibodies &
	Administration codes: M0247, M0248, Q0247 Effective: 04/05/2022.
06/2022	Coding Update Effective 07/01/2022 (Adaptive Maintenance Cycle):
	Revised code descriptor 0229U. Removed code 83880 off- cycle map
	as medically necessary. Removed codes 0648T & 0649T from NIV to requiring PA add to PA CAT Code 'MQM' per medical policy changes
	to be reviewed by AIM 07/01/2022. Removed code 42975, 87426 &
	C9776 - medically necessary. Removed codes 90626 & 90627 FDA
	approved covered travel. Removed code 90759 FDA approved -
	preventive grid. Added codes: 90584, 0714T, 0715T, 0716T, 0717T,
	0718T, 0719T,0720T, 0721T, 0722T, 0723T, 0724T, 0725T, 0726T, 0726T, 0727T, 0728T, 0729T, 0730T, 0731T, 0732T, 0733T, 0734T, 0735T,
	0736T, 0737T, 0323U, 0324U, 0325U, 0328U, 0329U, 0330U, 0331U
	A9601, Q4259, Q4260, Q4261. Re-sequenced code 0330T.
09/2022	Coding Update Effective 10/01/2022 (Adaptive Maintenance Cycle):
	Added Codes Q1005, S0596, V2787, V2788, added to the
	Investigational policy the codes are considered investigational per the Vision Corporate Medical Policy. Removed codes 95976, 95977 &
	58674 the codes will require prior approval. Removed codes 4181 as
	investigational. Added the following PLA codes: 0332U, 0333U,
	0334U, 0335U, 0336U, 0337U, 0338U, 0339U, 0340U, 0341U, 0342U,
	0343U, 0344U, 0345U, 0346U, 0347U, 0348U, 0349U, 0350U, 0351U,
	0352U as investigational. Added codes: A2014, A2015, A2016, A2017, A2018, A4596, C1834.
11/2022	Effective 11/01/2022: Removed codes: 0037U & 0129U from
	investigational to requiring prior approval. Removed codes 85384 &
	85385 from investigational to medically necessary. Removed codes
	0224U & 0225U from investigational to eligible at zero-cost share COVID-19.
12/2022	Effective 01/01/2023 (Adaptive Cycle Maintenance): Deleted Codes:
	0312T, 0313T, 0314T, 0315T, 0316T, 0317T, 0514T, 0702T, 0703T.
	C1841, G2170, G2171.Revised Codes: 0733T, 0734T.Added codes as
	Investigational: 22860, 30469, 36836, 36837, 43290, 43291,77089,
	77090, 77091, 77092, 81418, 81449, 81451, 81456, 90678, 98978, 0738T, 0739T, 0740T, 0741T, 0742T, 0743T, 0744T, 0745T, 0746T,
	0747T, 0748T, 0749T, 0750T, 0751T, 0752T, 0753T, 0754T, 0755T,
	0756T, 0757T, 0758T, 0759T, 0760T, 0761T, 0762T, 0763T, 0764T,
	0765T, 0766T, 0767T, 0768T, 0769T, 0770T, 0771T, 0772T, 0773T,
	0774T, 0775T, 0776T, 0777T, 0778T, 0779T, 0780T, 0781T, 0782T, 0783T, 0783T, 0355U, 0356U, 0357U, 0358U, 0359U, 0360U, 0361U, 0362U,
	0363U,C1747, C1826, C1827, C7501, C7502, Q4262, Q4263, Q4264.
	Removed code as Investigational: 0421T.
01/2023	Policy reviewed removed codes 0202U & 0223U from investigational
	to eligible at zero cost share COVID-19 effective 11/01/2022.
02/2023	Policy reviewed removed code 81518 from investigational to
	requiring prior approval effective 03/01/2023.
03/2023	Effective 04/01/2023 (Adaptive Maintenance Cycle): C1834, 0324U,
	0325U codes deleted. Code 0095U descriptor revised. Removed codes 0449T, 0450T, 90758 from investigational to medically necessary.

	Added codes: 0364U, 0365U, 0366U, 0367U, 0369U, 0370U, 0371U,
	0372U, 0374U, 0375U, 0376U, 0377U, 0378U, 0379U, 0380U, 0384U,
	0385U, 0386U, A2019, A2020, A2021, A4341, A4342, A4560, A6590,
	A6591, A7049, E0677, E0711, E1905, L8678, Q4265, Q4266, Q4267,
00 (0 00 0	Q4268, Q4269, Q4270, Q4271 as investigational to the coding table
03/2023	Effective 06/01/2023 Medical Policy Review- Added codes: E1806,
	<u>E1811, E1816, E1818, E1821, E1831, E1841</u>
06/2023	Effective 07/01/2023 (Adaptive Maintenance Cycle): Removed codes:
	83721, 90671. Deleted Code: 0053U.
	Added Codes: 0387U, 0389U, 0390U, 0391U, 0392U, 0393U, 0394U,
	0395U, 0398U, 0399Ú, 0400Ú, 0401Ú, 0791Ť, 0792Ť, 0793Ť, 0794Ť,
	0795T, 0796T, 0797T, 0798T, 0799T, 0800T, 0801T, 0802T, 0803T,
	0804T, 0805T, 0806T, 0807T, 0808T, 0809T, C9150, C9784, C9785,
	C9786, C9787, Q4272, Q4273, Q4274, Q4275, Q4276, Q4277, Q4278,
	Q4280, Q4281, Q4282, Q4283, Q4284.
	Added Codes (COVID-19): Refer to dates in table: 91300, 91301,
	91303, 91305, 91306, 91307, 91308, 91309, 91311, 0001A, 0002A,
	0003A, 0004A, 0011A, 0012A, 0013A, 0031A, 0034A, 0051A, 0052A,
	0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A,
	0083A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, M022O, M0221,
	M0222, M0223, M0240, M0241, M0243, M0244, M0245, M0246, M0247,
	M0248, Q0220, Q0221, Q0222, Q0240, Q0243, Q0244, Q0245, Q0247.
09/2023	Effective 10/01/2023 (Adaptive Maintenance Cycle): Revised: 0362U,
	0389U, 0401U, K1004, K1028. Deleted: 0357U, 0386U.Removed:
	90678 code medically necessary. Added: 0019M, 0071T, 0072T,
	0403U, 0404U, 0405U, 0406U, 0407U, 0408U, 0410U, 0411U, 0412U,
	0413U, 0414U, 0415U, 0416U, 0417U, 0418U, 0419U, A2022, A2023,
	A2024, A2025, A9268, A9269, A9292, A9573, A9603, A9697, C9788,
	C9790, C9791, C9792, E0490, E0491, K1036, Q4285, Q4286.
10/2023	Effective 12/01/2023: Codes 36473 & 36474 added as Investigational.
	5
	Adaptive Maintenance Effective 01/01/2024: Removed code 0404T from
	investigational to requiring prior approval.
	Added codes: 22836,, 22837, 22838, 31242, 31243, 33276, 33277, 33278,
	33279, 33280, 33281, 33287, 33288, 52284, 90589, 90683, 92972, 93150,
	93151, 93152, 93153, A6566, A6567,A7023, A9609,C1600, E0492, E0493,
	E0530, E0732, E0733, E0734, E2001, Q4279, Q4287, Q4288, Q4289, Q4290,
	Q4291, Q4292, Q4293, Q4294, Q4295, Q4296, Q4297, Q4298, Q4299, Q4300,
	Q4301, Q4302, Q4303, Q4304, 0420U, 0421U, 0422U, 0423U, 0424U, 0427U,
	0429U, 0430U, 0431U, 0432U, 0433U, 0434U, 0435U, 0436U, 0437U,
	0438U,0790T, 0811T, 0812T, 0813T, 0814T, 0815T, 0820T, 0821T, 0827T,
	0828T, 0829T, 0830T, 0831T, 0832T, 0833T, 0834T, 0835T, 0836T, 0837T,
	0838T, 0839T, 0840T, 0841T, 0842T, 0843T, 0844T, 0845T, 0846T, 0847T,
	0848T, 0849T, 0850T, 0851T, 0858T.
	0852T, 0853T, 0854T, 0855T, 0856T, 0857T, 0859T, 0860T, 0861T, 0862T,
	0863T, 0864T, 0865T, 0866T
	Revised Codes: 81451, 81456, 0517T, 0518T, 0519T, 0520T, 0587T, 0588T,
	0589T, 0590T, 0640T, 0656T, 0657T, 0766T, 0767T. 0095U, 0351U, 0356U,

· · · · · · · · · · · · · · · · · · ·	
	Deleted Codes: 0404T, 0424T, 0425T, 0426T, 0427T, 0428T, 0429T, 0430T, 0431T, 0432T, 0433T, 0434T, 0435T, 0436T, 0508T, 0533T, 0534T, 0533T, 0535T, 0536T, 0715T, 0768T, 0769T, 0775T, 0809T, 0014M, K1001, K1002,
	C9771, C9788, K1006, K1016, K1017, K1018, K1019, K1020, K1023, K1024, K1025, K1026, K1028, K1029, K1031, K1032, K1033,
04/2024	Removed code C2596 from investigational to medically necessary. Adaptive Maintenance Effective 04/01/2024: Added Codes: 27278, 0439U, 0440U, 0441U, 0442U, 0443U, 0444U, 0445U, 0446U, 0447U, 0449U, A2026, A4438, A4593, A4594, E0468, E0736, E0738, E0739, K1037, Q4305, Q4306, Q4307, Q4308, Q4309, Q4310, S4988, S9002 as investigational to coding table.
	Added Codes: C9796 & C9797 retroactive to 01/01/2024 Adaptive Maintenance Cycle as investigational to coding table.
	Removed Code: 0242U from investigational from coding table now requires PA.
	Deleted Code: 0416U from coding table.
	Revised Code: E2001 in coding table.
07/2024	Adaptive Maintenance Effective 07/01/2024: Added Codes: 0020M, 0867T, 0868T, 0870T, 0871T, 0872T, 0873T, 0874T, 0875T, 0876T, 0877T, 0878T, 0879T, 0880T, 0881T, 0882T, 0883T, 0884T, 0885T, 0886T, 0887T, 0888T, 0889T, 0890T, 0891T, 0892T, 0893T, 0894T, 0895T, 0896T, 0897T, 0898T, 0899T, 0900T,0450U, 0451U, 0452U, 0453U, 0456U, 0457U, 0458U, 0460U, 0461U, 0462U, 0463U, 0464U, 0465U, 0466U, 0467U, 0468U, 0469U, 0470U, 0472U, 0474U, 0475U, 90637, 90638, Q4311, Q4312, Q4313, Q4314, Q4315, Q4316, Q4317, Q4318, Q4319, Q4320, Q4321, Q4322, Q4323, Q4324, Q4325, Q4326, Q4327, Q4328, Q4329, Q4330, Q4331, Q4332, Q4333 as investigational to coding table.
	Removed Codes: 0279U, 0280U, 0281U, 0282U, 0283U, 0284U, C9359, 90589, 90683 from coding table.
	Deleted Codes: 0204U, C9787, C9790, Q4277 from coding table.
	Revised Codes: 0741T in coding table.
	Removed CPT® code 33274 from investigational coding table, code will require prior approval. Effective 10/01/2024.
	Adaptive Maintenance Effective 10/01/2024-Remove codes: 90637, 90638, 86352 (effective 07/01/2024) from investigational codes considered medically necessary. Removed codes: A9586, A9593, A9594, A9601, Q9982,

	Q9983, 0031U codes require prior approval and were not removed from investigational coding table.		
10/2024	Removed codes: 0364U, 0720T from investigational codes require prior approval. Added codes: 90624, 0476U, 0477U, 0479U, 0482U, 0483U, 0484U, 0485U, 0486U, 0487U, 0488U, 0489U, 0490U, 0491U, 0492U, 0493U, 0494U, 0495U, 0496U, 0497U, 0498U, 0499U, 0500U, 0501U, 0502U, 0503U, 0504U, 0505U, 0506U, 0507U, 0508U, 0509U, 0510U, 0511U, 0512U, 0513U, 0514U, 0515U, 0516U, 0517U, 0518U, 0519U, 0520U, A4540, A2027, A2028, A2029, A4543, A4544, A4545, A7021, A9610, C8000, E0469, E0683, E0715, E0716, E0721, E0737, E0743, E0767, E3200, L8720, L8721, P9027, Q4334, Q4335, Q4336, Q4337, Q4338, Q4339, Q4340, Q4341, Q4342, Q4343, Q4344, Q4345 as investigational to coding table. Deleted code: C9150 from coding table. Revised Code Descriptors: 0248U, 0403U, A2024, E0739.		
	11/01/2024.		
11/2024	Coding table reviewed removed codes 0889T, 0890T, 0891T, 0892T as investigational effective 01/01/2025.		
12/2024	Removed code 0047U as investigational effective 12/01/2024.		
12/2024	Adaptive Maintenance Effective 01/01/2025 -Codes Deleted from coding table: 96003, 0553T, 0380U, 0346U, 0456U, C9786. Codes Revised in coding table: 0615T, 0365U, 0095U.Codes Added as investigational to coding table: C1735, C1736, C1737, C1738, C8001, C8002, C8003, G0555, Q4346, Q4347, Q4348, Q4349, Q4350, Q4351, Q4352, Q4353, S4988, 0524U, 0525U, 0526U, 0901T, 0902T, 0903T, 0904T, 0905T, 0906T, 0907T, 0908T, 0909T, 0910T, 0911T, 0912T, 0913T, 0914T, 0915T, 0916T, 0917T, 0918T, 0919T, 0920T, 0921T, 0922T, 0923T, 0924T, 0925T, 0926T, 0927T, 0928T, 0929T, 0930T, 0931T, 0932T, 0933T, 0934T, 0935T, 0936T, 0937T, 0938T, 0939T, 0940T, 0941T, 0942T, 0943T, 0944T, 0945T, 0946T, 0947T,15011, 15012, 15013, 15014, 15015, 15016, 15017, 15018, 51721, 53865, 53866, 55881, 55882, 60660, 60661, 61715, 66683, 81195, 81515, 81558, 82233, 82234, 83884, 84393, 84394. Codes removed: 64585, 0334U.		

03/2025	Adaptive Maintenance Effective 04/01/2025: Codes Deleted COVID-19 Codes from coding table: M0220, M0221, M0222, M0223, M0240, M0241, M0243, M0244, M0247, Q0220, Q0221, Q0222, Q0240, Q0243, Q0244, Q0245, Q0247 effective 12/12/2024.
	Codes Deleted COVID-19 Codes from coding table: M0245, M0246 effective 12/13/2024.
	Codes Revised in codes: 0228U, 0308U, 0309U, 0310U, E1801, E1811, E1816, E1818, E1841.
	Codes Added as investigational to coding table: 0537U, 0538U, 0539U, 0541U, 0542U, 0544U, 0546U, 0547U, 0548U, 0549U, 0550U, 0551U, A2030, A2031, A2032, A2033, A2034, A2035, A9611, C8004, C8005, C9300, E0201, G0183, G0566, Q4354, Q4355, Q4356, Q4357, Q4358, Q4359, Q4360, Q4361, Q4362, Q4363, Q4364, Q4365, Q4366, Q4367, S4024.
03/2025	Effective 06/01/2025 Added codes A4541, A4542 to table as investigational.
04/2025	Effective 07/01/2025: Removed codes 0889T, 0890T, 0891T, 0892T as requiring prior approval to investigational. Removed code 81514 from investigational to medically necessary.
05/2025	Effective 08/01/2025 Code 0464U removed from the investigational coding table.
06/2025	

Eligible Providers

Qualified healthcare professionals practicing within the scope of their license(s).

Approved by Blue Cross VT Medical Directors

Tom Weigel, MD, MBA Vice President and Chief Medical Officer

Tammaji P. Kulkarni, MD Senior Medical Director

<u>Attachment I</u>

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
A2001	InnovaMatrix AC, per sq cm	Investigational
A2002	Mirragen Advanced Wound Matrix, per sq cm	Investigational
A2004	XCelliStem, per sq cm	Investigational
A2005	Microlyte Matrix, per sq cm	Investigational
A2006	NovoSorb SynPath dermal matrix, per sq cm	Investigational
A2007	Restrata, per sq cm	Investigational
A2008	TheraGenesis, per sq cm	Investigational
A2009	Symphony, per sq cm	Investigational
A2010	Apis, per sq cm	Investigational
A2013	Innovamatrix FS, per sq cm	Investigational
A2014	Omeza collagen matrix, per 100 mg	Investigational
A2015	Phoenix wound matrix, per square centimeter	Investigational
A2016	Permeaderm b, per square centimeter	Investigational
A2017	Permeaderm glove, each	Investigational
A2018	Permeaderm c, per square centimeter	Investigational
A2019	Kerecis omega3 marigen shield, per square centimeter	Investigational
A2020	Ac5 advanced wound system (ac5)	Investigational
A2021	Neomatrix, per square centimeter	Investigational
A2022	Innovaburn or innovamatrix xl, per square centimeter	Investigational
A2023	Innovamatrix pd, 1 mg	Investigational
A2024	Resolve matrix or xenopatch, per square centimeter	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
A2025	Miro3d, per cubic centimeter	Investigational
A2026	Restrata minimatrix, 5 mg	Investigational
A2027	Matriderm, per square centimeter	Investigational
A2028	Micromatrix flex, per mg	Investigational
A2029	Mirotract wound matrix sheet, per cubic centimeter	Investigational
A2030	Miro3d fibers, per milligram	Investigational
A2031	Miro3d fibers, per milligram	Investigational
A2032	Myriad matrix, per square centimeter	Investigational
A2033	Myriad morcells, 4 milligrams	Investigational
A2034	Foundation drs solo, per square centimeter	Investigational
A2035	Corplex p or theracor p or allacor p, per milligram	Investigational
A4341	Indwelling intraurethral drainage device with valve, patient inserted, replacement only, each	Investigational
A4342	Accessories for patient inserted indwelling intraurethral drainage device with valve, replacement only, each	Investigational
A4438	Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each	Investigational
A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm	Investigational
A4541	Monthly supplies for use of device coded at E0733	Investigational
A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist	Investigational
A4543	Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month	Investigational
A4544	Electrode for external lower extremity nerve stimulator for restless legs syndrome	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
A4545	Supplies and accessories for external tibial nerve stimulator (e.g., socks, gel pads, electrodes, etc.), needed for one month	Investigational
A4560	Neuromuscular electrical stimulator (nmes), disposable, replacement only	Investigational
A4563	Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each	Investigational
A4575	Topical hyperbaric oxygen chamber, disposable	Investigational
A4593	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime	Investigational
A4594	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each	Investigational
A4596	Cranial electrotherapy stimulation (ces) system supplies and accessories, per month	Investigational
A6566	Gradient compression garment, neck/head, each	Investigational
A6567	Gradient compression garment, neck/head, custom, each	Investigational
A6590	External urinary catheters; disposable, with wicking material, for use with suction pump, per month	Investigational
A6591	External urinary catheter; non- disposable, for use with suction pump, per month	Investigational
A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)	Investigational
A7023	Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical	Investigational
A7049	Expiratory positive airway pressure intranasal resistance valve	Investigational
A9268	Programmer for transient, orally ingested capsule	Investigational

A9269Programable, transient, orally ingested capsule, for use with external programmer, per monthInvestigationalA9291Prescription digital behavioral therapy, FDA-cleared, per course of treatmentInvestigationalA9292Prescription digital visual therapy, software-only, fda cleared, per course of treatmentInvestigational	
external programmer, per monthA9291Prescription digital behavioral therapy, FDA-cleared, per course of treatmentInvestigationalA9292Prescription digital visual therapy, software-only, fda cleared, perInvestigational	
A9291Prescription digital behavioral therapy, FDA-cleared, per course of treatmentInvestigationalA9292Prescription digital visual therapy, software-only, fda cleared, perInvestigational	
therapy, FDA-cleared, per course of treatmentofA9292Prescription digital visual therapy, software-only, fda cleared, perInvestigational	
of treatmentA9292Prescription digital visual therapy, software-only, fda cleared, perInvestigational	
A9292 Prescription digital visual therapy, Investigational software-only, fda cleared, per	
software-only, fda cleared, per	
A9507 Indium In-111 capromab Investigational	
pendetide, diagnostic, per study	
dose, up to 10 millicuries	
A9573 Injection, gadopiclenol, 1 ml Investigational	
A9584 Iodine I-123 ioflupane, diagnostic, Investigational	
per study dose, up to 5 mCi	
A9603 Injection, pafolacianine, 0.1 mg Investigational	
A9609 Gradient compression bandaging Investigational	
supply, not otherwise specified	
A9610 Xenon xe-129 hyperpolarized gas, Investigational	
diagnostic, per study dose	
A9611 Gradient compression wrap with Investigational	
adjustable straps, above knee, each, custom	
A9697 Injection, carboxydextran-coated Investigational	
superparamagnetic iron oxide, per	
study dose	
C1600 Catheter, transluminal Investigational	
intravascular lesion preparation	
device, bladed, sheathed	
(insertable)	
C1734 Orthopedic/device/drug matrix Investigational	
for opposing bone-to-bone or soft	
tissue-to bone (implantable)	
C1735 Catheter(s), intravascular for Investigational renal denervation,	
radiofrequency, including all	
single use system components	
C1736 Catheter(s), intravascular for Investigational	
renal denervation, ultrasound,	
including all single use system	
components	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
C1737	Joint fusion and fixation device(s), sacroiliac and pelvis, including all system components (implantable)	Investigational
C1738	Powered, single-use (i.e. disposable) endoscopic ultrasound-guided biopsy device	Investigational
C1747	Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable)	Investigational
C1761	Catheter, transluminal intravascular lithotripsy, coronary	Investigational
C1821	Interspinous process distraction device (implantable)	Investigational
C1823	Generator, neurostimulator (implantable), nonrechargeable, with transvenous sensing and stimulation leads	Investigational
C1825	Generator, neurostimulator (implantable), nonrechargeable with carotid sinus baroreceptor stimulation lead(s)	Investigational
C1826	Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system	Investigational
C1827	Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller	Investigational
C1831	Personalized, anterior and lateral interbody cage (implantable)	Investigational
C1832	Autograft suspension, including cell processing and application, and all system components	Investigational
C1833	Monitor, cardiac, including intracardiac lead and all system components (implantable)	Investigational
C2614	Probe, percutaneous lumbar discectomy	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
C7501	Percutaneous breast biopsies using stereotactic guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral and bilateral (for single lesion biopsy, use appropriate code)	Investigational
C7502	Percutaneous breast biopsies using magnetic resonance guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral or bilateral (for single lesion biopsy, use appropriate code)	Investigational
C8000	Support device, extravascular, for arteriovenous fistula (implantable)	Investigational
C8001	3d anatomical segmentation imaging for preoperative planning, data preparation and transmission, obtained from previous diagnostic computed tomographic or magnetic resonance examination of the same anatomy	Investigational
C8002	Preparation of skin cell suspension autograft, automated, including all enzymatic processing and device components (do not report with manual suspension preparation)	Investigational
C8003	Implantation of medial knee extraarticular implantable shock absorber spanning the knee joint from distal femur to proximal tibia, open, includes measurements, positioning and adjustments, with imaging guidance (eg, fluoroscopy)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
C8004	Simulation angiogram with use of a	Investigational
	pressure-generating catheter (e.g.,	
	one-way valve, intermittently	
	occluding), inclusive of all	
	radiological supervision and	
	interpretation, intraprocedural	
	roadmapping, and imaging guidance	
	necessary to complete the	
	angiogram, for subsequent	
	therapeutic radioembolization of tumors	
C8005	Bronchoscopy, rigid or flexible, non-	Investigational
60003	thermal transbronchial ablation of	Investigationat
	lesion(s) by pulsed electric field (pef)	
	energy, including fluoroscopic and/or	
	ultrasound guidance, when	
	performed, with computed	
	tomography acquisition(s) and 3d	
	rendering, computer-assisted, image-	
	guided navigation, and endobronchial	
	ultrasound (ebus) guided	
	transtracheal and/or transbronchial	
	sampling (e.g.,	
	aspiration[s]/biopsy[ies]) of all	
	mediastinal and/or hilar lymph node	
	stations or structures, and	
	therapeutic intervention(s)	
C8937	Computer-aided detection, including	Investigational
	-	
	• •	
<u> </u>		Investigational
C9300		Investigational
C0354		Investigational
C7554		Investigationat
(9356		Investigational
C8937 C9300 C9354 C9356	sampling (e.g., aspiration[s]/biopsy[ies]) of all mediastinal and/or hilar lymph node stations or structures, and therapeutic intervention(s)	Investigational Investigational Investigational Investigational Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
C9358	Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	Investigational
C9360	Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	Investigational
C9362	Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Strip), per 0.5 cc	Investigational
C9363	Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm	Investigational
C9364	Porcine implant, Permacol, per sq cm	Investigational
C9751	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)	Investigational
C9758	Blind procedure for NYHA Class III/IV heart failure; transcatheter implantation of interatrial shunt including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
C9759	Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed	Investigational
C9760	Nonrandomized, nonblinded procedure for NYHA Class II, III, IV heart failure; transcatheter implantation of interatrial shunt, including right and left heart catheterization, transeptal puncture, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	Investigational
C9762	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging	Investigational
C9763	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging	Investigational
C9764	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
C9765	Revascularization, endovascular,	Investigational
	open or percutaneous, lower	
	extremity artery(ies), except	
	tibial/peroneal; with intravascular	
	lithotripsy, and transluminal stent	
	placement(s), includes	
	angioplasty within the same	
	vessel(s), when performed	
С9766	Revascularization, endovascular,	Investigational
	open or percutaneous, lower	
	extremity artery(ies), except	
	tibial/peroneal; with intravascular	
	lithotripsy and atherectomy,	
	includes angioplasty within the	
	same vessel(s), when performed	
С9767	Revascularization, endovascular,	Investigational
	open or percutaneous, lower	
	extremity artery(ies), except	
	tibial/peroneal; with intravascular	
	lithotripsy and transluminal stent	
	placement(s), and atherectomy,	
	includes angioplasty within the	
	same vessel(s), when performed	
C9772	Revascularization, endovascular,	Investigational
	open or percutaneous,	
	tibial/peroneal artery(ies), with	
	intravascular lithotripsy, includes	
	angioplasty within the same	
	vessel(s), when performed	
C9773	Revascularization, endovascular,	Investigational
	open or percutaneous,	
	tibial/peroneal artery(ies); with	
	intravascular lithotripsy, and	
	transluminal stent placement(s),	
	includes angioplasty within the	
C0774	same vessel(s), when performed	
C9774	Revascularization, endovascular,	Investigational
	open or percutaneous,	
	tibial/peroneal artery(ies); with	
	intravascular lithotripsy and	
	atherectomy, includes angioplasty	
	within the same vessel(s), when	
	performed	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
C9775	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same	Investigational
	vessel(s), when performed	
С9777	Esophageal mucosal integrity testing by electrical impedance, transoral, includes esophagoscopy or esophagogastroduodenoscopy	Investigational
C9780	Insertion of central venous catheter through central venous occlusion via inferior and superior approaches (e.g., inside-out technique), including imaging guidance	Investigational
C9781	Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed	Investigational
C9784	Gastric restrictive procedure, endoscopic sleeve gastroplasty, with esophagogastroduodenoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components	Investigational
C9785	Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components	Investigational
C9791	Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
C9792	Blinded or nonblinded procedure	Investigational
	for symptomatic new york heart	
	association (nyha) class ii, iii, iva	
	heart failure; transcatheter	
	implantation of left atrial to	
	coronary sinus shunt using jugular	
	vein access, including all imaging	
	necessary to intra procedurally	
	map the coronary sinus for	
	optimal shunt placement (e.g.,	
	tee or ice ultrasound,	
	fluoroscopy), performed under	
	general anesthesia in an approved	
	investigational device exemption	
C9796	(ide) study) Repair of enterocutaneous fistula	Investigational
C9/90	small intestine or colon (excluding	Investigationat
	anorectal fistula) with plug (e.g.,	
	porcine small intestine submucosa	
	[sis])	
C9797	Vascular embolization or occlusion	Investigational
••••	procedure with use of a pressure-	
	generating catheter (e.g., one-	
	way valve, intermittently	
	occluding), inclusive of all	
	radiological supervision and	
	interpretation, intraprocedural	
	roadmapping, and imaging	
	guidance necessary to complete	
	the intervention; for tumors,	
	organ ischemia, or infarction	
E0201	Penile contracture device,	Investigational
	manual, greater than 3 lbs	
	traction force	
E0218	Fluid circulating cold pad with	Investigational
	pump, any type	
E0236	Pump for water circulating pad	Investigational
E0468	Home ventilator, dual-function	Investigational
	respiratory device, also performs	-
	additional function of cough	
	stimulation, includes all	
	accessories, components and	
	supplies for all functions	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization	Investigational
F0 400	device	
E0490	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle,	Investigational
	controlled by hardware remote	
E0491	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply	Investigational
E0492	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application	Investigational
E0493	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply	Investigational
E0530	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type	Investigational
E0677	Non-pneumatic sequential compression garment, trunk	Investigational
E0683	Non-pneumatic, non-sequential, peristaltic wave compression pump	Investigational
E0711	Upper extremity medical tubing/lines enclosure or covering device, restricts elbow range of motion	Investigational
E0715	Intravaginal device intended to strengthen pelvic floor muscles during kegel exercises	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
E0716 E0721	Supplies and accessories for intravaginal device intended to strengthen pelvic floor muscles during kegel exercises	Investigational
	Transcutaneous electrical nerve stimulatory, stimulates nerves in the auricular region	Investigational
E0732	Cranial electrotherapy stimulation (ces) system, any type	Investigational
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve	Investigational
E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist	Investigational
E0736	Transcutaneous tibial nerve stimulator	Investigational
E0737	Transcutaneous tibial nerve stimulator, controlled by phone application	Investigational
E0738	Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, include microprocessor, all components and accessories	Investigational
E0739	Rehabilitation system with interactive interface providing active assistance in rehabilitation therapy, includes all components and accessories, motors, microprocessors, sensors	Investigational
E0740	Nonimplanted pelvic floor electrical stimulator, complete system	Investigational
E0743	External lower extremity nerve stimulator for restless legs syndrome, each	Investigational
E0746	Electromyography (EMG), biofeedback device	Investigational
E0761	Nonthermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
E0762	Transcutaneous electrical joint stimulation device system, includes all accessories	Investigational
E0764	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program	Investigational
E0767	External lower extremity nerve stimulator for restless legs syndrome, each	nvestigational
E0769	Electrical stimulation or electromagnetic wound treatment device, not otherwise classified	nvestigational
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified	Investigational
E1700	Jaw motion rehabilitation system	Investigational
E1701	Replacement cushions for jaw motion rehabilitation system, package of 6	
E1702	Replacement measuring scales for jaw motion rehabilitation system, package of 200	Investigational
E1801	Static progressive stretch/patient actualized serial stretch elbow device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories	Investigational
E1806	Static progressive stretch wrist device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories	Investigational
E1811	Static progressive stretch/patient actualized serial stretch knee device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
E1816	Static progressive stretch/patient	Investigational
	actualized serial stretch ankle device, flexion and/or extension,	
	with or without range of motion	
	adjustment, includes all components	
	and accessories	
E1818	Static progressive stretch/patient	Investigational
	actualized serial stretch forearm	
	pronation / supination device, with	
	or without range of motion	
	adjustment, includes all components	
E1821	and accessories	Investigational
EIOZI	Replacement soft interface material/cuffs for bi-directional	Investigational
	static progressive stretch device	
E1831	Static progressive stretch toe device,	Investigational
	extension and/or flexion, with or	
	without range of motion adjustment,	
	includes all components and	
	accessories	
E1841	Static progressive stretch/patient	Investigational
	actualized serial stretch shoulder	
	device, with or without range of	
	motion adjustment, includes all components and accessories	
E1905	Virtual reality cognitive behavioral	Investigational
LIVOS	therapy device (cbt), including pre-	investigationat
	programmed therapy software	
E2001	Suction pump, home model, portable	Investigational
	or stationary, electric, any type, for	
	use with external urine/or fecal	
52200	management system	
E3200	Gait modulation system, rhythmic	Investigational
	auditory stimulation, including restricted therapy software, all	
	components and accessories,	
	prescription only	
G0166	External counterpulsation, per	Investigational
	treatment session	
G0183	Quantitative software	Investigational
	measurements of cardiac volume,	
	cardiac chambers volumes and	
	left ventricular wall mass derived	
	from ct scan(s) data of the	
	chest/heart (with or without	
	contrast)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
G0255	Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve	Investigational
G0276	Blinded procedure for lumbar stenosis, percutaneous image- guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial	Investigational
G0295	Electromagnetic therapy, to one or more areas, for wound care other than described in G0329 or for other uses	Investigational
G0327	Colorectal cancer screening; blood-based biomarker	Investigational
G0329	Electromagnetic therapy, to one or more areas for chronic Stage III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care	Investigational
G0465	Autologous platelet rich plasma (PRP) for diabetic chronic wounds/ulcers, using an FDA- cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment)	Investigational
G0555	Provision of replacement patient electronics system (e.g., system pillow, handheld reader) for home pulmonary artery pressure monitoring	Investigational
G0566	3d radiodensity-value bone imaging, algorithm derived, from previous magnetic resonance examination of the same anatomy	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
G2000	Blinded administration of	Investigational
	convulsive therapy procedure,	
	either electroconvulsive therapy	
	(ECT, current covered gold	
	standard) or magnetic seizure	
	therapy (MST, noncovered	
	experimental therapy), performed	
	in an approved IDE-based clinical	
	trial, per treatment session	
G9143	Warfarin responsiveness testing by	Investigational
	genetic technique using any	
	method, any number of	
	specimen(s)	
G9147	Outpatient Intravenous Insulin	Investigational
	Treatment (OIVIT) either pulsatile	
	or continuous, by any means,	
	guided by the results of	
	measurements for: respiratory	
	quotient; and/or, urine urea	
	nitrogen (UUN); and/or, arterial,	
	venous or capillary glucose;	
K4004	and/or potassium concentration	
K1004	Low frequency ultrasonic	Investigational
	diathermy treatment device for	
K4007	home use	lassesting time al
K1007	Bilateral hip, knee, ankle, foot	Investigational
	(HKAFO) device, powered,	
	includes pelvic component, single	
	or double upright(s), knee joints any type, with or without ankle	
	joints any type, includes all components and accessories,	
	motors, microprocessors, sensors	
K1030	External recharging system for	Investigational
KIUJU	battery (internal) for use with	Investigationat
	implanted cardiac contractility	
	modulation generator,	
	replacement only	
K1036	Supplies and accessories (e.g.,	Investigational
	transducer) for low frequency	estigationat
	-	
K1037		Investigational
K1037	ultrasonic diathermy treatment device, per month Docking station for use with oral device/appliance used to reduce upper airway collapsibility	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
L8608	Miscellaneous external component, supply or accessory for use with the Argus II Retinal Prosthesis System	Investigational
L8678	Electrical stimulator supplies (external) for use with implantable neurostimulator, per month	Investigational
L8720	External lower extremity sensory prosthesis, cutaneous stimulation of mechanoreceptors proximal to the ankle, per leg	Investigational
L8721	Receptor sole for use with L8720, replacement, each	Investigational
M0076	Prolotherapy	Investigational
M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	Investigational COVID-19 Effective:(04/05/2022)
P2031	Hair analysis (excluding arsenic)	Investigational
P9020	Platelet rich plasma, each unit	Investigational
P9027	Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced, each unit	Investigational
Q1005	New technology, intraocular lens, category 5 as defined in Federal Register notice	Investigational
Q4103	Oasis burn matrix, per sq cm	Investigational
Q4104	Integra bilayer matrix wound dressing (BMWD), per sq cm	Investigational
Q4110	PriMatrix, per sq cm	Investigational
Q4111	GammaGraft, per sq cm	Investigational
Q4112	Cymetra, injectable, 1 cc	Investigational
Q4113	GRAFTJACKET XPRESS, injectable, 1 cc	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
Q4115	AlloSkin, per sq cm	Investigational
Q4117	HYALOMATRIX, per sq cm	Investigational
Q4118	MatriStem micromatrix, 1 mg	Investigational
Q4123	AlloSkin RT, per sq cm	Investigational
Q4124	OASIS ultra tri-layer wound matrix, per sq cm	Investigational
Q4125	ArthroFlex, per sq cm	Investigational
Q4126	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm	Investigational
Q4127	Talymed, per sq cm	Investigational
Q4130	Strattice TM, per sq cm	Investigational
Q4134	HMatrix, per sq cm	Investigational
Q4135	Mediskin, per sq cm	Investigational
Q4136	E-Z Derm, per sq cm	Investigational
Q4141	AlloSkin AC, per sq cm	Investigational
Q4142	XCM biologic tissue matrix, per sq cm	Investigational
Q4143	Repriza, per sq cm	Investigational
Q4146	Tensix, per sq cm	Investigational
Q4147	Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm	Investigational
Q4149	Excellagen, 0.1 cc	Investigational
Q4152	DermaPure, per sq cm	Investigational
Q4158	Kerecis Omega3, per sq cm	Investigational
Q4161	bio-ConneKt wound matrix, per sq cm	Investigational
Q4164	Helicoll, per sq cm	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
Q4165	Keramatrix or Kerasorb, per sq cm	Investigational
Q4166	Cytal, per sq cm	Investigational
Q4167	Truskin, per sq cm	Investigational
Q4179	FlowerDerm, per sq cm	Investigational
Q4182	Transcyte, per sq cm	Investigational
Q4193	Coll-e-Derm, per sq cm	Investigational
Q4196	PuraPly AM, per sq cm	Investigational
Q4199	Cygnus matrix, per sq cm	Investigational
Q4200	SkinTE, per sq cm	Investigational
Q4202	Keroxx (2.5 g/cc), 1 cc	Investigational
Q4203	Derma-Gide, per sq cm	Investigational
Q4222	ProgenaMatrix, per sq cm	Investigational
Q4251	Vim, per sq cm	Investigational
Q4252	Vendaje, per sq cm	Investigational
Q4253	Zenith Amniotic Membrane, per sq cm	Investigational
Q4259	Celera dual layer or celera dual membrane, per square centimeter	Investigational
Q4260	Signature apatch, per square centimeter	Investigational
Q4261	Tag, per square centimeter	Investigational
Q4262	Dual layer impax membrane, per square centimeter	Investigational
Q4263	Surgraft tl, per square centimeter	Investigational
Q4264	Cocoon membrane, per square centimeter	Investigational
Q4265	Neostim tl, per square centimeter	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
Q4266	Neostim membrane, per square	Investigational
	centimeter	
Q4267	Neostim dl, per square centimeter	Investigational
Q4268	Surgraft ft, per square centimeter	Investigational
Q4269	Surgraft xt, per square centimeter	Investigational
0.4070	.	
Q4270	Complete sl, per square	Investigational
04074	centimeter	lavestigetical
Q4271	Complete ft, per square	Investigational
Q4272	centimeter	Investigational
Q4272	Esano a, per square centimeter	Investigationat
Q4273	Esano aaa, per square centimeter	Investigational
ل الم	Louis daa, per oquare centimeter	
Q4274	Esano ac, per square centimeter	Investigational
<u> </u>		
Q4275	Esano aca, per square centimeter	Investigational
-		5
Q4276	Orion, per square centimeter	Investigational
Q4278	Epieffect, per square centimeter	Investigational
Q4279	Vendaje ac, per square	Investigational
	centimeter	
Q4280	Xcell amnio matrix, per square	Investigational
04294	centimeter	Investigational
Q4281	Barrera sl or barrera dl, per	Investigational
Q4282	square centimeter	Investigational
<u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u></u>	Cygnus dual, per square centimeter	mesugationat
Q4283	Biovance tri-layer or biovance 3l,	Investigational
2.200	per square centimeter	
Q4284	Dermabind sl, per square	Investigational
	centimeter	
Q4285	Nudyn dl or nudyn dl mesh, per	Investigational
	square centimeter	
Q4286	Nudyn sl or nudyn slw, per square	Investigational
	centimeter	
Q4287	Dermabind dl, per square	Investigational
	centimeter	
Q4288	Dermabind ch, per square	Investigational
0.4000	centimeter	
Q4289	Revoshield + amniotic barrier, per	Investigational
	square centimeter	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
Q4290	Membrane wrap-hydro, per square centimeter	Investigational
Q4291	Lamellas xt, per square centimeter	Investigational
Q4292	Lamellas, per square centimeter	Investigational
Q4393	Acesso dl, per square centimeter	Investigational
Q4294	Amnio quad-core, per square centimeter	Investigational
Q4295	Amnio tri-core amniotic, per square centimeter	Investigational
Q4296	Rebound matrix, per square centimeter	Investigational
Q4297	Emerge matrix, per square centimeter	Investigational
Q4298	Amniocore pro, per square centimeter	Investigational
Q4299	Amnicore pro+, per square centimeter	Investigational
Q4300	Acesso tl, per square centimeter	Investigational
Q4301	Activate matrix, per square centimeter	Investigational
Q4302	Complete aca, per square centimeter	Investigational
Q4303	Complete aa, per square centimeter	Investigational
Q4304	Grafix plus, per square centimeter	Investigational
Q4305	American amnion ac tri-layer, per square centimeter"	Investigational
Q4306	American amnion ac, per square centimeter	Investigational
Q4307	American amnion, per square centimeter	Investigational
Q4308	Sanopellis, per square centimeter	Investigational
Q4309	Via matrix, per square centimeter	Investigational
Q4310	Procenta, per 100 mg	Investigational
Q4311	Acesso, per square centimeter	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
Q4312	Acesso ac, per square centimeter	Investigational
Q4313	Dermabind fm, per square centimeter	Investigational
Q4314	Reeva ft, per square cenitmeter	Investigational
Q4315	Regenelink amniotic membrane allograft, per square centimeter	Investigational
Q4316	Amchoplast, per square centimeter	Investigational
Q4317	Vitograft, per square centimeter	Investigational
Q4318	E-graft, per square centimeter	Investigational
Q4319	Sanograft, per square centimeter	Investigational
Q4320	Pellograft, per square centimeter	Investigational
Q4321	Renograft, per square centimeter	Investigational
Q4322	Caregraft, per square centimeter	Investigational
Q4323	Alloply, per square centimeter	Investigational
Q4324	Amniotx, per square centimeter	Investigational
Q4325	Acapatch, per square centimeter	Investigational
Q4326	Woundplus, per square centimeter	Investigational
Q4327	Duoamnion, per square centimeter	Investigational
Q4328	Most, per square centimeter	Investigational
Q4329	Singlay, per square centimeter	Investigational
Q4330	Total, per square centimeter	Investigational
Q4331	Axolotl graft, per square centimeter	Investigational
Q4332	Axolotl dualgraft, per square centimeter	Investigational
Q4333	Ardeograft, per square centimeter	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
Q4334	Amnioplast 1, per square	Investigational
	centimeter	
Q4335	Amnioplast 2, per square	Investigational
	centimeter	
Q4336	Artacent c, per square centimeter	Investigational
Q4337	Artacont tridont por coupro	Investigational
Q4337	Artacent trident, per square centimeter	Investigationat
Q4338	Artacent velos, per square	Investigational
2	centimeter	
Q4339	Artacent vericlen, per square	Investigational
	centimeter	
Q4340	Simpligraft, per square	Investigational
	centimeter	
Q4341	Simplimax, per square centimeter	Investigational
Q4342	Theramend, per square	Investigational
04242	centimeter	
Q4343	Dermacyte ac matrix amniotic	Investigational
	membrane allograft, per square centimeter	
Q4344	Tri-membrane wrap, per square	Investigational
QISTI	centimeter	investigationat
Q4345	Matrix hd allograft dermis, per	Investigational
	square centimeter	
Q4346	Shelter dm matrix, per square	Investigational
	centimeter	
Q4347	Rampart dl matrix, per square	Investigational
	centimeter	
Q4348	Sentry sl matrix, per square	Investigational
0.42.40	centimeter	Investigational
Q4349	Mantle dl matrix, per square centimeter	Investigational
Q4350	Palisade dm matrix, per square	Investigational
21330	centimeter	investigationat
Q4351	Enclose tl matrix, per square	Investigational
	centimeter	
Q4352	Overlay sl matrix, per square	Investigational
	centimeter	
Q4353	Xceed tl matrix, per square	Investigational
	centimeter	
Q4354	Palingen dual-layer membrane,	Investigational
0.4355	per square centimeter	
Q4355	Abiomend xplus membrane and	Investigational
	abiomend xplus hydromembrane,	
	per square centimeter	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
Q4356	Abiomend membrane and abiomend hydromembrane, per	Investigational
	square centimeter	
Q4357	Xwrap dual, per square centimeter	Investigational
Q4358	Xwrap dual, per square centimeter	Investigational
Q4359	Choriply, per square centimeter	Investigational
Q4360	Amchoplast fd, per square centimeter	Investigational
Q4361	Epixpress, per square centimeter	Investigational
Q4362	Cygnus disk, per square centimeter	Investigational
Q4363	Amnio burgeon membrane and hydromembrane, per square centimeter	Investigational
Q4364	Amnio burgeon xplus membrane and xplus hydromembrane, per square centimeter	Investigational
Q4365	Amnio burgeon dual-layer membrane, per square centimeter	Investigational
Q4366	Dual layer amnio burgeon x- membrane, per square centimeter	Investigational
Q4367	Amniocore sl, per square centimeter	Investigational
Q4368	Amchothick, per square centimeter	Investigational
Q4369	Amnioplast 3, per square centimeter	Investigational
Q4370	Aeroguard, per square centimeter	Investigational
Q4371	Neoguard, per square centimeter	Investigational
Q4372	Amchoplast excel, per square centimeter	Investigational
Q4373	Membrane wrap-lite, per square centimeter	Investigational
Q4375	Duograft ac, per square centimeter	Investigational
Q4376	Duograft aa, per square centimeter	Investigational
Q4377	Trigraft ft, per square centimeter	Investigational
Q4378	Renew ft matrix, per square centimeter	Investigational
Q4379	Amniodefend ft matrix, per square centimeter	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
Q4380	Advograft one, per square	Investigational
	centimeter	
Q4382	Advograft dual, per square	Investigational
	centimeter	
S0596	Phakic intraocular lens for	Investigational
	correction of refractive error	
S1091	Stent, noncoronary, temporary,	Investigational
	with delivery system (Propel)	
S2117	Arthroereisis, subtalar	Investigational
S2230	Implantation of magnetic	Investigational
	component of semi-implantable	
	hearing device on ossicles in	
	middle ear	
S2348	Decompression procedure,	Investigational
	percutaneous, of nucleus pulposus	
	of intervertebral disc, using	
	radiofrequency energy, single or	
\$3722	multiple levels, lumbar	leventingtional
33722	Dose optimization by area under	Investigational
	the curve (AUC) analysis, for infusional 5-fluorouracil	
S4024		Investigational
54024	Air polymer-type a intrauterine foam, per study dose	Investigational
S4988	Penile contracture device,	Investigational
54700	manual, greater than 3 lbs	investigationat
	traction force	
S8040	Topographic brain mapping	Investigational
		in escigationat
S8130	Interferential current stimulator,	Investigational
	2 channel	5
S8131	Interferential current stimulator,	Investigational
	4 channel	
S8930	Electrical stimulation of auricular	Investigational
	acupuncture points; each 15	
	minutes of personal one-on-one	
	contact with patient	
\$9002	Intra-vaginal motion sensor	Investigational
	system, provides biofeedback for	
	pelvic floor muscle rehabilitation	
	device	
S9090	Vertebral axial decompression,	Investigational
	per session	
V2787	Astigmatism correcting function of	Investigational
	intraocular lens	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
V2788	Presbyopia correcting function of	Investigational
	intraocular lens	
V2799	Vision item or service,	Investigational
	miscellaneous	
0001A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike protein, preservative free, 30	
	mcg/0.3mL dosage, diluent	
	reconstituted; first dose	
0002A	Immunization administration by	Investigational COVID-19
UUUZA	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 30	
	mcg/0.3mL dosage, diluent	
	reconstituted; second dose	
0003A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 30	
	mcg/0.3 mL dosage, diluent reconstituted; third dose	
0003U	Oncology (ovarian) biochemical	Investigational
00030	assays of five proteins	Investigational
	(apolipoprotein A-1, CA 125 II,	
	follicle stimulating hormone,	
	human epididymis protein 4,	
	transferrin), utilizing serum,	
	algorithm reported as a likelihood	
	score	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0004A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 30	
	mcg/0.3 mL dosage, diluent	
	reconstituted; booster dose	
0004M	Scoliosis, DNA analysis of 53 single	Investigational
	nucleotide polymorphisms (SNPs),	
	using saliva, prognostic algorithm	
	reported as a risk score	
0011A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 100	
001111	mcg/0.5mL dosage; first dose	
0011M	Oncology, prostate cancer, mRNA	Investigational
	expression assay of 12 genes (10	
	content and 2 housekeeping), RT-	
	PCR test utilizing blood plasma	
	and urine, algorithms to predict	
0012A	high-grade prostate cancer risk	Investigational COVID-19
UUTZA	Immunization administration by	Effective:(04/18/2023)
	intramuscular injection of severe acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 100	
	mcg/0.5mL dosage; second dose	
0013A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 100	
	mcg/0.5 mL dosage; third dose	
L		

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0016M	Oncology (bladder), mRNA,	Investigational
	microarray gene expression	
	profiling of 209 genes, utilizing	
	formalin-fixed paraffin-embedded	
	tissue, algorithm reported as	
	molecular subtype (luminal, luminal infiltrated, basal, basal	
	claudin-low, neuroendocrine-like)	
0018M	Transplantation medicine	Investigational
	(allograft rejection, renal),	investigationat
	measurement of donor and third-	
	party-induced CD154+T-cytotoxic	
	memory cells, utilizing whole	
	peripheral blood, algorithm	
	reported as a rejection risk score	
0019M	Cardiovascular disease, plasma,	Investigational
	analysis of protein biomarkers by	
	aptamer-based microarray and	
	algorithm reported as 4-year	
	likelihood of coronary event in	
0020M	high-risk populations Oncology (central nervous	Investigational
0020	system), analysis of 30000 DNA	investigationat
	methylation loci by methylation	
	array, utilizing DNA extracted	
	from tumor tissue, diagnostic	
	algorithm reported as probability	
	of matching a reference tumor	
	subclass	
0024U	Glycosylated acute phase proteins	Investigational
	(GlycA), nuclear magnetic	
	resonance spectroscopy,	
000511	quantitative	
0025U	Tenofovir, by liquid	Investigational
	chromatography with tandem	
	mass spectrometry (LC-MS/MS), urine, quantitative	
0031A	Immunization administration by	Investigational COVID-19
0051A	intramuscular injection of severe	Effective:(05/07/2023)
	acute respiratory syndrome	21100010070772023)
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, DNA, spike protein,	
	adenovirus type 26 (Ad26) vector,	
	preservative free, 5x1010 viral	
	particles/0.5mL dosage; single dose	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0034A	Immunization administration by intramuscular injection of severe acute respiratory syndrome	Investigational COVID-19 Effective:(05/07/2023)
	coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector,	
	preservative free, 5x1010 viral particles/0.5mL dosage; booster dose	
0034U	TPMT (thiopurine S- methyltransferase), NUDT15 (nudix hydroxylase 15) (eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)	Investigational
0035U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative	Investigational
0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative	Investigational
0039U	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity	Investigational
0041U	Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM	Investigational
0042U	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG	Investigational
0043U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM	Investigational
0044U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0045U	Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score	Investigational
0048U	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein- coding exons of 468 cancer- associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin- embedded tumor tissue, report of clinically significant mutation(s)	Investigational
0050U	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements	Investigational
0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	Investigational COVID-19 Effective:(04/18/2023)
0051U	Prescription drug monitoring, evaluation of drugs present by liquid chromatography tandem mass spectrommetry (LC-MS/MS), urine or blood, 31 drug panel, reported as quantitative results, detected or not detected, per date of service	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0052A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike protein,	
	preservative free, 30 mcg/0.3 mL	
	dosage, tris-sucrose formulation;	
0052U	second dose Lipoprotein, blood, high resolution	Investigational
00520	fractionation and quantitation of	Investigational
	lipoproteins, including all five major	
	lipoprotein classes and subclasses of	
	HDL, LDL, and VLDL by vertical auto	
	profile ultracentrifugation	
0053A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 30	
	mcg/0.3 mL dosage, tris-sucrose	
	formulation; third dose	
0054A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 30	
	mcg/0.3 mL dosage, tris-sucrose	
	formulation; booster dose	
0054U	Prescription drug monitoring, 14	Investigational
	or more classes of drugs and	
	substances, definitive tandem	
	mass spectrometry with	
	chromatography, capillary blood,	
	quantitative report with	
	therapeutic and toxic ranges,	
	including steady-state range for	
	the prescribed dose when	
	detected, per date of service	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0055U	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma	Investigational
0058U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative	Investigational
0059U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative	Investigational
0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood	Investigational
0061U	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis	Investigational
0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score	Investigational
0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose	Investigational COVID-19 Effective:(04/18/2023)

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0067U	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP- 1], carcinoembryonic antigen- related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin- embedded precancerous breast tissue, algorithm reported as carcinoma risk score	Investigational
0069U	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score	Investigational
0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris- sucrose formulation; first dose	Investigational COVID-19 Effective:(04/18/2023)
0071T	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue	Investigational
0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris- sucrose formulation; second dose	Investigational COVID-19 Effective:(04/18/2023)
0072T	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0073A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike protein,	
	preservative free, 10 mcg/0.2 mL	
	dosage, diluent reconstituted, tris-	
	sucrose formulation; third dose	
0074A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike protein,	
	preservative free, 10 mcg/0.2 mL	
	dosage, diluent reconstituted, tris-	
	sucrose formulation; booster dose	
0075T	Transcatheter placement of	Investigational
	extracranial vertebral artery	
	stent(s), including radiologic	
	supervision and interpretation, open	
	or percutaneous; initial vessel	
0076T	Transcatheter placement of	Investigational
	extracranial vertebral artery	
	stent(s), including radiologic	
	supervision and interpretation,	
	open or percutaneous; each	
	additional vessel (List separately	
	in addition to code for primary	
	procedure)	
0078U	Pain management (opioid-use	Investigational
	disorder) genotyping panel, 16	
	common variants (ie, ABCB1, COMT,	
	DAT1, DBH, DOR, DRD1, DRD2, DRD4,	
	GABA, GAL, HTR2A, HTTLPR, MTHFR,	
	MUOR, OPRK1, OPRM1), buccal swab	
	or other germline tissue sample,	
	algorithm reported as positive or	
	negative risk of opioid-use disorder	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0080U	Oncology (lung), mass spectrometric	Investigational
	analysis of galectin-3-binding	
	protein and scavenger receptor	
	cysteine-rich type 1 protein M130,	
	with five clinical risk factors (age,	
	smoking status, nodule diameter,	
	nodule-spiculation status and nodule	
	location), utilizing plasma,	
	algorithm reported as a categorical	
	probability of malignancy	
0081A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike protein,	
	preservative free, 3 mcg/0.2 mL	
	dosage, diluent reconstituted, tris-	
	sucrose formulation; first dose	
0082A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike protein,	
	preservative free, 3 mcg/0.2 mL	
	dosage, diluent reconstituted, tris-	
	sucrose formulation; second dose	
0082U	Drug test(s), definitive, 90 or more	Investigational
	drugs or substances, definitive	
	chromatography with mass	
	spectrometry, and presumptive, any	
	number of drug classes, by	
	instrument chemistry analyzer	
	(utilizing immunoassay), urine,	
	report of presence or absence of	
	each drug, drug metabolite or	
	substance with description and	
	severity of significant interactions	
	per date of service	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0083A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 3	
	mcg/0.2 mL dosage, diluent	
	reconstituted, tris-sucrose	
	formulation; third dose	
0083U	Oncology, response to	Investigational
	chemotherapy drugs using motility	
	contrast tomography, fresh or	
	frozen tissue, reported as	
	likelihood of sensitivity or	
	resistance to drugs or drug	
0084U	combinations	Investigational
00040	Red blood cell antigen typing,	Investigational
	DNA, genotyping of 10 blood	
	groups with phenotype prediction of 37 red blood cell antigens	
0087U	Cardiology (heart transplant),	Investigational
00070	mRNA gene expression profiling by	Investigationat
	microarray of 1283 genes,	
	transplant biopsy tissue, allograft	
	rejection and injury algorithm	
	reported as a probability score	
0088U	Transplantation medicine (kidney	Investigational
	allograft rejection), microarray	5
	gene expression profiling of 1494	
	genes, utilizing transplant biopsy	
	tissue, algorithm reported as a	
	probability score for rejection	
0089U	Oncology (melanoma), gene	Investigational
	expression profiling by RTqPCR,	
	PRAME and LINC00518, superficial	
	collection using adhesive patch(es)	
0090U	Oncology (cutaneous melanoma),	Investigational
	mRNA gene expression profiling by	
	RT-PCR of 23 genes (14 content and 9	
	housekeeping), utilizing formalin-	
	fixed paraffin-embedded (FFPE)	
	tissue, algorithm reported as a	
	categorical result (ie, benign,	
	intermediate, malignant)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0091A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years	Investigational COVID-19 Effective:(04/18/2023)
0091U	Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result	Investigational
0092A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years	Investigational COVID-19 Effective:(04/18/2023)
0092U	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy	Investigational
0093A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years	Investigational COVID-19 Effective:(04/18/2023)

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0094A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike protein,	
	preservative free, 50 mcg/0.5 mL	
	dosage; booster dose, when	
	administered to individuals 18 years	
	and overEosinophilic esophagitis	
	(Eotaxin-3 [CCL26 {C-C motif	
	chemokine ligand 26}] and major	
	basic protein [PRG2 {proteoglycan 2, pro eosinophil major basic	
	protein}]), enzyme-linked	
	immunosorbent assays (ELISA),	
	specimen obtained by esophageal	
	string test device, algorithm	
	reported as probability of active or	
	inactive eosinophilic esophagitis	
0095U	Eosinophilic esophagitis, 2 protein	Investigational
	biomarkers (Eotaxin-3 [CCL26 {C-C	-
	motif chemokine ligand 26}] and	
	Major Basic Protein [PRG2	
	{proteoglycan 2, pro eosinophil	
	major basic protein}]-1), enzyme-	
	linked immunosorbent assays	
	(ELISA), specimen obtained by	
	esophageal string test device,	
	algorithm reported as probability	
	of active or inactive eosinophilic	
0100T	esophagitis	Investigational
01001	Placement of a subconjunctival	Investigational
	retinal prosthesis receiver and pulse generator, and implantation	
	of intra-ocular retinal electrode	
	array, with vitrectomy	
0101T	Extracorporeal shock wave	Investigational
	involving musculoskeletal system,	intestigationat
	not otherwise specified	
	not other mise specified	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0101U	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])	Investigational
0102T	Extracorporeal shock wave performed by a physician, requiring anesthesia other than local, and involving the lateral humeral epicondyle	Investigational
0102U	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])	Investigational
0103U	Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0105U	Nephrology (chronic kidney disease),	Investigational
	multiplex electrochemiluminescent	
	immunoassay (ECLIA) of tumor	
	necrosis factor receptor 1A,	
	receptor superfamily 2 (TNFR1,	
	TNFR2), and kidney injury molecule-	
	1 (KIM-1) combined with longitudinal	
	clinical data, including APOL1	
	genotype if available, and plasma	
	(isolated fresh or frozen), algorithm reported as probability score for	
	rapid kidney function decline (RKFD)	
0106T	Quantitative sensory testing	Investigational
01001	(QST), testing and interpretation	investigationat
	per extremity; using touch	
	pressure stimuli to assess large	
	diameter sensation	
0106U	Gastric emptying, serial collection	Investigational
	of 7 timed breath specimens, non-	
	radioisotope carbon-13 (13C)	
	spirulina substrate, analysis of	
	each specimen by gas isotope	
	ratio mass spectrometry, reported	
0407T	as rate of 13CO2 excretion	luventingtigen
0107T	Quantitative sensory testing (QST),	Investigational
	testing and interpretation per extremity; using vibration stimuli to	
	assess large diameter fiber	
	sensation	
0108T	Quantitative sensory testing	Investigational
	(QST), testing and interpretation	5
	per extremity; using cooling	
	stimuli to assess small nerve fiber	
	sensation and hyperalgesia	

0108UGastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancerInvestigational0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective: (04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) varcine mRNA-I NP, snikeInvestigational COVID-19	CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancerInvestigational0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19])Investigational COVID-19	0108U		Investigational
analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD4SRO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancerInvestigational0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancerInvestigational0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SAR5-COV-2) (coronavirus disease [COVID-19])Investigational COVID-19		• • • • • • • • • • • • • • • • • • • •	
paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancerInvestigational0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
algorithm reported as risk of progression to high-grade dysplasia or cancerInvestigational0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
progression to high-grade dysplasia or cancerInvestigational0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19		•	
dysplasia or cancer0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19])Investigational COVID-19		•	
0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational			
(QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19	04007		
per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19	01091		Investigational
stimuli to assess small nerve fiber sensation and hyperalgesiaInvestigational0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
sensation and hyperalgesia0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective: (04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
Lesting and interpretation per extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19	0110T		Investigational
extremity; using other stimuli to assess sensationInvestigational0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19	01101		Investigational
assess sensation0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
0110UPrescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-19 Effective:(04/18/2023)0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19	011011		Investigational
substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19	01100		Investigational
mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected 0111A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])		• •	
blood, quantitative report with steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
steady-state range for the prescribed drug(s) when detectedInvestigational COVID-190111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19			
prescribed drug(s) when detected0111AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])Investigational COVID-19 Effective:(04/18/2023)			
0111A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])			
intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	0111Δ		Investigational COVID-19
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])			
coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])			
(coronavirus disease [COVID-19])			
		vaccine, mRNA-LNP, spike	
protein, preservative free, 100		•	
mcg/0.5mL dosage; first dose			

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0112A	Immunization administration by	Investigational COVID-19
	intramuscular injection of severe	Effective:(04/18/2023)
	acute respiratory syndrome	
	coronavirus 2 (SARS-CoV-2)	
	(coronavirus disease [COVID-19])	
	vaccine, mRNA-LNP, spike	
	protein, preservative free, 25	
	mcg/0.25 mL dosage; second dose	
0113U	Oncology (prostate),	Investigational
	measurement of PCA3 and	
	TMPRSS2-ERG in urine and PSA in	
	serum following prostatic	
	massage, by RNA amplification	
	and fluorescence-based	
	detection, algorithm reported as risk score	
0114U	Gastroenterology (Barrett's	Investigational
01140	esophagus), VIM and CCNA1	investigationat
	methylation analysis, esophageal	
	cells, algorithm reported as	
	likelihood for Barrett's esophagus	
0118U	Transplantation medicine,	Investigational
	quantification of donor-derived cell-	
	free DNA using whole genome next-	
	generation sequencing, plasma,	
	reported as percentage of donor-	
	derived cell-free DNA in the total	
	cell-free DNA	
0119U	Cardiology, ceramides by liquid	Investigational
	chromatography-tandem mass	
	spectrometry, plasma,	
	quantitative report with risk score	
	for major cardiovascular events	
0120U	Oncology (B-cell lymphoma	Investigational
	classification), mRNA, gene	
	expression profiling by fluorescent	
	probe hybridization of 58 genes	
	(45 content and 13 housekeeping	
	genes), formalin-fixed paraffin-	
	embedded tissue, algorithm reported as likelihood for primary	
	mediastinal B-cell lymphoma	
	(PMBCL) and diffuse large B-cell	
	lymphoma (DLBCL) with cell of	
	origin subtyping in the latter	
	ongin subtyping in the latter	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0121U	Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood	Investigational
0122U	Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood	Investigational
0123U	Mechanical fragility, RBC, shear stress and spectral analysis profiling	Investigational
0130U	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure)	Investigational
0131U	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure)	Investigational
0132U	Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure)	Investigational
0133U	Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0134U	Hereditary pan cancer (eg, hereditary breast and ovarian	Investigational
	cancer, hereditary endometrial	
	cancer, hereditary colorectal	
	cancer), targeted mRNA sequence	
	analysis panel (18 genes) (List	
	separately in addition to code for	
	primary procedure)	
0135U	Hereditary gynecological cancer	Investigational
	(eg, hereditary breast and ovarian cancer, hereditary endometrial	
	cancer, hereditary colorectal	
	cancer), targeted mRNA sequence	
	analysis panel (12 genes) (List	
	separately in addition to code for	
	primary procedure)	
0136U	ATM (ataxia telangiectasia	Investigational
	mutated) (eg, ataxia	
	telangiectasia) mRNA sequence	
	analysis (List separately in	
	addition to code for primary procedure)	
0137U	PALB2 (partner and localizer of	Investigational
	BRCA2) (eg, breast and pancreatic	in escigational
	cancer) mRNA sequence analysis	
	(List separately in addition to code	
	for primary procedure)	
0138U	BRCA1 (BRCA1, DNA repair	Investigational
	associated), BRCA2 (BRCA2, DNA	
	repair associated) (eg, hereditary breast and ovarian cancer) mRNA	
	sequence analysis (List separately in	
	addition to code for primary	
	procedure)	
0152U	Infectious disease (bacteria,	Investigational
	fungi, parasites, and DNA viruses),	
	microbial cell-free DNA, plasma,	
	untargeted next-generation	
	sequencing, report for significant	
	positive pathogens	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0153U	Oncology (breast), mRNA, gene	Investigational
	expression profiling by next-	
	generation sequencing of 101 genes,	
	utilizing formalin-fixed paraffin-	
	embedded tissue, algorithm reported	
	as a triple negative breast cancer	
	clinical subtype(s) with information	
	on immune cell involvement	
0163T	Total disc arthroplasty (artificial	Investigational
	disc), anterior approach, including	
	discectomy to prepare interspace	
	(other than for decompression),	
	each additional interspace, lumbar	
	(List separately in addition to code	
044011	for primary procedure)	
0163U	Oncology (colorectal) screening,	Investigational
	biochemical enzyme-linked	
	immunosorbent assay (ELISA) of 3	
	plasma or serum proteins	
	(teratocarcinoma derived growth	
	factor-1 [TDGF-1, Cripto-1],	
	carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]),	
	with demographic data (age,	
	gender, CRC-screening compliance)	
	using a proprietary algorithm and	
	reported as likelihood of CRC or	
	advanced adenomas	
0164T	Removal of total disc	Investigational
••••	arthroplasty, (artificial disc),	in estigational
	anterior approach, each	
	additional interspace, lumbar	
	(List separately in addition to	
	code for primary procedure)	
0164U	Gastroenterology (irritable bowel	Investigational
	syndrome [IBS]), immunoassay for	5
	anti-CdtB and anti-vinculin	
	antibodies, utilizing plasma,	
	algorithm for elevated or not	
	elevated qualitative results	
0165T	Revision including replacement of	Investigational
	total disc arthroplasty (artificial	
	disc), anterior approach, each	
	additional interspace, lumbar (List	
	separately in addition to code for	
	primary procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0165U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy	Investigational
0166U	Liver disease, 10 biochemical assays (a2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation	Investigational
0169U	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S- methyltransferase) (eg, drug metabolism) gene analysis, common variants	Investigational
0170U	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis	Investigational
0171U	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence	Investigational
0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0176U	Cytolethal distending toxin B	Investigational
	(CdtB) and vinculin IgG antibodies	
0178U	by immunoassay (ie, ELISA)	Investigational
01780	Peanut allergen-specific quantitative assessment of	Investigational
	multiple epitopes using enzyme-	
	linked immunosorbent assay	
	(ELISA), blood, report of minimum	
	eliciting exposure for a clinical	
	reaction	
0179U	Oncology (non-small cell lung	Investigational
	cancer), cell-free DNA, targeted	
	sequence analysis of 23 genes	
	(single nucleotide variations, insertions and deletions, fusions	
	without prior knowledge of	
	partner/breakpoint, copy number	
	variations), with report of	
	significant mutation(s)	
0180U	Red cell antigen (ABO blood group)	Investigational
	genotyping (ABO), gene analysis	
	Sanger/chain	
	termination/conventional	
	sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and	
	alpha 1-3-galactosyltransferase)	
	gene, including subtyping, 7 exons	
0181U	Red cell antigen (Colton blood	Investigational
	group) genotyping (CO), gene	
	analysis, AQP1 (aquaporin 1	
	[Colton blood group]) exon 1	
0182U	Red cell antigen (Cromer blood	Investigational
	group) genotyping (CROM), gene	
	analysis, CD55 (CD55 molecule	
0183U	[Cromer blood group]) exons 1-10 Red cell antigen (Diego blood group)	Investigational
01030	genotyping (DI), gene analysis,	investigationat
	SLC4A1 (solute carrier family 4	
	member 1 [Diego blood group]) exon	
	19	
0184U	Red cell antigen (Dombrock blood	Investigational
	group) genotyping (DO), gene	
	analysis, ART4 (ADP-	
	ribosyltransferase 4 [Dombrock	
	blood group]) exon 2	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0185U	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4	Investigational
0186U	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2	Investigational
0187U	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2	Investigational
0188U	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4	Investigational
0189U	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2	Investigational
0190U	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3	Investigational
0191U	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6	Investigational
0192U	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9	Investigational
0193U	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26	Investigational
0194U	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo- endopeptidase [Kell blood group]) exon 8	Investigational
0195U	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0196U	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3	Investigational
0197U	Red cell antigen (Landsteiner- Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1	Investigational
0198U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5	Investigational
0199U	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12	Investigational
0200U	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3	Investigational
0201U	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2	Investigational
0202T	Posterior vertebral joint(s) arthroplasty (eg, facet joint[s] replacement), including facetectomy, laminectomy, foraminotomy, and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0203U	Autoimmune (inflammatory bowel	Investigational
	disease), mRNA, gene expression	
	profiling by quantitative RT-PCR,	
	17 genes (15 target and 2	
	reference genes), whole blood,	
	reported as a continuous risk	
	score and classification of	
	inflammatory bowel disease	
0205U	aggressiveness Ophthalmology (age-related	Investigational
02030	macular degeneration), analysis of	Investigational
	3 gene variants (2 CFH gene, 1	
	ARMS2 gene), using PCR and	
	MALDI-TOF, buccal swab, reported	
	as positive or negative for	
	neovascular age-related macular-	
	degeneration risk associated with	
	zinc supplements	
0206U	Neurology (Alzheimer disease);	Investigational
	cell aggregation using	
	morphometric imaging and	
	protein kinase C-epsilon (PKCe)	
	concentration in response to	
	amylospheroid treatment by	
	ELISA, cultured skin fibroblasts,	
	each reported as positive or	
0207T	negative for Alzheimer disease	Investigational
0207T	Evacuation of meibomian glands, automated, using heat and	Investigational
	intermittent pressure, unilateral	
0207U	Neurology (Alzheimer disease);	Investigational
02070	quantitative imaging of	investigationat
	phosphorylated ERK1 and ERK2 in	
	response to bradykinin treatment by	
	in situ immunofluorescence, using	
	cultured skin fibroblasts, reported as	
	a probability index for Alzheimer	
	disease (List separately in addition	
	to code for primary procedure)	
0209U	Cytogenomic constitutional	Investigational
	(genome-wide) analysis,	
	interrogation of genomic regions for	
	copy number, structural changes and	
	areas of homozygosity for	
	chromosomal abnormalities	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0211U	Oncology (pan-tumor), DNA and	Investigational
	RNA by next-generation	
	sequencing, utilizing formalin-	
	fixed paraffin-embedded tissue,	
	interpretative report for single	
	nucleotide variants, copy number	
	alterations, tumor mutational	
	burden, and microsatellite	
	instability, with therapy	
	association	
0216U	Neurology (inherited ataxias),	Investigational
	genomic DNA sequence analysis of	
	12 common genes including small	
	sequence changes, deletions,	
	duplications, short tandem repeat	
	gene expansions, and variants in	
	non-uniquely mappable regions,	
	blood or saliva, identification and	
0217U	categorization of genetic variants Neurology (inherited ataxias),	Investigational
02170	genomic DNA sequence analysis of	Investigational
	51 genes including small sequence	
	changes, deletions, duplications,	
	short tandem repeat gene	
	expansions, and variants in non-	
	uniquely mappable regions, blood or	
	saliva, identification and	
	categorization of genetic variants	
0218U	Neurology (muscular dystrophy),	Investigational
	DMD gene sequence analysis,	5
	including small sequence changes,	
	deletions, duplications, and	
	variants in non-uniquely mappable	
	regions, blood or saliva,	
	identification and	
	characterization of genetic	
	variants	
0219U	Infectious agent (human	Investigational
	immunodeficiency virus), targeted	
	viral next-generation sequence	
	analysis (ie, protease [PR], reverse	
	transcriptase [RT], integrase [INT]),	
	algorithm reported as prediction of	
	antiviral drug susceptibility	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0220U	Red cell antigen (RH blood group)	Investigational
	genotyping (RHD and RHCE), gene	
	analysis, next-generation	
	sequencing, RH proximal promoter,	
	exons 1-10, portions of introns 2-3	
0227U	Drug assay, presumptive, 30 or	Investigational
	more drugs or metabolites, urine,	
	liquid chromatography with	
	tandem mass spectrometry (LC-	
	MS/MS) using multiple reaction monitoring (MRM), with drug or	
	metabolite description, includes	
	• ·	
0228U	sample validation Oncology (prostate), multianalyte	Investigational
02280	molecular profile by photometric	Investigationat
	detection of macromolecules	
	adsorbed on nanosponge array	
	slides with machine learning,	
	utilizing first morning voided urine,	
	algorithm reported as likelihood of	
	prostate cancer	
0229U	BCAT1 (Branched chain amino	Investigational
	acid transaminase 1) and IKZF1	Jan 1
	(IKAROS family zinc finger 1) (eg,	
	colorectal cancer) promoter	
	methylation analysis	
0232T	Injection(s), platelet rich plasma,	Investigational
	any site, including image guidance,	
	harvesting and preparation when	
	performed	
0243U	Obstetrics (preeclampsia),	Investigational
	biochemical assay of placental-	
	growth factor, time-resolved	
	fluorescence immunoassay,	
	maternal serum, predictive	
	algorithm reported as a risk score	
	for preeclampsia	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0244U	Oncology (solid organ), DNA,	Investigational
	comprehensive genomic profiling,	
	257 genes, interrogation for single-	
	nucleotide variants,	
	insertions/deletions, copy number	
	alterations, gene rearrangements, tumor-mutational burden and	
	microsatellite instability, utilizing formalin-fixed paraffin-embedded	
	tumor tissue	
0247U	Obstetrics (preterm birth),	Investigational
02110	insulin-like growth factor-binding	investigationat
	protein 4 (IBP4), sex hormone-	
	binding globulin (SHBG),	
	quantitative measurement by LC-	
	MS/MS, utilizing maternal serum,	
	combined with clinical data,	
	reported as predictive-risk	
	stratification for spontaneous	
	preterm birth	
0248U	Oncology spheroid cell culture in	Investigational
	a 3D microenvironment, 12 drug	
	panel, brain or brain metastasis	
024011	response prediction for each drug	
0249U	Oncology (breast),	Investigational
	semiquantitative analysis of 32 phosphoproteins and protein	
	analytes, includes laser capture	
	microdissection, with algorithmic	
	analysis and interpretative report	
0250U	Oncology (solid organ neoplasm),	Investigational
	targeted genomic sequence DNA	
	analysis of 505 genes,	
	interrogation for somatic	
	alterations (SNVs [single	
	nucleotide variant], small	
	insertions and deletions, one	
	amplification, and four	
	translocations), microsatellite	
	instability and tumor-mutation	
025411	burden	
0251U	Hepcidin-25, enzyme-linked	Investigational
	immunosorbent assay (ELISA),	
	serum or plasma	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0252U	Fetal aneuploidy short tandem- repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and compared anounloidy.	Investigational
0253T	and segmental aneuploidy Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space	Investigational
0253U	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)	Investigational
0255U	Andrology (infertility), sperm- capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score	Investigational
0258U	Autoimmune (psoriasis), mRNA, next- generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics	Investigational
0259U	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo- inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0260U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural	Investigational
0261U	variants by optical genome mapping Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score	Investigational
0262U	Oncology (solid tumor), gene expression profiling by real-time RT- PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score	Investigational
0263T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest	Investigational
0263U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, a-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S- sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC- MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0264T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest	Investigational
0264U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	Investigational
0265T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy	Investigational
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra- operative interrogation, programming, and repositioning, when performed)	Investigational
0266U	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole- transcriptome and next- generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0267T	Implantation or replacement of	Investigational
	carotid sinus baroreflex activation	
	device; lead only, unilateral	
	(includes intra-operative	
	interrogation, programming, and	
0267U	repositioning, when performed)	Investigational
02070	Rare constitutional and other	Investigational
	heritable disorders, identification of copy number variations,	
	inversions, insertions,	
	translocations, and other	
	structural variants by optical	
	genome mapping and whole	
	genome sequencing	
0268T	Implantation or replacement of	Investigational
	carotid sinus baroreflex activation	
	device; pulse generator only	
	(includes intra-operative	
	interrogation, programming, and	
	repositioning, when performed)	
0269T	Revision or removal of carotid	Investigational
	sinus baroreflex activation device;	
	total system (includes generator placement, unilateral or bilateral	
	lead placement, intra-operative	
	interrogation, programming, and	
	repositioning, when performed)	
0270T	Revision or removal of carotid	Investigational
	sinus baroreflex activation device;	
	lead only, unilateral (includes	
	intra-operative interrogation,	
	programming, and repositioning,	
	when performed)	
0271T	Revision or removal of carotid	Investigational
	sinus baroreflex activation device;	
	pulse generator only (includes	
	intra-operative interrogation,	
	programming, and repositioning,	
	when performed)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0272T	Interrogation device evaluation	Investigational
	(in person), carotid sinus	
	baroreflex activation system,	
	including telemetric iterative	
	communication with the	
	implantable device to monitor	
	device diagnostics and	
	programmed therapy values, with	
	interpretation and report (eg,	
	battery status, lead impedance,	
	pulse amplitude, pulse width,	
	therapy frequency, pathway	
	mode, burst mode, therapy	
	start/stop times each day);	
0273T	Interrogation device evaluation	Investigational
	(in person), carotid sinus	
	baroreflex activation system,	
	including telemetric iterative	
	communication with the	
	implantable device to monitor	
	device diagnostics and	
	programmed therapy values, with	
	interpretation and report (eg,	
	battery status, lead impedance,	
	pulse amplitude, pulse width,	
	therapy frequency, pathway	
	mode, burst mode, therapy	
	start/stop times each day); with	
0274T	programming Percutaneous	Investigational
02/41	laminotomy/laminectomy	investigationat
	(interlaminar approach) for	
	decompression of neural elements,	
	(with or without ligamentous	
	resection, discectomy, facetectomy	
	and/or foraminotomy), any method,	
	under indirect image guidance (eg,	
	fluoroscopic, CT), single or multiple	
	levels, unilateral or bilateral;	
	cervical or thoracic	
<u>i</u>		

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0275T	Percutaneous	Investigational
	laminotomy/laminectomy	
	(interlaminar approach) for	
	decompression of neural elements,	
	(with or without ligamentous	
	resection, discectomy, facetectomy	
	and/or foraminotomy), any method, under indirect image guidance (eg,	
	fluoroscopic, CT), single or multiple	
	levels, unilateral or bilateral; lumbar	
0278T	Transcutaneous electrical	Investigational
	modulation pain reprocessing (eg,	
	scrambler therapy), each treatment	
	session (includes placement of	
	electrodes)	
0285U	Oncology, response to radiation,	Investigational
	cell-free DNA, quantitative	
	branched chain DNA	
	amplification, plasma, reported as	
0288U	a radiation toxicity score	Investigational
02880	Oncology (lung), mRNA, quantitative PCR analysis of 11	Investigational
	genes (BAG1, BRCA1, CDC6,	
	CDK2AP1, ERBB3, FUT3, IL11,	
	LCK, RND3, SH3BGR, WNT3A) and	
	3 reference genes (ESD, TBP,	
	YAP1), formalin-fixed paraffin-	
	embedded (FFPE) tumor tissue,	
	algorithmic interpretation	
	reported as a recurrence risk	
	score	
0289U	Neurology (Alzheimer disease),	Investigational
	mRNA, gene expression profiling	
	by RNA sequencing of 24 genes,	
	whole blood, algorithm reported	
0290U	as predictive risk score Pain management, mRNA, gene	Investigational
02700	expression profiling by RNA	investigationat
	sequencing of 36 genes, whole	
	blood, algorithm reported as	
	predictive risk score	
0291U	Psychiatry (mood disorders), mRNA,	Investigational
	gene expression profiling by RNA	
	sequencing of 144 genes, whole	
	blood, algorithm reported as	
	predictive risk score	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0292U	Psychiatry (stress disorders),	Investigational
	mRNA, gene expression profiling	
	by RNA sequencing of 72 genes,	
	whole blood, algorithm reported	
000011	as predictive risk score	
0293U	Psychiatry (suicidal ideation),	Investigational
	mRNA, gene expression profiling	
	by RNA sequencing of 54 genes,	
	whole blood, algorithm reported as predictive risk score	
0294U	Longevity and mortality risk,	Investigational
02940	mRNA, gene expression profiling	Investigationat
	by RNA sequencing of 18 genes,	
	whole blood, algorithm reported	
	as predictive risk score	
0295U	Oncology (breast ductal	Investigational
	carcinoma in situ), protein	3
	expression profiling by	
	immunohistochemistry of 7	
	proteins (COX2, FOXA1, HER2, Ki-	
	67, p16, PR, SIAH2), with 4	
	clinicopathologic factors (size,	
	age, margin status, palpability),	
	utilizing formalin-fixed paraffin-	
	embedded (FFPE) tissue,	
	algorithm reported as a	
000/11	recurrence risk score	
0296U	Oncology (oral and/or	Investigational
	oropharyngeal cancer), gene	
	expression profiling by RNA	
	sequencing at least 20 molecular features (eg, human and/or	
	microbial mRNA), saliva,	
	algorithm reported as positive or	
	negative for signature associated	
	with malignancy	
0297U	Oncology (pan tumor), whole	Investigational
	genome sequencing of paired	
	malignant and normal DNA	
	specimens, fresh or formalin-fixed	
	paraffin-embedded (FFPE) tissue,	
	blood or bone marrow,	
	comparative sequence analyses	
	and variant identification	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0298U	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification	Investigational
0299U	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification	Investigational
0300U	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification	Investigational
0303U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic	Investigational
0304U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic	Investigational
0305U	Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0306U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future	Investigational
0307U	comparisons to evaluate for MRD Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD	Investigational
0308U	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD	Investigational
0309U	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event	Investigational
0310U	Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD	Investigational
0311U	Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organisms identified	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0312U	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment	Investigational
0313U	Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)	Investigational
0314U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	Investigational
0315U	Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin- fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B)	Investigational
0316U	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0317U	Oncology (lung cancer), four- probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm- generated evaluation reported as decreased or increased risk for lung cancer	Investigational
0318U	Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood	Investigational
0319U	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection	Investigational
0320U	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection	Investigational
0321U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique	Investigational
0322U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome- derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0323U	Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, Cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites or fungi	Investigational
0328U	Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient adverse event, per date of service	Investigational
0329U	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with and DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations	Investigational
0330U	Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab	Investigational
0330T	Tear film imaging, unilateral or bilateral, with interpretation and report	Investigational
0331U	Oncology (hematolymphoid neoplasia), optical for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alternations	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0332T	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT	Investigational
0332U	Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint-inhibitor therapy	Investigational
0333U	Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in highrisk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des- gammacarboxy-prothrombin (DCP), algorithm reported as normal or abnormal result	Investigational
0335T	Insertion of sinus tarsi implant	Investigational
0335U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0336U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent)	Investigational
0337U	Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood	Investigational
0338T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0338U	Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood	Investigational
0339T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral	Investigational
0339U	Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT- PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer	Investigational
0340U	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0341U	Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism,	Investigational
02.4211	and segmental aneuploid	
0342U	Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline	Investigational
0343U	Oncology (prostate), exosome- based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT- qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer	Investigational
0344U	Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH	Investigational
0345U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0347U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes	Investigational
0348U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes	Investigational
0349U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene- drug interactions	Investigational
0350U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes	Investigational
0351U	Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis- inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C- reactive protein, serum, or venous whole blood, algorithm reported as likelihood of bacterial infection	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0352U	Infectious disease (bacterial vaginosis and vaginitis), multiplex	Investigational
	amplified probe technique, for	
	detection of bacterial vaginosis-	
	associated bacteria (BVAB-2,	
	Atopobium vaginae, and	
	Megasphera type 1), algorithm	
	reported as detected or not detected and separate detection	
	of Candida species (C. albicans, C.	
	tropicalis, C. parapsilosis, C.	
	dubliniensis), Candida	
	glabrata/Candida krusei, and	
	trichomonas vaginalis, vaginal-	
	fluid specimen, each result	
	reported as detected or not detected	
0355U	APOL1 (apolipoprotein L1) (eg,	Investigational
	chronic kidney disease), risk	investigationat
	variants (G1, G2)	
0356U	Oncology (oropharyngeal or anal),	Investigational
	evaluation of 17 DNA biomarkers	
	using droplet digital PCR (ddPCR),	
	cell-free DNA, algorithm reported as a prognostic risk score for	
	cancer recurrence	
0358U	Neurology (mild cognitive	Investigational
	impairment), analysis of B-	
	amyloid 1-42 and 1-40,	
	chemiluminescence enzyme	
	immunoassay, cerebral spinal	
	fluid, reported as positive, likely	
0359U	positive, or negative Oncology (prostate cancer),	Investigational
	analysis of all prostate-specific	intestigationat
	antigen (PSA) structural isoforms	
	by phase separation and	
	immunoassay, plasma, algorithm	
02/011	reports risk of cancer	
0360U	Oncology (lung), enzyme-linked	Investigational
	immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1,	
	CAGE, GBU4-5, SOX2, MAGE A4,	
	and HuD), plasma, algorithm	
	reported as a categorical result	
	for risk of malignancy	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0361U	Neurofilament light chain, digital	Investigational
	immunoassay, plasma, quantitative	
0362U	Oncology (papillary thyroid	Investigational
05020	cancer), gene-expression profiling	investigationat
	via targeted hybrid capture-	
	enrichment RNA sequencing of 82	
	content genes fine needle	
	aspiration or formalin-fixed	
	paraffin embedded (FFPE) tissue,	
	algorithm reported as one of	
0363U	three molecular subtypes Oncology (urothelial), mRNA,	Investigational
03030	geneexpression profiling by real-	investigationat
	time quantitative PCR of 5 genes	
	(MDK, HOXA13, CDC2 [CDK1],	
	IGFBP5, and CXCR2), utilizing	
	urine, algorithm incorporates age,	
	sex, smoking history, and	
	macrohematuria frequency,	
	reported as a risk score for having urothelial carcinoma	
0365U	Oncology (bladder), 10 protein	Investigational
	biomarkers (A1AT, ANG, APOE,	
	CA9, IL8, MMP9, MMP10, PAI1,	
	SDC1, and VEGFA) by	
	immunoassays, urine, diagnostic,	
	algorithm including patient's age,	
	race and gender reported as a probability of harboring	
	urothelial cancer	
0366U	Oncology (bladder), analysis of 10	Investigational
	protein biomarkers (A1AT, ANG,	5
	APOE, CA9, IL8, MMP9, MMP10,	
	PAI1, SDC1 and VEGFA) by	
	immunoassays, urine, algorithm	
	reported as a probability of	
	recurrent bladder cancer	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0367U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic	Investigational
	algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection	
0371U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine	Investigational
0372U	Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score	Investigational
0375U	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score	Investigational
0376U	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)	Investigational
0378U	RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat- primed PCR, blood, saliva, or buccal swab	Investigational
0379U	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next- generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden	Investigational
0384U	Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LCMS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0385U	Nephrology (chronic kidney	Investigational
	disease), apolipoprotein A4	
	(ApoA4), CD5 antigen-like (CD5L),	
	and insulin-like growth factor	
	binding protein 3 (IGFBP3) by	
	enzyme-linked immunoassay	
	(ELISA), plasma, algorithm combining results with HDL,	
	estimated glomerular filtration	
	rate (GFR) and clinical data	
	reported as a risk score for	
	developing diabetic kidney	
	disease	
0387U	Oncology (melanoma), autophagy	Investigational
	and beclin 1 regulator 1 (AMBRA1)	
	and loricrin (AMLo) by	
	immunohistochemistry,	
	formalinfixed paraffn-embedded	
	(FFPE) tissue, report for risk of	
028011	progression	
0389U	Pediatric febrile illness (Kawasaki	Investigational
	disease [KD]), interferon alphainducible protein 27 (IFI27)	
	and mast cell-expressed	
	membrane protein 1 (MCEMP1),	
	RNA, using quantitative reverse	
	transcription polymerase chain	
	reaction (RT-qPCR), blood,	
	reported as a risk score for KD	
0390U	Obstetrics (preeclampsia), kinase	Investigational
	insert domain receptor (KDR),	
	Endoglin (ENG), and retinol-	
	binding	
	protein 4 (RBP4), by	
	immunoassay, serum, algorithm	
	reported as a risk score	

CPT®/HCPCS Code		Instructions
0391U	"Oncology (solid tumor), DNA and	Investigational
	RNA by next-generation	
	sequencing, utilizing formalin- fixed paraffin-embedded (FFPE)	
	tissue, 437 genes, interpretive	
	report for single nucleotide	
	variants, splicesite variants,	
	insertions/deletions, copy number	
	alterations, gene fusions, tumor	
	mutational burden,	
	and microsatellite instability,	
	with algorithm quantifying	
020211	immunotherapy response score"	
0392U	"Drug metabolism (depression,	Investigational
	anxiety, attention deficit hyperactivity disorder [ADHD]),	
	gene-drug interactions, variant	
	analysis of 16 genes, including	
	deletion/duplication analysis of	
	CYP2D6, reported as impact of	
	gene-drug interaction for each	
	drug"	
0393U	SYNTap® Biomarker Test by	Investigational
	Amprion Clinical Laboratory. The	
	lab, this chemistry test aids in the	
	diagnosis of synucleinopathies (e.g., Parkinson's disease, Lewy	
	body dementia, multiple system	
	atrophy (MSA), Lewy body variant	
	of Alzheimer's disease) and	
	differential diagnosis of other	
	movement and cognitive	
	disorders. A CSF specimen is	
	subjected to qualitative seed	
	amplification assay assessment for	
	detection of misfolded aggregates	
	of α-synuclein protein	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
CPT®/HCPCS Code 0394U	CPT®/HCPCS Code Description PFAS Testing & PFASureTM, by National Medical Services (NMS Labs). Per the lab, this chemistry quantitative toxicology test, monitors for Perfluoroalkyl Substances, (eg. perfluorooctanoic acid, perfluorooctane sulfonic acid). Plasma or serum is analyzed by HPLC/Tandem Mass Spectrometry (LC-MS/MS) for 16 PFAS compounds and reported with a calculated NASEM Summation value (National Academies of Science, Engineering and Medicine guidance value). The US Department of Defense, Lab Corp (and other large national clinical laboratories) and individual State- Level agencies will order this testing in Serum/Plasma matrix to	Investigational
0395U	"Oncology (lung), multi-omics (microbial DNA by shotgun nextgeneration sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease"	Investigational
0397T	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)	Investigational
0398U	"Gastroenterology (Barrett esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin- embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer"	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0399U	Neurology (cerebral folate	Investigational
	deficiency), serum, detection of anti-	
	human folate receptor IgGbinding	
	antibody and blocking autoantibodies	
	by enzyme-linked immunoassay	
	(ELISA), qualitative, and blocking	
	autoantibodies, using a functional	
	blocking assay for IgG or IgM,	
	quantitative, reported as positive or	
0.40011	not detected	
0400U	Obstetrics (expanded carrier	Investigational
	screening), 145 genes by	
	nextgeneration sequencing,	
	fragment analysis and multiplex	
	ligationdependent probe amplification, DNA, reported as	
	carrier positive or negative	
0401U	Cardiology (coronary heart disease [-	Investigational
04010	CHD]), 9 genes (12 variants),	investigationat
	targeted variant genotyping, blood,	
	saliva, or buccal swab, algorithm	
	reported as a genetic risk score for a	
	coronary event	
0403U	Oncology (prostate), mRNA, gene	Investigational
	expression profiling of 18 genes, first-	-
	catch urine, algorithm reported as	
	percentage of likelihood of detecting	
	clinically significant prostate cancer	
0404U	Oncology (breast), semiquantitative	Investigational
	measurement of thymidine kinase	
	activity by immunoassay, serum,	
	results reported as risk of disease	
040511	progression	Investigational
0405U	Oncology (pancreatic), 59	Investigational
	methylation haplotype block markers, next-generation	
	sequencing, plasma, reported as	
	cancer signal detected or not	
	detected	
0406U	Oncology (lung), flow cytometry,	Investigational
	sputum, 5 markers (meso-tetra [4-	
	carboxyphenyl] porphyrin [TCPP],	
	CD206, CD66b, CD3, CD19), algorithm	
	reported as likelihood of lung cancer	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0407U	Nephrology (diabetic chronic kidney	Investigational
	disease [CKD]), multiplex	
	electrochemiluminescent	
	immunoassay (ECLIA) of soluble	
	tumor necrosis factor receptor 1	
	(sTNFR1), soluble tumor necrosis	
	receptor 2 (sTNFR2), and kidney	
	injury molecule 1 (KIM-1) combined	
	with clinical data, plasma, algorithm	
	reported as risk for progressive	
0.40011	decline in kidney function	
0408U	Infectious agent antigen detection by	Investigational
	bulk acoustic wave biosensor	
	immunoassay, severe acute	
	respiratory syndrome coronavirus 2	
	(SARS-CoV-2) (coronavirus disease	
0410U	[COVID-19])	Investigational
04100	Oncology (pancreatic), DNA, whole genome sequencing with 5-	Investigational
	hydroxymethylcytosine enrichment,	
	whole blood or plasma, algorithm	
	reported as cancer detected or not	
	detected	
0411U	Psychiatry (eg, depression, anxiety,	Investigational
01110	attention deficit hyperactivity	investigationat
	disorder [ADHD]), genomic analysis	
	panel, variant analysis of 15 genes,	
	including deletion/duplication	
	analysis of CYP2D6	
	(For additional PLA code with	
	identical clinical descriptor, see	
	0345U. See Appendix O to determine	
	appropriate code assignment)	
0412U	Beta amyloid, AB42/40 ratio,	Investigational
	immunoprecipitation with	_
	quantitation by liquid	
	chromatography with tandem mass	
	spectrometry (LC-MS/MS) and	
	qualitative ApoE isoform-specific	
	proteotyping, plasma combined with	
	age, algorithm reported as presence	
	or absence of brain amyloid	
	pathology	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0413U	Oncology (hematolymphoid	Investigational
	neoplasm), optical genome mapping	
	for copy number alterations,	
	aneuploidy, and balanced/complex	
	structural rearrangements, DNA from	
	blood or bone marrow, report of	
0414U	clinically significant alterations Oncology (lung), augmentative	Investigational
04140	algorithmic analysis of digitized	Investigationat
	whole slide imaging for 8 genes (ALK,	
	BRAF, EGFR, ERBB2, MET, NTRK1-3,	
	RET, ROS1), and KRAS G12C and PD-	
	L1, if performed, formalin-fixed	
	paraffinembedded (FFPE) tissue,	
	reported as positive or negative for	
	each biomarker	
0415U	Cardiovascular disease (acute	Investigational
	coronary syndrome [ACS]), IL-16,	
	FAS, FASLigand, HGF, CTACK,	
	EOTAXIN, and MCP-3 by immunoassay	
	combined with age, sex, family	
	history, and personal history of	
	diabetes, blood, algorithm reported	
	as a 5-year (deleted risk) score for	
0417U	ACS	Investigational
04170	Rare diseases	Investigational
	(constitutional/heritable disorders), whole mitochondrial genome	
	sequence with heteroplasmy	
	detection and deletion analysis,	
	nuclearencoded mitochondrial gene	
	analysis of 335 nuclear genes,	
	including sequence changes,	
	deletions, insertions, and copy	
	number variants analysis, blood or	
	saliva, identification and	
	categorization of mitochondrial	
	disorder-associated genetic variants	
0418U	Oncology (breast), augmentative	Investigational
	algorithmic analysis of digitized	
	whole slide imaging of 8 histologic	
	and immunohistochemical features,	
	reported as a recurrence score	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0419U	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each	Investigational
	gene phenotype	
0420U	Oncology (bladder), mRNA expression profiling by real time quantitative PCR of 5 genes (MDK, HOXA13, CDC2, IGFBP5, and CXCR2) in combination with ddPCR analysis of 6 single nucleotide polymorphisms in two genes (TERT and FGFR3) utilizing a midstream voided urine sample, algorithm reported as a risk score of	Investigational
0421U	having urothelial carcinoma Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 RNA markers (GAPDH, SMAD4, ACY1, AREG, CDH1, KRAS, TNFRSF10B, and EGLN2) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result	Investigational
0422U	Oncology (pan-cancer), analysis of DNA biomarker response to anti- cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate	Investigational
0423U	Gene analysis panel for detection of variants in 26 genes associated with psychiatric and other pharmaceutical treatment (eg, depression, anxiety), genomic analysis panel, variant analysis of 26 genes	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0424U	Oncology (prostate) analysis of 53 small noncoding RNAs (sncRNAs), extracted from urinary exosomes, by quantitative real time polymerase chain reaction (rt-qPCR), reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer	Investigational
0427U	Monocyte distribution width, whole blood (list separately in addition to code for primary procedure)	Investigational
0429U	Infectious disease (viral), real-time PCR testing for 14 high-risk HPV types using oropharyngeal swab	Investigational
0430U	Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative	Investigational
0431U	Glycine Receptor Alpha1 IgG, serum or cerebrospinal fluid (CSF), live Cell- Binding Assay (LCBA), qualitative	Investigational
0432U	Kelch-Like Protein 11 (KLHL11) Antibody, serum or cerebrospinal fluid (CSF), cell-binding assay, qualitative	Investigational
0433U	Oncology (prostate) 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate- specific antigen, reported as likelihood of cancer.	Investigational
0434U	Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes	Investigational
0435U	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0436U	Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy.	Investigational
0437U	Psychiatry (anxiety disorders), mRNA gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score	Investigational
0438U	Drug Metabolism (adverse dr4ug reactions and drug response) buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions	Investigational
0439U	Cardiology (coronary heart disease [CHD]), DNA, analysis of 5 single- nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], rs3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (cg00300879 [transcription start site {TSS200} of CNKSR1], cg09552548 [intergenic], and cg14789911 [body of SPATC1L]), qPCR and digital PCR, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic CHD	Investigational

CPT®/HCPCS Code		Instructions
0440U	Cardiology (coronary heart disease	Investigational
	[CHD]), DNA, analysis of 10 single-	
	nucleotide polymorphisms (SNPs)	
	(rs710987 [LINC010019], rs1333048	
	[CDKN2B-AS1], rs12129789 [KCND3],	
	rs942317 [KTN1-AS1], rs1441433	
	[PPP3CA], rs2869675 [PREX1],	
	rs4639796 [ZBTB41], rs4376434	
	[LINC00972], rs12714414 [TMEM18], and rs7585056 [TMEM18]) and 6 DNA	
	methylation markers (cg03725309	
	[SARS1], cg12586707 [CXCL1,	
	cg04988978 [MPO], cg17901584	
	[DHCR24-DT], cg21161138 [AHRR],	
	and cg12655112 [EHD4]), qPCR and	
	digital PCR, whole blood, algorithm	
	reported as detected or not detected	
	for CHD	
0441U	Infectious disease (bacterial, fungal	Investigational
	or viral infection), semiquantitative	_
	biomechanical assessment (via	
	deformability cytometry), whole	
	blood, with algorithmic analysis and	
	result reported as an index.	
0442U	Infectious disease (respiratory	Investigational
	infection), Myxovirus resistance	
	protein A (MxA) and C-reactive	
	protein (CRP), fingerstick whole	
	blood specimen, each biomarker	
0443U	reported as present or absent Neurofilament light chain (NfL),	Investigational
04430	ultra-sensitive immunoassay, serum	Investigational
	or cerebrospinal fluid	
0444U	Oncology (solid organ neoplasia),	Investigational
	targeted genomic sequence panel of	intestigationat
	361 genes, interrogation for gene	
	fusions, translocations, or other	
	rearrangements, using DNA from	
	formalin-fixed paraffin-embedded	
	(DDPE) tumor tissue, report of	
	clinically significant variant(s)	

CPT [®] /HCPCS Code		Instructions
0445U	Bamyloid (Abeta42) and Phospho Tau (181P) (pTau181), electrochemiluminescence immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology	Investigational
0446U	Autoimmune diseases (systemic lupus erythematosus) [SLE], analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity	Investigational
0447U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare	
0449U	Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemias) regardless of race or self-identified ancestry, genomic sequence analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)	Investigational
0441T	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve	Investigational
0450U	Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides	Investigational
0451U	Oncology (multiple myeloma), LC- MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0452U	Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer	Investigational
0453U	Oncology (colorectal cancer), cell- free DNA (cfDNA), methylation- based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)	Investigational
0457U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative	Investigational
0458U	Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score	Investigational
0460U	Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes	Investigational
0461U	Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene- drug interactions and reported phenotypes	Investigational
0462U	Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0463U	Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker	Investigational
0465U	Oncology (urothelial carcinoma), DNA, quantitative methylation- specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative	Investigational
0466U	Cardiology (coronary artery disease [CAD]), DNA, genome-wide association studies (564856 single- nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease	Investigational
0467U	Oncology (bladder), DNA, next- generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden	Investigational
0468U	Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0469U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental	Investigational
	disomy (UPD), and aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination	
0470U	Oncology (oropharyngeal), detection of minimal residual disease by next- generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma	Investigational
0472U	Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme- linked immunosorbent assay (ELISA), semiqualitative, blood, reported as predictive evidence of early Sjogren syndrome	Investigational
0474U	Hereditary pan-cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0475U	Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation- dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer	Investigational
0476U	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes	Investigational
0477U	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes	Investigational
0479U	Tau, phosphorylated, pTau217	Investigational
0482U	Obstetrics (preeclampsia), biochemical assay of soluble fms-like tyrosine kinase 1 (sFlT-1) and placental growth factor (PIGF), serum, ratio reported for sFlT- 1/PIGF, with risk of progression for preeclampsia with severe features within 2 weeks	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0483U	Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral/rectal/vaginal swab, algorithm reported as probability of fluoroquinolone resistance	Investigational
0484U	Infectious disease (Mycoplasma genitalium), macrolide sensitivity, (23S rRNA point mutation), oral/rectal/vaginal swab, algorithm reported as probability of macrolide resistance	Investigational
0485U	Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability and tumor mutational burden.	Investigational
0486U	Oncology (pan-solid tumor), nextgeneration sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction	Investigational
0487U	Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidycorrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instability	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0488U	Obstetrics (fetal antigen noninvasive	Investigational
	prenatal test), cellfree DNA	
	sequence analysis for detection of	
	fetal presence or absence of 1 or	
	more of the Rh, C, c, D, E, Duffy	
	(Fya), or Kell (K) antigen in	
	alloimmunized pregnancies,	
	reported as selected antigen(s)	
	detected or not detected	
0489U	Obstetrics (single-gene noninvasive	Investigational
	prenatal test), cellfree DNA	
	sequence analysis of 1 or more	
	targets (eg, CFTR, SMN1, HBB,	
	HBA1, HBA2) to identify paternally	
	inherited pathogenic variants, and	
	relative mutation-dosage analysis	
	based on molecular counts to	
	determine fetal inheritance of	
	maternal mutation, algorithm	
	reported as a fetal risk score for the	
	condition (eg, cystic fibrosis, spinal	
	muscular atrophy, beta	
	hemoglobinopathies [including sickle	
	cell disease], alpha thalassemia)	
0490U	Oncology (cutaneous or uveal	Investigational
	melanoma), circulating tumor cell	
	selection, morphological	
	characterization and enumeration	
	based on differential CD146, high	
	molecular-weight melanoma	
	associated antigen, CD34 and CD45	
	protein biomarkers, peripheral blood	
0491U	Oncology (solid tumor), circulating	Investigational
	tumor cell selection, morphological	
	characterization and enumeration	
	based on differential epithelial cell	
	adhesion molecule (EpCAM),	
	cytokeratins 8, 18, and 19, CD45	
	protein biomarkers, and	
	quantification of estrogen receptor	
	(ER) protein biomarker-expressing	
	cells, peripheral blood	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0492U	Oncology (solid tumor), circulating tumor cell selection, morphological	Investigational
	characterization and enumeration	
	based on differential epithelial cell	
	adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45	
	protein biomarkers, and	
	quantification of PD-L1 protein	
	biomarker- expressing cells,	
	peripheral blood	
0493U	Transplantation medicine,	Investigational
	quantification of donor-derived cell-	
	free DNA (cfDNA) using	
	nextgeneration sequencing, plasma,	
	reported as percentage of donor derived cell-free DNA	
0494U	Red blood cell antigen (fetal RhD	Investigational
	gene analysis), next-generation	investigationat
	sequencing of circulating cell-free	
	DNA (cfDNA) of blood in pregnant	
	individuals known to be RhD	
	negative, reported as positive or	
0.40511	negative	
0495U	Oncology (prostate), analysis of circulating plasma proteins (tPSA,	Investigational
	fPSA, KLK2, PSP94, and GDF15),	
	germline polygenic risk score (60	
	variants), clinical information (age,	
	family history of prostate cancer,	
	prior negative prostate biopsy),	
	algorithm reported as risk of	
	likelihood of detecting clinically	
0.40(1)	significant prostate cancer	la ventine tiene l
0496U	Oncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for	Investigational
	methylation by real-time RT-PCR,	
	and 4 proteins by enzyme-linked	
	immunosorbent assay, blood,	
	reported positive or negative for	
	colorectal cancer or advanced	
	adenoma risk	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0497U	Oncology (prostate), mRNA gene expression profiling by real-time RT- PCR of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing formalin fixed paraffin-embedded (FFPE) tissue, algorithm reported as a risk score for prostate cancer	Investigational
0498U	Oncology (colorectal), next generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin- embedded (FFPE) tissue, report of variants and methylation pattern with interpretation	Investigational
0499U	Oncology (colorectal and lung), DNA from formalin-fixed paraffin embedded (FFPE) tissue, next generation sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection	Investigational
0500U	Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis (M41T, M41V, M41L, c.118-2A>C, c.118-1G>C, c.118- 9_118-2del, S56F, S621C)	Investigational
0501U	Oncology (colorectal), blood, cell free DNA (cfDNA)	Investigational
0502U	Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for HPV	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0503U	Neurology (Alzheimer disease), beta amyloid (AB40, AB42, AB42/40 ratio) and tau-protein (ptau217, np- tau217, ptau217/nptau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorithm score reported as likelihood of positive or negative for amyloid plaques	Investigational
0504U	Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real- time PCR, reported as positive or negative for each organism	Investigational
0505U	Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real- time PCR, reported as positive or negative for each organism	Investigational
0506T	Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report	Investigational
0506U	Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next- generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus	Investigational
0507T	Near-infrared dual imaging (ie, simultaneous reflective and trans- illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report	Investigational
0507U	Oncology (ovarian), DNA, whole genome sequencing with 5- hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0508U	Transplantation medicine, quantification of donor-derived cell- free DNA using 40 single nucleotide	Investigational
	polymorphisms (SNPs), plasma, and urine, initial evaluation reported as	
	percentage of donor-derived cell free DNA with risk for active rejection	
0509T	Electroretinography (ERG) with interpretation and report, pattern (PERG)	Investigational
0509U	Transplantation medicine, quantification of donor-derived cell- free DNA using 40 single nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell free DNA with risk for active rejection	Investigational
0510T	Removal of sinus tarsi implant	Investigational
0510U	Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA whole transcriptome data, reported as probability of predicted molecular subtype	Investigational
0511T	Removal and reinsertion of sinus tarsi implant	Investigational
0511U	Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug	Investigational
0512T	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; initial wound	Investigational
0512U	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffin embedded (FFPE) tissue, reported as increased or decreased probability of MSI-high (MSI-H)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0513T	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; each additional wound (List separately in addition to	Investigational
0513U	code for primary procedure) Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalin fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of each biomarker	Investigational
0514U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)	Investigational
0515T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])	Investigational
0515U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)	Investigational

CPT [®] /HCPCS Code		Instructions
0516T	Insertion of wireless cardiac	Investigational
	stimulator for left ventricular	
	pacing, including device	
	interrogation and programming, and	
	imaging supervision and	
	interpretation, when performed;	
	electrode only	
0516U	Drug metabolism, whole blood,	Investigational
	pharmacogenomic genotyping of 40	
	genes and CYP2D6 copy number	
	variant analysis, reported as	
	metabolizer status	
0517T	Insertion of wireless cardiac	Investigational
	stimulator for left ventricular	
	pacing, including device	
	interrogation and programming, and	
	imaging supervision and	
	interpretation, when performed;	
	both components of pulse generator	
	(battery and transmitter) only	
0517U	Therapeutic drug monitoring, 80 or	Investigational
	more psychoactive drugs or	
	substances, LC-MS/MS, plasma,	
	qualitative and quantitative	
	therapeutic minimally and	
	maximally effective dose of	
	prescribed and non-prescribed	
	medications	
0518T	Removal of pulse generator for	Investigational
	wireless cardiac stimulator for left	
	ventricular pacing; battery	
	component only	
0518U	Therapeutic drug monitoring, 90 or	Investigational
	more pain and mental health drugs	
	or substances, LC-MS/MS, plasma,	
	qualitative and quantitative	
	therapeutic minimally effective	
	range of prescribed and non-	
	prescribed medications	
0519T	Removal and replacement of pulse	Investigational
	generator for wireless cardiac	
	stimulator for left ventricular	
	pacing, including device	
	interrogation and programming;	
	both components (battery and	
	transmitter)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0519U	Therapeutic drug monitoring,	Investigational
	medications specific to pain,	
	depression, and anxiety, LCMS/MS,	
	plasma, 110 or more drugs or	
	substances, qualitative and	
	quantitative therapeutic minimally	
	effective range of prescribed, non- prescribed, and illicit medications in	
	circulation	
0520T	Removal and replacement of pulse	Investigational
	generator for wireless cardiac	_
	stimulator for left ventricular	
	pacing, including device	
	interrogation and programming;	
	battery component only	
0520U	Therapeutic drug monitoring, 200 or	Investigational
	more drugs or substances, LCMS/MS,	
	plasma, qualitative and quantitative	
	therapeutic minimally effective range of prescribed and non-	
	prescribed medications	
0521T	Interrogation device evaluation (in	Investigational
05211	person) with analysis, review and	investigationat
	report, includes connection,	
	recording, and disconnection per	
	patient encounter, wireless cardiac	
	stimulator for left ventricular pacing	
0522T	Programming device evaluation	Investigational
	(in person) with iterative	_
	adjustment of the implantable	
	device to test the function of the	
	device and select optimal	
	permanent programmed values	
	with analysis, including review	
	and report, wireless cardiac	
	stimulator for left ventricular	
	pacing	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0523T	Intraprocedural coronary	Investigational
	fractional flow reserve (FFR) with 3D functional mapping of color-	
	coded FFR values for the coronary	
	tree, derived from coronary	
	angiogram data, for real-time	
	review and interpretation of	
	possible atherosclerotic	
	stenosis(es) intervention (List	
	separately in addition to code for primary procedure)	
0524U	Obstetrics (preeclampsia),	Investigational
	sFlt1/PlGF ratio, immunoassay,	
	utilizing serum or plasma, reported	
	as a value	
0524T	Endovenous catheter directed	Investigational
	chemical ablation with balloon	
	isolation of incompetent extremity vein, open or percutaneous,	
	including all vascular access,	
	catheter manipulation, diagnostic	
	imaging, imaging guidance and	
	monitoring	
0525T	Insertion or replacement of	Investigational
	intracardiac ischemia monitoring system, including testing of the lead	
	and monitor, initial system	
	programming, and imaging	
	supervision and interpretation;	
	complete system (electrode and	
050511	implantable monitor)	
0525U	"Oncology, spheroid cell culture, 11-	Investigational
	drug panel (carboplatin, docetaxel, doxorubicin,	
	etoposide, gemcitabine, niraparib,	
	olaparib, paclitaxel, rucaparib,	
	topotecan, veliparib) ovarian,	
	fallopian, or peritoneal response	
052/7	prediction for each drug"	Investigational
0526T	Insertion or replacement of intracardiac ischemia monitoring	Investigational
	system, including testing of the lead	
	and monitor, initial system	
	programming, and imaging	
	supervision and interpretation;	
	electrode only	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0526U	"Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time"	Investigational
0527T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only	Investigational
0528T	Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report	Investigational
0529T	Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report	Investigational
0529U	"Hematology (venous thromboembolism [VTE]), genome- wide single-nucleotide polymorphism variants, including F2 and F5 gene analysis, and Leiden variant, by microarray analysis, saliva, report as risk score for VTE"	Investigational
0530T	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)	Investigational
0531T	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only	Investigational
0531U	Infectious disease (acid-fast bacteria and invasive fungi), DNA (673 organisms), next-generation sequencing, plasma	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0532T	Removal of intracardiac ischemia monitoring system, including all	Investigational
	imaging supervision and	
	interpretation; implantable monitor	
	only	
0533U	Drug metabolism (adverse drug	Investigational
	reactions and drug response),	
	genotyping of 16 genes (ie, ABCG2,	
	CYP2B6, CYP2C9, CYP2C19, CYP2C, CYP2D6, CYP3A5, CYP4F2, DPYD,	
	G6PD, GGCX, NUDT15, SLCO1B1,	
	TPMT, UGT1A1, VKORC1), reported	
	as metabolizer status and	
	transporter function	
0534U	Oncology (prostate), microRNA,	Investigational
	single-nucleotide polymorphisms	
	(SNPs) analysis by RT-PCR of 32	
	variants, using buccal swab,	
0535U	algorithm reported as a risk score Perfluoroalkyl substances (PFAS)	Investigational
03330	(eg, perfluorooctanoic acid,	Investigationat
	perfluorooctane sulfonic acid), by	
	liquid chromatography with tandem	
	mass spectrometry (LC-MS/MS),	
	plasma or serum, quantitative	
0536U	Red blood cell antigen (fetal RhD),	Investigational
	PCR analysis of exon 4 of RHD gene	
	and housekeeping control gene	
	GAPDH from whole blood in	
	pregnant individuals at 10+ weeks	
	gestation known to be RhD negative, reported as fetal RhD status	
0537U	Oncology (colorectal cancer),	Investigational
	analysis of cell-free DNA for	
	epigenomic patterns, next-	
	generation sequencing, >2500	
	differentially methylated regions	
	(DMRs), plasma, algorithm reported	
	as positive or negative	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0538U	Oncology (solid tumor), next-	Investigational
	generation targeted sequencing	
	analysis, formalin-fixed paraffin-	
	embedded (FFPE) tumor tissue, DNA	
	analysis of 600 genes, interrogation	
	for single-nucleotide variants,	
	insertions/deletions, gene rearrangements, and copy number	
	alterations, microsatellite	
	instability, tumor mutation burden,	
	reported as actionable variant	
0539U	Oncology (solid tumor), cell-free	Investigational
	circulating tumor DNA (ctDNA), 152	
	genes, next-generation sequencing,	
	interrogation for single-nucleotide	
	variants, insertions/deletions, gene	
	rearrangements, copy number	
	alterations, and microsatellite	
	instability, using whole-blood	
	samples, mutations with clinical	
	actionability reported as actionable	
	variant	
0541T	Myocardial imaging by	Investigational
	magnetocardiography (MCG) for	
	detection of cardiac ischemia, by	
	signal acquisition using minimum 36	
	channel grid, generation of magnetic-field time-series images,	
	quantitative analysis of magnetic	
	dipoles, machine learning-derived	
	clinical scoring, and automated	
	report generation, single study;	
0541U	Cardiovascular disease (HDL reverse	Investigational
	cholesterol transport), cholesterol	-
	efflux capacity, LC-MS/MS,	
	quantitative measurement of 5	
	distinct HDL-bound apolipoproteins	
	(apolipoproteins A1, C1, C2, C3, and	
	C4), serum, algorithm reported as	
	prediction of coronary artery disease	
	(pCAD) score	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0542T	Myocardial imaging by	Investigational
	magnetocardiography (MCG) for	
	detection of cardiac ischemia, by	
	signal acquisition using minimum 36	
	channel grid, generation of	
	magnetic-field time-series images,	
	quantitative analysis of magnetic dipoles, machine learning-derived	
	clinical scoring, and automated	
	report generation, single study;	
	interpretation and report	
0542U	Nephrology (renal transplant), urine,	Investigational
	nuclear magnetic resonance (NMR)	5
	spectroscopy measurement of 84	
	urinary metabolites, combined with	
	patient data, quantification of BK	
	virus (human polyomavirus 1) using	
	real-time PCR and serum creatinine,	
	algorithm reported as a probability	
0543T	score for allograft injury status	Investigational
05431	Transapical mitral valve repair, including transthoracic	Investigational
	echocardiography, when performed,	
	with placement of artificial chordae	
	tendineae	
0544U	Nephrology (transplant	Investigational
	monitoring), 48 variants by digital	5
	PCR, using cell-free DNA from	
	plasma, donor-derived cell-free	
	DNA, percentage reported as risk	
	for rejection	
0545T	Transcatheter tricuspid valve	Investigational
	annulus reconstruction with	
	implantation of adjustable annulus reconstruction device,	
	percutaneous approach	
0546T	Radiofrequency spectroscopy, real	Investigational
	time, intraoperative margin	
	assessment, at the time of partial	
	mastectomy, with report	
0546U	Low-density lipoprotein receptor-	Investigational
	related protein 4 (LRP4), antibody	
	identification by	
	immunofluorescence, using live	
	cells, reported as positive or	
	negative	

CPT [®] /HCPCS Code		Instructions
0547T	Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score	Investigational
0547U	Neurofilament light chain (NfL), chemiluminescent enzyme immunoassay, plasma, quantitative	Investigational
0548U	Glial fibrillary acidic protein (GFAP), chemiluminescent enzyme immunoassay, using plasma	Investigational
0549U	Oncology (urothelial), DNA, quantitative methylated real-time PCR of TRNA-Cys, SIM2, and NKX1- 1, using urine, diagnostic algorithm reported as a probability index for bladder cancer and/or upper tract urothelial carcinoma (UTUC)	Investigational
0550U	Oncology (prostate), enzyme- linked immunosorbent assays (ELISA) for total prostate-specific antigen (PSA) and free PSA, serum, combined with age, previous negative prostate biopsy status, digital rectal examination findings, prostate volume, and image and data reporting of the prostate, algorithm reported as a risk score for the presence of high-grade prostate cancer	Investigational
0551U	Tau, phosphorylated, pTau217, by single-molecule array (ultrasensitive digital protein detection), using plasma	Investigational
0554T	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0555T	Bone strength and fracture risk using	Investigational
	finite element analysis of functional	
	data, and bone-mineral density,	
	utilizing data from a computed	
	tomography scan; retrieval and	
	transmission of the scan data	
0556T	Bone strength and fracture risk using	Investigational
	finite element analysis of functional	
	data, and bone-mineral density,	
	utilizing data from a computed	
	tomography scan; assessment of	
	bone strength and fracture risk and	
05577	bone mineral density	
0557T	Bone strength and fracture risk	Investigational
	using finite element analysis of	
	functional data, and bone-mineral	
	density, utilizing data from a	
	computed tomography scan;	
0558T	interpretation and report	Investigational
00001	Computed tomography scan taken for the purpose of biomechanical	Investigational
	computed tomography analysis	
0558U	Oncology (colorectal), quantitative	Investigational
05500	enzyme-linked immunoassay (ELISA)	investigationat
	for secreted colorectal cancer	
	protein marker (BF7 antigen), using	
	serum, result reported as indicative	
	of response/no response to therapy	
	or disease progression/regression	
0559T	Anatomic model 3D-printed from	Investigational
	image data set(s); first individually	5
	prepared and processed component	
	of an anatomic structure	
0559U	Oncology (breast), quantitative	Investigational
	enzyme-linked immunoassay (ELISA)	
	for secreted breast cancer protein	
	marker (BF9 antigen), serum, result	
	reported as indicative of	
	response/no response to therapy or	
	disease progression/regression	
0560T	Anatomic model 3D-printed from	Investigational
	image data set(s); each additional	
	individually prepared and processed	
	component of an anatomic structure	
	(List separately in addition to code	
	for primary procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0561T	Anatomic guide 3D-printed and	Investigational
	designed from image data set(s); first	
0562T	anatomic guide Anatomic guide 3D-printed and	Investigational
05021	designed from image data set(s);	Investigationat
	each additional anatomic guide (List	
	separately in addition to code for	
	primary procedure)	
0562U	Oncology (solid tumor) targeted	Investigational
	genomic sequence analysis, 33	
	genes, detection of single nucleotide	
	variants (SNVs), insertions and	
	deletions, copy number	
	amplifications, and translocations in human genomic circulating cell-free	
	DNA, plasma, reported as presence	
	of actionable variants	
0563T	Evacuation of meibomian glands,	Investigational
	using heat delivered through	
	wearable, open-eye eyelid	
	treatment devices and manual gland	
	expression, bilateral	
0564T	Oncology, chemotherapeutic drug	Investigational
	cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs	
	and primary tumor cells,	
	categorical drug response	
	reported based on percent of	
	cytotoxicity observed, a minimum	
	of 14 drugs or drug combinations	
0565T	Autologous cellular implant	Investigational
	derived from adipose tissue for	
	the treatment of osteoarthritis of	
	the knees; tissue harvesting and	
0566T	cellular implant creation Autologous cellular implant derived	Investigational
05001	from adipose tissue for the	investigationat
	treatment of osteoarthritis of the	
	knees; injection of cellular implant	
	into knee joint including ultrasound	
	guidance, unilateral	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0566U	"Oncology (lung), qPCR-based analysis of 13 differentially methylated regions (CCDC181, HOXA7, LRRC8A, MARCHF11, MIR129-2, NCOR2, PANTR1, PRKCB, SLC9A3, TBR1_2, TRAP1, VWC2, ZNF781), pleural fluid, algorithm reported as a qualitative result"	Investigational
0567T	Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound	Investigational
0567U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis combination of short and long reads, for single nucleotide variants, deletions/insertions and characterized intronic variants, copy number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variants	Investigational
0568U	Neurology (dementia), beta amyloid (AB40, AB42, AB42/40 ratio), tau-protein phosphorylated at residue (eg, pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0568T	Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach,	Investigational
	including transvaginal ultrasound and pelvic ultrasound	
0569U	Oncology (solid tumor) next- generation sequencing analysis of tumor methylation markers (>20,000 differentially methylated regions) present in cell-free circulating tumor DNA (ctDNA), whole blood, algorithm reported as presence or absence of ctDNA with tumor fraction, if appropriate	Investigational
0569T	Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis	Investigational
0570T	Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)	Investigational
0570U	Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), immunoassay, whole blood or plasma, individual components reported with overall result of elevated or not elevated based on threshold comparison	Investigational
0571U	Oncology (solid tumor), DNA (80 genes) and RNA (10 genes), by next- generation sequencing, plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, reported as clinically actionable variants	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0572U	Oncology (prostate), high- throughput telomere length quantification by FISH, whole blood, diagnostic algorithm reported as risk of prostate cancer	Investigational
0573U	Oncology (pancreas), 3 biomarkers (glucose, carcinoembryonic antigen, and gastricsin), pancreatic cyst lesion fluid, algorithm reported as categorical mucinous or non- mucinous	Investigational
0574U	Mycobacterium tuberculosis, culture filtrate protein-10-kDa (CFP-10), serum or plasma, liquid chromatography-mass spectrometry (LC-MS)	Investigational
0581T	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral	Investigational
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance	Investigational
0583T	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia	Investigational
0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0588T	Revision or removal of	Investigational
	percutaneously placed integrated	
	single device neurostimulation	
	system for bladder dysfunction	
	including electrode array and	
	receiver or pulse generator,	
	including analysis, programming,	
	and imaging guidance when	
	performed, posterior tibial nerve	
0589T	Electronic analysis with simple	Investigational
	programming of implanted integrated	
	neurostimulation system for bladder	
	dysfunction (eg, electrode array and	
	receiver), including contact group(s),	
	amplitude, pulse width, frequency	
	(Hz), on/off cycling, burst, dose	
	lockout, patient-selectable	
	parameters, responsive	
	neurostimulation, detection	
	algorithms, closed-loop parameters,	
	and passive parameters, when	
	performed by physician or other	
	qualified health care professional,	
0590T	posterior tibial nerve, 1-3 parameters	Investigational
03901	Electronic analysis with complex	Investigational
	programming of implanted	
	integrated neurostimulation system for bladder dysfunction (eg,	
	electrode array and receiver),	
	including contact group(s),	
	amplitude, pulse width, frequency	
	(Hz), on/off cycling, burst, dose	
	lockout, patient-selectable	
	parameters, responsive	
	neurostimulation, detection	
	algorithms, closed-loop parameters,	
	and passive parameters, when	
	performed by physician or other	
	qualified health care professional,	
	posterior tibial nerve, 4 or more	
	parameters	
4	parameters	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0594T	Osteotomy, humerus, with insertion	Investigational
	of an externally controlled	
	intramedullary lengthening device,	
	including intraoperative imaging,	
	initial and subsequent alignment	
	assessments, computations of	
	adjustment schedules, and	
	management of the intramedullary lengthening device	
0596T	Temporary female intraurethral	Investigational
05701	valve-pump (ie, voiding	investigationat
	prosthesis); initial insertion,	
	including urethral measurement	
0597T	Temporary female intraurethral	Investigational
	valve-pump (ie, voiding	-
	prosthesis); replacement	
0598T	Noncontact real-time fluorescence	Investigational
	wound imaging, for bacterial	
	presence, location, and load, per	
	session; first anatomic site (eg,	
	lower extremity)	
0599T	Noncontact real-time	Investigational
	fluorescence wound imaging, for	
	bacterial presence, location, and	
	load, per session; each additional	
	anatomic site (eg, upper	
	extremity) (List separately in addition to code for primary	
	procedure)	
0602T	Glomerular filtration rate (GFR)	Investigational
	measurement(s), transdermal,	
	including sensor placement and	
	administration of a single dose of	
	fluorescent pyrazine agent	
0603T	Glomerular filtration rate (GFR)	Investigational
	monitoring, transdermal, including	
	sensor placement and administration	
	of more than one dose of	
	fluorescent pyrazine agent, each 24	
	hours	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0604T	Optical coherence tomography	Investigational
	(OCT) of retina, remote, patient-	
	initiated image capture and	
	transmission to a remote	
	surveillance center unilateral or	
	bilateral; initial device provision,	
	set-up and patient education on use of equipment	
0605T	Optical coherence tomography	Investigational
00001	(OCT) of retina, remote, patient-	investigationat
	initiated image capture and	
	transmission to a remote	
	surveillance center unilateral or	
	bilateral; remote surveillance center	
	technical support, data analyses and	
	reports, with a minimum of 8 daily	
	recordings, each 30 days	
0606T	Optical coherence tomography	Investigational
	(OCT) of retina, remote, patient-	
	initiated image capture and	
	transmission to a remote	
	surveillance center unilateral or bilateral; review, interpretation and	
	report by the prescribing physician	
	or other qualified health care	
	professional of remote surveillance	
	center data analyses, each 30 days	
0607T	Remote monitoring of an external	Investigational
	continuous pulmonary fluid	5
	monitoring system, including	
	measurement of radiofrequency-	
	derived pulmonary fluid levels,	
	heart rate, respiration rate,	
	activity, posture, and	
	cardiovascular rhythm (eg, ECG	
	data), transmitted to a remote	
	24-hour attended surveillance	
	center; set-up and patient education on use of equipment	
	education on use of equipment	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0608T	Remote monitoring of an external	Investigational
	continuous pulmonary fluid	
	monitoring system, including	
	measurement of radiofrequency-	
	derived pulmonary fluid levels,	
	heart rate, respiration rate, activity,	
	posture, and cardiovascular rhythm	
	(eg, ECG data), transmitted to a	
	remote 24-hour attended	
	surveillance center; analysis of data	
	received and transmission of reports	
	to the physician or other qualified	
0/00T	health care professional	
0609T	Magnetic resonance spectroscopy,	Investigational
	determination and localization of	
	discogenic pain (cervical,	
	thoracic, or lumbar); acquisition	
	of single voxel data, per disc, on	
	biomarkers (ie, lactic acid,	
	carbohydrate, alanine, laal,	
	propionic acid, proteoglycan, and collagen) in at least 3 discs	
0610T	Magnetic resonance spectroscopy,	Investigational
00101	determination and localization of	investigationat
	discogenic pain (cervical,	
	thoracic, or lumbar); transmission	
	of biomarker data for software	
	analysis	
0611T	Magnetic resonance spectroscopy,	Investigational
	determination and localization of	
	discogenic pain (cervical,	
	thoracic, or lumbar);	
	postprocessing for algorithmic	
	analysis of biomarker data for	
	determination of relative	
	chemical differences between	
	discs	
0612T	Magnetic resonance spectroscopy,	Investigational
	determination and localization of	
	discogenic pain (cervical,	
	thoracic, or lumbar);	
	interpretation and report	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0613T	Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography,	Investigational
	and imaging guidance by the proceduralist, when performed	
0614T	Removal and replacement of substernal implantable defibrillator pulse generator	Investigational
0615T	Automated analysis of binocular eye movements without spatial calibration, including disconjugacy, saccades, and pupillary dynamics for the assessment of concussion, with interpretation and report	Investigational
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed	Investigational
0620T	Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed	Investigational
0621T	Trabeculostomy ab interno by laser	Investigational
0622T	Trabeculostomy ab interno by laser; with use of ophthalmic endoscope	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0623T	Automated quantification and	Investigational
	characterization of coronary	
	atherosclerotic plaque to assess	
	severity of coronary disease, using	
	data from coronary computed	
	tomographic angiography; data	
	preparation and transmission,	
	computerized analysis of data, with	
	review of computerized analysis	
	output to reconcile discordant data,	
	interpretation and report	
0624T	Automated quantification and	Investigational
	characterization of coronary	
	atherosclerotic plaque to assess	
	severity of coronary disease, using	
	data from coronary computed	
	tomographic angiography; data	
0.057	preparation and transmission	
0625T	Automated quantification and	Investigational
	characterization of coronary	
	atherosclerotic plaque to assess	
	severity of coronary disease, using	
	data from coronary computed	
	tomographic angiography;	
	computerized analysis of data from	
	coronary computed tomographic	
0626T	angiography Automated quantification and	Investigational
00201	characterization of coronary	Investigational
	atherosclerotic plaque to assess	
	severity of coronary disease, using	
	data from coronary computed	
	tomographic angiography; review of	
	computerized analysis output to	
	reconcile discordant data,	
	interpretation and report	
0627T	Percutaneous injection of allogeneic	Investigational
	cellular and/or tissue-based product,	·······································
	intervertebral disc, unilateral or	
	bilateral injection, with fluoroscopic	
	guidance, lumbar; first level	
	guidance, lumbar; first level	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	Investigational
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level	Investigational
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	Investigational
0631T	Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity	Investigational
0632T	Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance	Investigational
0633T	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material	Investigational
0634T	Computed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0635T	Computed tomography, breast, including 3D rendering, when	Investigational
	performed, unilateral; without	
	contrast, followed by contrast	
	material(s)	
0636T	Computed tomography, breast,	Investigational
	including 3D rendering, when	
	performed, bilateral; without	
	contrast material(s)	
0637T	Computed tomography, breast,	Investigational
	including 3D rendering, when	
	performed, bilateral; with contrast	
	material(s)	
0638T	Computed tomography, breast,	Investigational
	including 3D rendering, when	
	performed, bilateral; without	
	contrast, followed by contrast material(s)	
0639T	Wireless skin sensor thermal	Investigational
00371	anisotropy measurement(s) and	investigationat
	assessment of flow in cerebrospinal	
	fluid shunt, including ultrasound	
	guidance, when performed	
0640T	Noncontact near-infrared	Investigational
	spectroscopy (eg, for	
	measurement of	
	deoxyhemoglobin, oxyhemoglobin,	
	and ratio of tissue oxygenation),	
	other than for screening for	
	peripheral arterial disease, image	
	acquisition, interpretation, and report; first anatomic site	
0643T	Transcatheter left ventricular	Investigational
	restoration device implantation	intestigationat
	including right and left heart	
	catheterization and left	
	ventriculography when	
	performed, arterial approach	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0646T	Transcatheter tricuspid valve implantation (TTVI)/replacement with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed	Investigational
0647T	Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report	Investigational
0651T	Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report	Investigational
0652T	Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	Investigational
0653T	Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple	Investigational
0654T	Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter	Investigational
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging	Investigational
0656T	Anterior lumbar or thoracolumbar vertebral body tethering; up to 7 vertebral segments	Investigational
0657T	Anterior lumbar or thoracolumbar vertebral body tethering; 8 or more vertebral segments	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0658T	Electrical impedance spectroscopy	Investigational
	of 1 or more skin lesions for	
0659T	automated melanoma risk score	Investigational
00591	Transcatheter intracoronary infusion of supersaturated oxygen	Investigational
	in conjunction with percutaneous	
	coronary revascularization during	
	acute myocardial infarction,	
	including catheter placement,	
	imaging guidance (eg,	
	fluoroscopy), angiography, and	
	radiologic supervision and	
	interpretation	
0660T	Implantation of anterior segment	Investigational
	intraocular nonbiodegradable	
	drug-eluting system, internal	
0661T	approach Removal and reimplantation of	Investigational
00011	anterior segment intraocular	Investigationat
	nonbiodegradable drug-eluting	
	implant	
0664T	Donor hysterectomy (including	Investigational
	cold preservation); open, from	
	cadaver donor	
0665T	Donor hysterectomy (including cold	Investigational
	preservation); open, from living	
0///T	donor	Investigational
0666T	Donor hysterectomy (including	Investigational
	cold preservation); laparoscopic or robotic, from living donor	
0667T	Donor hysterectomy (including	Investigational
	cold preservation); recipient	
	uterus allograft transplantation	
	from cadaver or living donor	
0668T	Backbench standard preparation	Investigational
	of cadaver or living donor uterine	
	allograft prior to transplantation,	
	including dissection and removal	
	of surrounding soft tissues and	
	preparation of uterine vein(s) and	
0669T	uterine artery(ies), as necessary Backbench reconstruction of	Investigational
00071	cadaver or living donor uterus	
	allograft prior to transplantation;	
	venous anastomosis, each	
L		1

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0670T	Backbench reconstruction of	Investigational
	cadaver or living donor uterus	
	allograft prior to transplantation;	
	arterial anastomosis, each	
0672T	Endovaginal cryogen-cooled,	Investigational
	monopolar radiofrequency	
	remodeling of the tissues	
	surrounding the female bladder	
	neck and proximal urethra for	
	urinary incontinence	
0673T	Ablation, benign thyroid	Investigational
	nodule(s), percutaneous, laser,	
	including imaging guidance	
0674T	Laparoscopic insertion of new or	Investigational
	replacement of permanent	
	implantable synchronized	
	diaphragmatic stimulation system	
	for augmentation of cardiac	
	function, including an implantable	
	pulse generator and diaphragmatic	
0/7FT	lead(s)	
0675T	Laparoscopic insertion of new or	Investigational
	replacement of diaphragmatic	
	lead(s), permanent implantable	
	synchronized diaphragmatic	
	stimulation system for	
	augmentation of cardiac function,	
	including connection to an	
0676T	existing pulse generator; first lead	Investigational
00701	Laparoscopic insertion of new or	Investigationat
	replacement of diaphragmatic lead(s), permanent implantable	
	synchronized diaphragmatic	
	stimulation system for	
	augmentation of cardiac function,	
	including connection to an	
	existing pulse generator; each	
	additional lead (List separately in	
	addition to code for primary	
	procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0677T	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first	Investigational
0678T	repositioned lead Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure)	Investigational
0679T	Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	Investigational
0680T	Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s)	Investigational
0681T	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads	Investigational
0682T	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0683T	Programming device evaluation	Investigational
	(in-person) with iterative	
	adjustment of the implantable	
	device to test the function of the	
	device and select optimal	
	permanent programmed values	
	with analysis, review and report	
	by a physician or other qualified	
	health care professional,	
	permanent implantable	
	synchronized diaphragmatic	
	stimulation system for	
	augmentation of cardiac function	
0684T	Peri-procedural device evaluation	Investigational
	(in-person) and programming of	
	device system parameters before	
	or after a surgery, procedure, or	
	test with analysis, review, and	
	report by a physician or other	
	qualified health care professional,	
	permanent implantable	
	synchronized diaphragmatic	
	stimulation system for	
0/057	augmentation of cardiac function	leventingtional
0685T	Interrogation device evaluation (in-	Investigational
	person) with analysis, review and	
	report by a physician or other	
	qualified health care professional,	
	including connection, recording and	
	disconnection per patient	
	encounter, permanent implantable synchronized diaphragmatic	
	stimulation system for augmentation	
	of cardiac function	
0686T	Histotripsy (ie, non-thermal	Investigational
00001	ablation via acoustic energy	investigationat
	delivery) of malignant	
	hepatocellular tissue, including	
	image guidance	
0687T	Treatment of amblyopia using an	Investigational
	online digital program; device	intestigationat
	supply, educational set-up, and	
	initial session	
	111111111 35331011	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0688T	Treatment of amblyopia using an	Investigational
	online digital program;	
	assessment of patient	
	performance and program data by	
	physician or other qualified health	
	care professional, with report,	
	per calendar month	
0689T	Quantitative ultrasound tissue	Investigational
	characterization (non-	
	elastographic), including	
	interpretation and report,	
	obtained without diagnostic	
	ultrasound examination of the	
	same anatomy (eg, organ, gland,	
0/007	tissue, target structure)	
0690T	Quantitative ultrasound tissue	Investigational
	characterization (non-	
	elastographic), including	
	interpretation and report,	
	obtained with diagnostic	
	ultrasound examination of the	
	same anatomy (eg, organ, gland,	
	tissue, target structure) (List	
	separately in addition to code for primary procedure)	
0691T	Automated analysis of an existing	Investigational
00711	computed tomography study for	investigationat
	vertebral fracture(s), including	
	assessment of bone density when	
	performed, data preparation,	
	interpretation, and report	
0693T	Comprehensive full body	Investigational
	computer-based markerless 3D	
	kinematic and kinetic motion	
	analysis and report	
0694T	3-dimensional volumetric imaging	Investigational
	and reconstruction of breast or	ž
	axillary lymph node tissue, each	
	excised specimen, 3-dimensional	
	automatic specimen	
	reorientation, interpretation and	
	report, real-time intraoperative	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0695T	Body surface-activation mapping	Investigational
	of pacemaker or pacing	
	cardioverter-defibrillator lead(s)	
	to optimize electrical synchrony,	
	cardiac resynchronization therapy	
	device, including connection,	
	recording, disconnection, review,	
	and report; at time of implant or	
0/0/ T	replacement	
0696T	Body surface-activation mapping	Investigational
	of pacemaker or pacing	
	cardioverter-defibrillator lead(s)	
	to optimize electrical synchrony,	
	cardiac resynchronization therapy device, including connection,	
	recording, disconnection, review,	
	and report; at time of follow-up	
	interrogation or programming	
	device evaluation	
0697T	Quantitative magnetic resonance	Investigational
	for analysis of tissue composition	
	(eg, fat, iron, water content),	
	including multiparametric data	
	acquisition, data preparation and	
	transmission, interpretation and	
	report, obtained without	
	diagnostic MRI examination of the	
	same anatomy (eg, organ, gland,	
	tissue, target structure) during	
	the same session; multiple organs	
0698T	Quantitative magnetic resonance	Investigational
	for analysis of tissue composition	
	(eg, fat, iron, water content),	
	including multiparametric data	
	acquisition, data preparation and	
	transmission, interpretation and	
	report, obtained with diagnostic MRI examination of the same	
	anatomy (eg, organ, gland, tissue,	
	target structure); multiple organs	
	(List separately in addition to	
	code for primary procedure)	
0700T	Molecular fluorescent imaging of	Investigational
	5 5	
07001	Molecular fluorescent imaging of suspicious nevus; first lesion	investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0701T	Molecular fluorescent imaging of	Investigational
	suspicious nevus; each additional	
	lesion (List separately in addition to code for primary procedure)	
0704T	Remote treatment of amblyopia	Investigational
07041	using an eye tracking device; device	investigationat
	supply with initial set-up and	
	patient education on use of	
	equipment	
0705T	Remote treatment of amblyopia	Investigational
	using an eye tracking device;	
	surveillance center technical	
	support including data transmission	
	with analysis, with a minimum of 18	
0706T	training hours, each 30 days	Investigational
07061	Remote treatment of amblyopia using an eye tracking device;	Investigational
	interpretation and report by	
	physician or other qualified health	
	care professional, per calendar	
	month	
0707T	Injection(s), bone substitute	Investigational
	material (eg, calcium phosphate)	
	into subchondral bone defect (ie,	
	bone marrow lesion, bone bruise,	
	stress injury, microtrabecular	
	fracture), including imaging	
	guidance and arthroscopic assistance	
0708T	for joint visualization Intradermal cancer immunotherapy;	Investigational
07001	preparation and initial injection	investigationat
0709T	Intradermal cancer immunotherapy;	Investigational
	each additional injection (List	Jan 1
	separately in addition to code for	
	primary procedure)	
0710T	Noninvasive arterial plaque analysis	Investigational
	using software processing of data	
	from non-coronary computerized	
	tomography angiography; including	
	data preparation and transmission,	
	quantification of the structure and	
	composition of the vessel wall and assessment for lipid-rich necrotic	
	core plaque to assess atherosclerotic	
	plaque stability, data review,	
	interpretation and report	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0711T	Noninvasive arterial plaque analysis using software processing of data	Investigational
	from non-coronary computerized	
	tomography angiography; data	
	preparation and transmission	
0712T	Noninvasive arterial plaque analysis	Investigational
	using software processing of data	
	from non-coronary computerized tomography angiography;	
	quantification of the structure and	
	composition of the vessel wall and	
	assessment for lipid-rich necrotic	
	core plaque to assess atherosclerotic	
07407	plaque stability	
0713T	Noninvasive arterial plaque analysis	Investigational
	using software processing of data from non-coronary computerized	
	tomography angiography; data	
	review, interpretation and report	
0714T	Transperineal laser ablation of	Investigational
	benign prostatic hyperplasia,	
	including imaging guidance;	
	prostate volume less than 50 mL	
0716T	Cardiac acoustic waveform	Investigational
	recording with automated analysis	
	and generation of coronary artery disease risk score	
0717T	"Autologous adipose-derived	Investigational
	regenerative cell (ADRC) therapy	5
	for partial thickness rotator cuff	
	tear; adipose tissue harvesting,	
	isolation and preparation of	
	harvested cells, including	
	incubation with cell dissociation	
	enzymes, filtration, washing and concentration of ADRCs	
0718T	Autologous adipose-derived	Investigational
	regenerative cell (ADRC) therapy	~
	for partial thickness rotator cuff	
	tear; injection into supraspinatus	
	tendon including ultrasound	
	guidance, unilateral	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0719T	Posterior vertebral joint	Investigational
	replacement, including bilateral	
	facetectomy, laminectomy, and	
	radical discectomy, including	
	imaging guidance, lumbar spine,	
0724T	single segment	Investigational
0721T	Quantitative computed	Investigational
	tomography (CT) tissue characterization, including	
	interpretation and report,	
	obtained without concurrent CT	
	examination of any structure	
	contained in previously acquired	
	diagnostic imaging	
0722T	Quantitative computed	Investigational
	tomography (CT) tissue	
	characterization, including	
	interpretation and report,	
	obtained with concurrent CT	
	examination of any	
	structure contained in the	
	concurrently acquired diagnostic imaging dataset (List	
	separately in addition to code for	
	primary procedure)	
0723T	Quantitative magnetic resonance	Investigational
	cholangiopancreatography	5
	(QMRCP) including data	
	preparation and transmission,	
	interpretation and report,	
	obtained without diagnostic	
	magnetic resonance imaging (MRI)	
	examination of the same anatomy	
	(eg, organ, gland, tissue, target	
0724T	structure) during the same session Quantitative magnetic resonance	Investigational
07241	cholangiopancreatography (QMRCP)	Investigationat
	including data preparation and	
	transmission, interpretation and	
	report, obtained with diagnostic	
	magnetic resonance imaging (MRI)	
	examination of the same anatomy	
	(eg, organ, gland, tissue, target	
	structure) (List separately in	
	addition to code for primary	
	procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0725T	Vestibular device implantation, unilateral	Investigational
0726T	Removal of implanted vestibular device, unilateral	Investigational
0727T	Removal and replacement of implanted vestibular device, unilateral	Investigational
0728T	Diagnostic analysis of vestibular implant, unilateral; with initial programming	Investigational
0729T	with subsequent programming (For initial and subsequent diagnostic analysis and programming of cochlear implant	Investigational
0730T	Trabeculotomy by laser, including optical coherence tomography (OCT) guidance	Investigational
0731T	Augmentative AI-based facial phenotype analysis with report	Investigational
0732T	Immunotherapy administration with electroporation, intramuscular	Investigational
0733T	Remote therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days	Investigational
0734T	Remote body and limb kinematic measurement-based therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days; treatment management services by a physician or other qualified health care professional, per calendar month"	Investigational
0735T	"Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0736T	Colonic lavage, 35 or more liters of water, gravity-fed, with induced	Investigational
	defecation, including insertion of rectal catheter	
0737T	Xenograft implantation into the articular surface	Investigational
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination	Investigational
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation	Investigational
0740T	Remote autonomous algorithm- based recommendation system for insulin dose calculation and titration; initial set-up and patient education	Investigational
0741T	Remote autonomous algorithm- based recommendation system for insulin dose calculation and titration; initial set-up and patient education; provision of software, data collection, transmission, and storage, each 30 days	Investigational
0742T	Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List separately in addition to code for primary procedure)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0743T	Bone strength and fracture risk	Investigational
	usig finite element analysis of	
	functional data and bone-mineral	
	density, with concurrent vertebral	
	fracture assessment, utilizing data	
	from a computed tomography	
	scan, retrieval and transmission of	
	the scan data, measurement of	
	bone strength and bone mineral	
	density and classification of any	
	vertebral fractures, with overall	
	fracture risk assessment,	
	interpretation and report	
0744T	Insertion of bioprosthetic valve,	Investigational
	open, femoral vein, including	
	duplex ultrasound imaging	
	guidance, when performed,	
	including autogenous or	
	nonautogenous patch graft (eg,	
	polyester, ePTFE, bovine	
	pericardium), when performed	
0745T	Cardiac focal ablation utilizing	Investigational
	radiation therapy for arrhythmia;	
	noninvasive arrhythmia	
	localization and mapping of	
	arrhythmia site (nidus), derived	
	from anatomical image data (eg,	
	CT, MRI, or myocardial perfusion	
	scan) and electrical data (eg, 12-	
	lead ECG data), and identification	
0746T	of areas of avoidance	Investigational
07461	Cardiac focal ablation utilizing	Investigational
	radiation therapy for arrhythmia;	
	conversion of arrhythmia	
	localization and mapping of	
	arrhythmia site (nidus) into a	
	multidimensional radiation	
0747T	treatment plan	Investigational
0/4/1	Cardiac focal ablation utilizing	Investigational
	radiation therapy for arrhythmia;	
	delivery of radiation therapy,	
	arrhythmia	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0748T	Injections of stem cell product into perianal perifistular soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings)	Investigational
0749T	Bone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report	Investigational
0750T	Bone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report; with single-view digital X- ray examination of the hand taken for the purpose of DXR-BMD	Investigational
0751T	Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational
0752T	Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0753T	Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational
0754T	Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational
0755T	Digitization of glass microscope slide for level VI, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational
0756T	Digitization of glass microscope slides for special stain, including interpretation and report, group I, for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for primary procedure)	Investigational
0757T	Digitization of glass microscope slides for special stain, including interpretation and report, group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry (List separately in addition to code for primary procedure)	Investigational
0758T	Digitization of glass microscope slides for special stain, including interpretation and report, histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0759T	Digitization of glass microscope	Investigational
	slides for special stain, including	
	interpretation and report, group	
	III, for enzyme constituents (List	
	separately in addition to code for	
07/07	primary procedure)	
0760T	Digitization of glass microscope	Investigational
	slides for immunohistochemistry	
	or immunocytochemistry, per	
	specimen, initial single antibody	
	stain procedure (List separately in	
	addition to code for primary	
0761T	procedure)	Investigational
07011	Digitization of glass microscope slides for immunohistochemistry	Investigational
	or immunocytochemistry, per	
	specimen, each additional single	
	antibody stain procedure (List	
	separately in addition to code for	
	primary procedure)	
0762T	Digitization of glass microscope	Investigational
	slides for immunohistochemistry	
	or immunocytochemistry, per	
	specimen, each multiplex	
	antibody stain procedure (List	
	separately in addition to code for	
	primary procedure)	
0763T	Digitization of glass microscope	Investigational
	slides for morphometric analysis,	
	tumor immunohistochemistry (eg,	
	Her-2/neu, estrogen	
	receptor/progesterone receptor),	
	quantitative or semiquantitative,	
	per specimen, each single	
	antibody stain procedure, manual	
	(List separately in addition to	
	code for primary procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0764T	Assistive algorithmic	Investigational
	electrocardiogram risk-based	
	assessment for cardiac	
	dysfunction (eg, low-ejection	
	fraction, pulmonary hypertension,	
	hypertrophic cardiomyopathy);	
	related to concurrently performed	
	electrocardiogram (List separately	
	in addition to code for primary	
07/57	procedure)	
0765T	Assistive algorithmic	Investigational
	electrocardiogram risk-based	
	assessment for cardiac	
	dysfunction (eg, low-ejection	
	fraction, pulmonary hypertension,	
	hypertrophic cardiomyopathy);	
	related to previously performed	
0766T	electrocardiogram Transcutaneous magnetic	Investigational
07001	stimulation by focused low-	Investigationat
	frequency electromagnetic pulse,	
	peripheral nerve, with	
	identification and marking of the	
	treatment location, including	
	noninvasive electroneurographic	
	localization (nerve conduction	
	localization), when performed;	
	first nerve	
0767T	Transcutaneous magnetic	Investigational
	stimulation by focused low-	_
	frequency electromagnetic pulse,	
	peripheral nerve, with	
	identification and marking of the	
	treatment location, including	
	noninvasive electroneurographic	
	localization (nerve conduction	
	localization), when performed;	
	each additional nerve (List	
	separately in addition to code for	
07707	primary procedure)	
0770T	Virtual reality technology to assist	Investigational
	therapy (List separately in	
	addition to code for primary	
	procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0771T	Virtual reality (VR) procedural	Investigational
	dissociation services provided by	
	the same physician or other	
	qualified health care professional	
	performing the diagnostic or	
	therapeutic service that the VR	
	procedural dissociation supports,	
	requiring the presence of an	
	independent, trained observer to	
	assist in the monitoring of the	
	patient's level of dissociation or	
	consciousness and physiological	
	status; initial 15 minutes of	
	intraservice time, patient age 5	
	years or older	
0772T	Virtual reality (VR) procedural	Investigational
	dissociation services provided by	
	the same physician or other	
	qualified health care professional	
	performing the diagnostic or	
	therapeutic service that the VR	
	procedural dissociation supports,	
	requiring the presence of an	
	independent, trained observer to	
	assist in the monitoring of the	
	patient's level of dissociation or	
	consciousness and physiological	
	status; each additional 15 minutes	
	intraservice time (List separately	
	in addition to code for primary	
	service)	
0773T	Virtual reality (VR) procedural	Investigational
	dissociation services provided by a	
	physician or other qualified health	
	care professional other than the	
	physician or other qualified health	
	care professional performing the	
	diagnostic or therapeutic service	
	that the VR procedural	
	dissociation supports; initial 15	
	minutes of intraservice time,	
	patient age 5 years or older	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0774T	Virtual reality (VR) procedural dissociation services provided by a	Investigational
	physician or other qualified health	
	care professional other than the physician or other qualified health	
	care professional performing the	
	diagnostic or therapeutic service	
	that the VR procedural	
	dissociation supports; each	
	additional 15 minutes intraservice	
	time (List separately in	
	addition to code for primary	
0776T	service) Therapeutic induction of intra-	Investigational
0//01	brain hypothermia, including	investigationat
	placement of a mechanical	
	temperature-controlled cooling	
	device to the neck over carotids	
	and head, including monitoring	
	(eg, vital signs and sport	
	concussion assessment tool 5	
0777T	[SCAT5]), 30 minutes of treatment	Investigational
07771	Real-time pressure-sensing epidural guidance system (List	Investigationat
	separately in addition to code for	
	primary procedure)	
0778T	Surface mechanomyography	Investigational
	(sMMG) with concurrent	
	application of inertial	
	measurement unit (IMU) sensors	
	for measurement of multi-joint	
	range of motion, posture, gait,	
0779T	and muscle function Gastrointestinal myoelectrical	Investigational
0///1	activity study, stomach through	investigationat
	colon, with interpretation and	
	report	
0780T	Instillation of fecal microbiota	Investigational
	suspension via rectal enema into	
	lower gastrointestinal tract	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0781T	Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi	Investigational
0782T	Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus	Investigational
0783T	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment	Investigational
0790T	Revision (eg, augmentation, division of tether), replacement, or removal of thoracolumbar or lumbar vertebral body tethering, including thoracoscopy, when performed	Investigational
0791T	Motor-cognitive, semi-immersive virtual reality-facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure)	Investigational
0792T	Application of silver diamine fluoride 38%, by a physician or other qualified health care professional	Investigational
0793T	Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0794T	Patient-specific, assistive, rules- based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately	Investigational
0795T	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; complete system (i.e., right atrial and right ventricular pacemaker components)	Investigational
0796T	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0797T	Transcatheter insertion of	Investigational
	permanent dual-chamber leadless	
	pacemaker, including imaging	
	guidance (e.g., fluoroscopy,	
	venous ultrasound, right atrial	
	angiography, right	
	ventriculography, femoral	
	venography) and device	
	evaluation (e.g., interrogation or	
	programming), when performed;	
	right ventricular pacemaker	
	component (when part of a dual-	
	chamber leadless pacemaker	
0798T	system)	Investigational
0/981	Transcatheter removal of	Investigational
	permanent dual-chamber leadless	
	pacemaker, including imaging	
	guidance (e.g., fluoroscopy, venous ultrasound, right atrial	
	angiography, right	
	ventriculography, femoral	
	venography), when performed;	
	complete system (i.e., right atrial	
	and right ventricular pacemaker	
	components)	
0799T	Transcatheter removal of	Investigational
	permanent dual-chamber leadless	
	pacemaker, including imaging	
	guidance (e.g., fluoroscopy,	
	venous ultrasound, right atrial	
	angiography, right	
	ventriculography, femoral	
	venography), when performed;	
	right atrial pacemaker component	
0800T	Transcatheter removal of	Investigational
	permanent dual-chamber leadless	
	pacemaker, including imaging	
	guidance (e.g., fluoroscopy,	
	venous ultrasound, right atrial	
	angiography, right	
	ventriculography, femoral	
	venography), when performed;	
	right ventricular pacemaker	
	component (when part of a dual-	
	chamber leadless pacemaker	
	system)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0801T	Transcatheter removal and replacement of permanent dual-	Investigational
	chamber leadless pacemaker,	
	including imaging guidance (e.g.,	
	fluoroscopy, venous ultrasound,	
	right atrial angiography, right	
	ventriculography, femoral	
	venography) and device	
	evaluation (e.g., interrogation or	
	programming), when performed; dual-chamber system (i.e., right	
	atrial and right ventricular	
	pacemaker components)	
0802T	Transcatheter removal and	Investigational
	replacement of permanent dual-	
	chamber leadless pacemaker,	
	including imaging guidance (e.g.,	
	fluoroscopy, venous ultrasound,	
	right atrial angiography, right	
	ventriculography, femoral	
	venography) and device	
	evaluation (e.g., interrogation or	
	programming), when performed;	
0803T	right atrial pacemaker component Transcatheter removal and	Investigational
00051	replacement of permanent dual-	Investigationat
	chamber leadless pacemaker,	
	including imaging guidance (e.g.,	
	fluoroscopy, venous ultrasound,	
	right atrial angiography, right	
	ventriculography, femoral	
	venography) and device	
	evaluation (e.g., interrogation or	
	programming), when performed;	
	right ventricular pacemaker	
	component (when part of a dual-	
	chamber leadless pacemaker	
	system)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0804T	Programming device evaluation	Investigational
	(in person) with iterative	
	adjustment of implantable device	
	to test the function of device and	
	to select optimal permanent	
	programmed values, with analysis,	
	review, and report, by a physician	
	or other qualified health care	
	professional, leadless pacemaker	
0805T	system in dual cardiac chambers	Investigational
00001	Transcatheter superior and	Investigational
	inferior vena cava prosthetic	
	valve implantation (i.e., caval	
	valve implantation [CAVI]);	
	percutaneous femoral vein	
0806T	approach Transcatheter superior and	Investigational
00001	inferior vena cava prosthetic	Investigationat
	valve implantation (i.e., caval	
	valve implantation [CAVI]); open	
	femoral vein approach	
0807T	Pulmonary tissue ventilation	Investigational
	analysis using software-based	
	processing of data from	
	separately captured	
	cinefluorograph images; in	
	combination with previously	
	acquired computed tomography	
	(CT) images, including data	
	preparation and transmission,	
	quantification of pulmonary tissue	
	ventilation, data review,	
	interpretation and report	
0808T	Pulmonary tissue ventilation	Investigational
	analysis using software-based	
	processing of data from	
	separately captured	
	cinefluorograph images; in	
	combination with computed	
	tomography (CT) images taken for	
	the purpose of pulmonary tissue	
	ventilation analysis, including	
	data preparation and	
	transmission, quantification of	
	pulmonary tissue ventilation, data	
	review, interpretation and report	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0811T	Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); setup and patient education on use of equipment	Investigational
0812T	Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); device supply with automated report generation, up to 10 days	Investigational
0813T	Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon	Investigational
0814T	Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral	Investigational
0815T	Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bonedensity study and fracture-risk assessment, 1 or more sites, hips, pelvis or spine	Investigational
0820T	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour	Investigational
0821T	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0822T	Continuous in-person monitoring	Investigational
	and intervention (eg,	
	psychotherapy, crisis	
	intervention), as needed, during	
	psychedelic medication therapy;	
	clinical staff under the direction	
	of a physician or other qualified	
	health care professional, concurrent with first physician or	
	other gualified health care	
	professional, each hour (List	
	separately in addition to code for	
	primary procedure)	
0827T	Digitization of glass microscope	Investigational
	slides for cytopathology, fluids,	5
	washings, or brushings, except	
	cervical or vaginal; smears with	
	interpretation (List separately in	
	addition to code for primary	
	procedure) (Use 0827T in	
	conjunction with 88104)	
0828T	Digitization of glass microscope	Investigational
	slides for cytopathology, fluids,	
	washings, or brushings, except	
	cervical or vaginal; simple filter	
	method with interpretation (List	
	separately in addition to code	
	for primary procedure) (Use 0828T in conjunction with	
	88106)	
0829T	Digitization of glass microscope	Investigational
	slides for cytopathology,	estigationat
	concentration technique, smears,	
	and interpretation (eg,	
	Saccomanno technique) (List	
	separately in addition to code for	
	primary procedure) (Use 0829T in	
	conjunction with 88108)	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0830T	Digitization of glass microscope	Investigational
	slides for cytopathology,	
	selective-cellular enhancement	
	technique with interpretation (eg,	
	liquid-based slide preparation	
	method), except cervical or	
	vaginal (List separately in addition	
	to code for primary procedure)	
	(Use 0830T in conjunction with 88112)	
0831T	Digitization of glass microscope	Investigational
	slides for cytopathology, cervical	Jan 1
	or vaginal (any reporting system),	
	requiring interpretation by	
	physician (List separately in	
	addition to code for primary	
	procedure) (Use 0831T in	
	conjunction with 88141)	
0832T	Digitization of glass microscope	Investigational
	slides for cytopathology, smears,	
	any other source; screening and	
	interpretation (List separately in	
	addition to code for primary	
	procedure)	
	(Use 0832T in conjunction with	
	88160)	
0833T	Digitization of glass microscope	Investigational
	slides for cytopathology, smears,	
	any other source; preparation,	
	screening and interpretation (List	
	separately in addition to code for	
	primary procedure)	
	(Use 0833T in conjunction with	
	88161)	
0834T	Digitization of glass microscope	Investigational
	slides for cytopathology, smears,	
	any other source; extended study	
	involving over 5 slides and/or	
	multiple stains (List separately in	
	addition to code for primary	
	procedure) (Use 0834T in	
	conjunction with 88162)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0835T	Digitization of glass microscope	Investigational
	slides for cytopathology,	
	evaluation of fine needle	
	aspirate; immediate	
	cytohistologic study to determine adequacy for diagnosis, first	
	evaluation episode, each site (List	
	separately in addition to code for	
	primary procedure)	
	(Use 0835T in conjunction with	
	88172)	
0836T	Digitization of glass microscope	Investigational
	slides for cytopathology,	
	evaluation of fine needle	
	aspirate; immediate	
	cytohistologic study to determine	
	adequacy for diagnosis, each	
	separate additional evaluation	
	episode, same site (List separately in	
	addition to code for primary	
	procedure) (Use 0836T in	
	conjunction with 88177)	
0837T	Digitization of glass microscope	Investigational
	slides for cytopathology,	
	evaluation of fine needle	
	aspirate; interpretation and	
	report (List separately in addition	
	to code for primary procedure)	
	(Use 0837T in conjunction with 88173)	
0838T	Digitization of glass microscope	Investigational
	slides for consultation and report	
	on referred slides prepared	
	elsewhere (List separately in	
	addition to code for primary	
	procedure)	
	(Use 0838T in conjunction with	
00007	88321)	
0839T	Digitization of glass microscope	Investigational
	slides for consultation and report	
	on referred material requiring	
	preparation of slides (List separately in addition to code for	
	primary procedure) (Use 0839T in	
	conjunction with 88323)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0840T	Digitization of glass microscope	Investigational
	slides for consultation,	
	comprehensive, with review of	
	records and specimens, with	
	report on referred material (List	
	separately in addition to code for	
	primary procedure) (Use 0840T in	
	conjunction with 88325)	
0841T	Digitization of glass microscope	Investigational
	slides for pathology consultation	
	during surgery; first tissue block,	
	with frozen section(s), single	
	specimen (List separately in	
	addition to code for primary	
	procedure) (Use 0841T in	
0842T	conjunction with 88331)	Investigational
08421	Digitization of glass microscope	Investigational
	slides for pathology consultation	
	during surgery; each additional tissue block with frozen section(s)	
	(List separately in addition to	
	code for primary procedure) (Use 0842T in conjunction with	
	88332)	
0843T	Digitization of glass microscope	Investigational
00151	slides for pathology consultation	investigationat
	during surgery; cytologic	
	examination (eg, touch	
	preparation, squash preparation),	
	initial site (List separately in	
	addition to code for primary	
	procedure) (Use 0843T in	
	conjunction with 88333)	
0844T	Digitization of glass microscope	Investigational
	slides for pathology consultation	
	during surgery; cytologic	
	examination (eg, touch	
	preparation, squash preparation),	
	each additional site (List	
	separately in addition to code for	
	primary procedure) (Use 0844T in	
	conjunction with 88334)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0845T	Digitization of glass microscope slides for immunofluorescence, per specimen; initial single antibody stain procedure (List separately in addition to code for primary procedure) (Use 0845T in conjunction with 88346)	Investigational
0846T	Digitization of glass microscope slides for immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure) (Use 0846 Cystourethroscopy, with urethral mechanical dilation and drug delivery by drug-coated balloon catheter T in conjunction with 88350)	Investigational
0847T	Digitization of glass microscope slides for examination and selection of retrieved archival (ie, previously diagnosed) tissue(s) for molecular analysis (eg, KRAS mutational analysis) (List separately in addition to code for primary procedure) (Use 0847T in conjunction with 88363)	Investigational
0848T	Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure) (Use 0848T in conjunction with 88365)	Investigational
0849T	Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure) (Use 0849T in conjunction with 88364)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0850T	Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure) (Use 0850T in conjunction with 88366)	Investigational
0851T	Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure) (Use 0851T in conjunction with 88368)	Investigational
0852T	Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure) (Use 0852T in conjunction with 88369)	Investigational
0853T	Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure) (Use 0853T in conjunction with 88377)	Investigational
0854T	Digitization of glass microscope slides for blood smear, peripheral, interpretation by physician with written report (List separately in addition to code for primary procedure) (Use 0854T in conjunction with 85060)	Investigational

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0855T	Digitization of glass microscope	Investigational
	slides for bone marrow, smear	
	interpretation (List separately in	
	addition to code for primary	
	procedure) (Use 0855T in	
	conjunction with 85097)	
0856T	Digitization of glass microscope	Investigational
	slides for electron microscopy,	
	diagnostic (List separately in	
	addition to code for primary	
	procedure)	
	(Use 0856T in conjunction with	
0857T	88348)	Investigational
00571	Opto-acoustic imaging, breast,	Investigational
	unilateral, including axilla when performed, realtime with image	
	documentation, augmentative	
	analysis and report (List	
	separately in addition to code for	
	primary procedure) (Use 0857T in	
	conjunction with 76641, 76642)	
0858T	Externally applied transcranial	Investigational
	magnetic stimulation with	
	concomitant measurement of	
	evoked cortical potentials with	
	automated report (Do not report	
	0858T in conjunction with 95836,	
	95957, 95961, 95965, 95966)	
0859T	Noncontact near-infrared	Investigational
	spectroscopy (eg, for	_
	measurement of	
	deoxyhemoglobin, oxyhemoglobin,	
	and ratio of tissue oxygenation),	
	other than for screening for	
	peripheral arterial disease, image	
	acquisition, interpretation, and	
	report; each additional anatomic	
	site (List separately in addition to	
	code for primary procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0860T	Noncontact near-infrared	Investigational
	spectroscopy (eg, for	
	measurement of	
	deoxyhemoglobin, oxyhemoglobin,	
	and ratio of tissue oxygenation),	
	for screening for peripheral	
	arterial disease, including	
	provocative maneuvers, image	
	acquisition, interpretation, and	
	report, one or both lower extremities	
0861T	Removal of pulse generator for	Investigational
00011	wireless cardiac stimulator for	investigationat
	left ventricular pacing; both	
	components (battery and	
	transmitter)	
0862T	Relocation of pulse generator for	Investigational
	wireless cardiac stimulator for	_
	left ventricular pacing, including	
	device interrogation and	
	programming; battery component	
	only	
0863T	Relocation of pulse generator for	Investigational
	wireless cardiac stimulator for	
	left ventricular pacing, including	
	device interrogation and	
	programming; transmitter	
0864T	component only Low-intensity extracorporeal	Investigational
0001	shock wave therapy involving	investigationat
	corpus cavernosum, low energy	
	(Do not report 0864T in	
	conjunction with 0101T when	
	treating the same area)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0865T	Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the brain during the same session (Do not report 0865T in conjunction with 70551, 70552, 70553)	Investigational
0866T	Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion detection, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the brain (List separately in addition to code for primary procedure) (Use 0866T in conjunction with 70551, 70552, 70553)	Investigational
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL	Investigational
0868T	High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0870T	Implantation of subcutaneous	Investigational
	peritoneal ascites pump system,	
	percutaneous, including pump- pocket creation, insertion of	
	tunneled indwelling bladder and	
	peritoneal catheters with pump	
	connections, including all imaging	
	and initial programming, when	
	performed	
0871T	Replacement of a subcutaneous	Investigational
	peritoneal ascites pump, including	
	reconnection between pump and	
	indwelling bladder and peritoneal catheters, including initial	
	programming and imaging, when	
	performed	
0872T	Replacement of indwelling	Investigational
	bladder and peritoneal catheters,	
	including tunneling of catheter(s)	
	and connection with previously	
	implanted peritoneal ascites	
	pump, including imaging and	
0873T	programming, when performed Revision of a subcutaneously	Investigational
00751	implanted peritoneal ascites	investigationat
	pump system, any component	
	(ascites pump, associated	
	peritoneal catheter, associated	
	bladder catheter), including	
	imaging and programming, when	
0874T	performed	Investigational
00/41	Removal of a peritoneal ascites pump system, including implanted	Investigational
	peritoneal ascites pump and	
	indwelling bladder and peritoneal	
	catheters	
0875T	Programming of subcutaneously	Investigational
	implanted peritoneal ascites	
	pump system by physician or	
	other qualified health care	
097/T	professional	Investigational
0876T	Duplex scan of hemodialysis	Investigational
	fistula, computer-aided, limited (volume flow, diameter, and	
	depth, including only body of	
	fistula)	
L	i i statu)	

0877T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging Investigational 0878T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure Investigational 0879T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure Investigational 0879T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission Investigational 0880T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report Investigational 0881T Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to transmet and removal of the transmet and removal of the	CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
 imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic inaging 0878T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure 0879T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure 0879T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission 0880T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report 0881T Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to 	0877T	· ·	Investigational
categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging0878TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging Investigational 0878T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure Investigational 0879T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission Investigational 0880T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission Investigational 0880T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report Investigational 0881T Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to Investigational			
disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging0878TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational		• • • •	
concurrent CT examination of any structure contained in previously acquired diagnostic imaging0878TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
structure contained in previously acquired diagnostic imaging0878TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity 			
acquired diagnostic imaging0878TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
0878TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
 computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure 0879T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission 0880T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission 0880T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report 0881T Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to 			
imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational	08781		Investigational
categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide 			
classification of interstitial lung disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide classification and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
disease; obtained with concurrent CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational		• • • •	
CT examination of the same structureInvestigational0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational		-	
structure0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission 0880T Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report 0881T Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to	0970T		Investigational
imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational	08/91	• •	Investigational
categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
classification of interstitial lung disease; radiological data preparation and transmissionInvestigational0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
disease; radiological data preparation and transmission0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational		• • • •	
preparation and transmission0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational		-	
0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report 0881T Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to	0880T		Investigational
imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report 0881T Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to	00001	• •	Investigationat
categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
classification of interstitial lung disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, 			
disease; physician or other qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational		• • • •	
qualified health care professional interpretation and reportInvestigational0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational		-	
interpretation and report0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance toInvestigational			
0881T Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to			
using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to	0881T		Investigational
cooling system, including placement of an oral device, monitoring of patient tolerance to			
placement of an oral device, monitoring of patient tolerance to			
monitoring of patient tolerance to			
		•	
		treatment, and removal of the	
oral device		·	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0882T	Intraoperative therapeutic	Investigational
	electrical stimulation of	
	peripheral nerve to promote	
	nerve regeneration, including lead	
	placement and removal, upper	
	extremity, minimum of 10	
	minutes; initial nerve (List	
	separately in addition to code for	
	primary procedure)	
0883T	Intraoperative therapeutic	Investigational
	electrical stimulation of	
	peripheral nerve to promote	
	nerve regeneration, including lead	
	placement and removal, upper	
	extremity, minimum of 10	
	minutes; each additional nerve	
	(List separately in addition to	
	code for primary procedure)	
0884T	Esophagoscopy, flexible,	Investigational
	transoral, with initial	
	transendoscopic mechanical	
	dilation (eg, nondrug-coated	
	balloon) followed by therapeutic	
	drug delivery by drug-coated	
	balloon catheter for esophageal	
	stricture, including fluoroscopic	
	guidance, when performed	
0885T	Colonoscopy, flexible, with initial	Investigational
	transendoscopic mechanical	
	dilation (eg, nondrug-coated	
	balloon) followed by therapeutic	
	drug delivery by drug-coated	
	balloon catheter for colonic	
	stricture, including fluoroscopic	
	guidance, when performed	
0886T	Sigmoidoscopy, flexible, with	Investigational
	initial transendoscopic mechanical	
	dilation (eg, nondrug-coated	
	balloon) followed by therapeutic	
	drug delivery by drug-coated	
	balloon catheter for colonic	
	stricture, including fluoroscopic	
	guidance, when performed	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0887T	End-tidal control of inhaled	Investigational
	anesthetic agents and oxygen to	
	assist anesthesia care delivery	
	(List separately in addition to	
	code for primary procedure)	
0888T	Histotripsy (ie, non-thermal	Investigational
	ablation via acoustic energy	
	delivery) of malignant renal	
	tissue, including imaging guidance	
0889T	Personalized target development	Investigational
	for accelerated, repetitive high-	
	dose functional connectivity MRI-	
	guided theta-burst stimulation	
	derived from a structural and	
	resting-state functional MRI,	
	including data preparation and	
	transmission, generation of the	
	target, motor threshold-starting	
	location, neuronavigation files	
	and target report, review and	
	interpretation	
0890T	Accelerated, repetitive high-dose	Investigational
	functional connectivity MRI-	
	guided theta-burst stimulation,	
	including target assessment,	
	initial motor threshold	
	determination, neuronavigation,	
	delivery and management, initial	
	treatment day	
0891T	Accelerated, repetitive high-dose	Investigational
	functional connectivity MRI-	
	guided theta-burst stimulation,	
	including neuronavigation,	
	delivery and management,	
	subsequent treatment day	
0892T	Accelerated, repetitive high-dose	Investigational
	functional connectivity MRI-	
	guided theta-burst stimulation,	
	including neuronavigation,	
	delivery and management,	
	subsequent motor threshold	
	redetermination with delivery and	
	management, per treatment day	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0893T	Noninvasive assessment of blood	Investigational
	oxygenation, gas exchange	
	efficiency, and cardiorespiratory	
	status, with physician or other	
	qualified health care professional	
	interpretation and report	
0894T	Cannulation of the liver allograft	Investigational
	in preparation for connection to	
	the normothermic perfusion	
	device and decannulation of the	
	liver allograft following	
	normothermic perfusion	
0895T	Connection of liver allograft to	Investigational
	normothermic machine perfusion	
	device, hemostasis control; initial	
	4 hours of monitoring time,	
	including hourly physiological and	
	laboratory assessments (eg,	
	perfusate temperature, perfusate	
	pH, hemodynamic parameters,	
	bile production, bile pH, bile	
	glucose, biliary bicarbonate,	
	lactate levels, macroscopic	
0896T	assessment)	Investigational
08901	Connection of liver allograft to	Investigational
	normothermic machine perfusion	
	device, hemostasis control; each	
	additional hour, including	
	physiological and laboratory	
	assessments (eg, perfusate	
	temperature, perfusate pH,	
	hemodynamic parameters, bile	
	production, bile pH, bile glucose, biliary bicarbonate, lactate	
	levels, macroscopic assessment) (List separately in addition to	
	code for primary procedure)	
	code for primary procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0897T	Noninvasive augmentative	Investigational
	arrhythmia analysis derived from	
	quantitative computational	
	cardiac arrhythmia simulations,	
	based on selected intervals of	
	interest from 12-lead	
	electrocardiogram and uploaded	
	clinical parameters, including	
	uploading clinical parameters with	
	interpretation and report	
0898T	Noninvasive prostate cancer	Investigational
	estimation map, derived from	
	augmentative analysis of image-	
	guided fusion biopsy and	
	pathology, including visualization	
	of margin volume and location,	
	with margin determination and physician interpretation and	
	report	
0899T	Noninvasive determination of	Investigational
00771	absolute quantitation of	investigationat
	myocardial blood flow (AQMBF),	
	derived from augmentative	
	algorithmic analysis of the dataset	
	acquired via contrast cardiac	
	magnetic resonance (CMR),	
	pharmacologic stress, with	
	interpretation and report by a	
	physician or other qualified health	
	care professional (List separately	
	in addition to code for primary	
	procedure)	
0900T	Noninvasive estimate of absolute	Investigational
	quantitation of myocardial blood	
	flow (AQMBF), derived from	
	assistive algorithmic analysis of	
	the dataset acquired via contrast	
	cardiac magnetic resonance	
	(CMR), pharmacologic stress, with	
	interpretation and report by a	
	physician or other qualified health	
	care professional (List separately	
	in addition to code for primary	
	procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0901T	Placement of bone marrow	Investigational
	sampling port, including imaging	
00007	guidance when performed	
0902T	QTc interval derived by	Investigational
	augmentative algorithmic analysis	
	of input from an external, patient-activated mobile ECG	
	device	
0903T	Electrocardiogram,	Investigational
0,001	algorithmically generated 12-lead	investigationat
	ECG from a reduced-lead ECG;	
	with interpretation and report	
0904T	Electrocardiogram,	Investigational
	algorithmically generated 12-lead	5
	ECG from a reduced-lead ECG;	
	tracing only	
0905T	Electrocardiogram,	Investigational
	algorithmically generated 12-lead	
	ECG from a reduced-lead ECG;	
	interpretation and report only	
0906T	Concurrent optical and magnetic	Investigational
	stimulation (COMS) therapy,	
	wound assessment and dressing	
	care; first application, total	
	wound(s) surface area less than or equal to 50 sq cm	
0907T	Concurrent optical and magnetic	Investigational
	stimulation (COMS) therapy,	in escigacionat
	wound assessment and dressing	
	care; each additional application,	
	total wound(s) surface area less	
	than or equal to 50 sq cm (List	
	separately in addition to code for	
	primary procedure)	
0908T	Open implantation of integrated	Investigational
	neurostimulation system, vagus	
	nerve, including analysis and	
0909T	programming, when performed	Investigational
09091	Replacement of integrated	Investigational
	neurostimulation system, vagus	
	nerve, including analysis and programming, when performed	
0910T	Removal of integrated	Investigational
	neurostimulation system, vagus	investigationat
	nerve	
L		

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0911T	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; without programming by physician or other qualified health care professional	Investigational
0912T	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; with simple programming by physician or other qualified health care professional	Investigational
0913T	Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug- eluting), including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0914T	Percutaneous transcatheter	Investigational
	therapeutic drug delivery by	
	intracoronary drug-delivery	
	balloon (eg, drug-coated, drug-	
	eluting) performed on a separate	
	target lesion from the target	
	lesion treated with balloon	
	angioplasty, coronary stent	
	placement or coronary	
	atherectomy, including	
	mechanical dilation by nondrug-	
	delivery balloon angioplasty,	
	endoluminal imaging using	
	intravascular ultrasound (IVUS) or	
	optical coherence tomography	
	(OCT) when performed, imaging	
	supervision, interpretation, and	
	report, single major coronary	
	artery or branch (List separately	
	in addition to code for	
	percutaneous coronary stent or	
	atherectomy intervention)	
0915T	Insertion of permanent cardiac	Investigational
	contractility modulation-	
	defibrillation system	
	component(s), including	
	fluoroscopic guidance, and	
	evaluation and programming of	
	sensing and therapeutic	
	parameters; pulse generator and	
	dual transvenous electrodes/leads	
004/7	(pacing and defibrillation)	
0916T	Insertion of permanent cardiac	Investigational
	contractility modulation-	
	defibrillation system	
	component(s), including	
	fluoroscopic guidance, and	
	evaluation and programming of	
	sensing and therapeutic	
	parameters; pulse generator only	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0917T	Insertion of permanent cardiac	Investigational
	contractility modulation-	
	defibrillation system	
	component(s), including	
	fluoroscopic guidance, and	
	evaluation and programming of	
	sensing and therapeutic	
	parameters; single transvenous	
	lead (pacing or defibrillation) only	
0918T	Insertion of permanent cardiac	Investigational
	contractility modulation-	
	defibrillation system	
	component(s), including	
	fluoroscopic guidance, and	
	evaluation and programming of	
	sensing and therapeutic	
	parameters; dual transvenous	
	leads (pacing and defibrillation) only	
0919T	Removal of a permanent cardiac	Investigational
07171	contractility modulation-	Investigationat
	defibrillation system	
	component(s); pulse generator	
	only	
0920T	Removal of a permanent cardiac	Investigational
	contractility modulation-	
	defibrillation system	
	component(s); single transvenous	
	pacing lead only	
0921T	Removal of a permanent cardiac	Investigational
	contractility modulation-	
	defibrillation system	
	component(s); single transvenous	
	defibrillation lead only	
0922T	Removal of a permanent cardiac	Investigational
	contractility modulation-	
	defibrillation system	
	component(s); dual (pacing and	
	defibrillation) transvenous leads	
00007	only	
0923T	Removal and replacement of	Investigational
	permanent cardiac contractility	
	modulation-defibrillation pulse	
	generator only	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0924T	Repositioning of previously	Investigational
	implanted cardiac contractility	
	modulation-defibrillation	
	transvenous electrode(s)/lead(s),	
	including fluoroscopic guidance	
	and programming of sensing and	
00257	therapeutic parameters	lavatiantianal
0925T	Relocation of skin pocket for	Investigational
	implanted cardiac contractility	
	modulation-defibrillation pulse	
0926T	generator Programming device evaluation	Investigational
07201	Programming device evaluation (in person) with iterative	Investigationat
	adjustment of the implantable	
	device to test the function of the	
	device and select optimal	
	permanent programmed values	
	with analysis, including review	
	and report, implantable cardiac	
	contractility modulation-	
	defibrillation system	
0927T	Interrogation device evaluation	Investigational
	(in person) with analysis, review,	
	and report, including connection,	
	recording, and disconnection, per	
	patient encounter, implantable	
	cardiac contractility modulation-	
	defibrillation system	
0928T	Interrogation device evaluation	Investigational
	(remote), up to 90 days, cardiac	
	contractility modulation-	
	defibrillation system with interim	
	analysis and report(s) by a	
	physician or other qualified health	
0929T	care professional Interrogation device evaluation	Investigational
07271	(remote), up to 90 days, cardiac	investigationat
	contractility modulation-	
	defibrillation system, remote data	
	acquisition(s), receipt of	
	transmissions, technician review,	
	technical support, and	
	distribution of results	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0930T	Electrophysiologic evaluation of	Investigational
	cardiac contractility modulation-	
	defibrillator leads, including	
	defibrillation-threshold evaluation	
	(induction of arrhythmia,	
	evaluation of sensing and therapy	
	for arrhythmia termination), at	
	time of initial implantation or	
	replacement with testing of	
	cardiac contractility modulation-	
0024T	defibrillator pulse generator	
0931T	Electrophysiologic evaluation of	Investigational
	cardiac contractility modulation-	
	defibrillator leads, including	
	defibrillation-threshold evaluation	
	(induction of arrhythmia,	
	evaluation of sensing and therapy	
	for arrhythmia termination),	
	separate from initial implantation or replacement with testing of	
	cardiac contractility modulation-	
	defibrillator pulse generator	
0932T	Noninvasive detection of heart	Investigational
07521	failure derived from augmentative	investigationat
	analysis of an echocardiogram	
	that demonstrated preserved	
	ejection fraction, with	
	interpretation and report by a	
	physician or other qualified health	
	care professional	
0933T	Transcatheter implantation of	Investigational
	wireless left atrial pressure sensor	5
	for long-term left atrial pressure	
	monitoring, including sensor	
	calibration and deployment, right	
	heart catheterization, transseptal	
	puncture, imaging guidance, and	
	radiological supervision and	
	interpretation	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0934T	Remote monitoring of a wireless left atrial pressure sensor for up to 30 days, including data from daily uploads of left atrial pressure recordings, interpretation(s) and trend analysis, with adjustments to the diuretics plan, treatment paradigm thresholds, medications or lifestyle modifications, when performed, and report(s) by a physician or other qualified health care professional	Investigational
0935T	Cystourethroscopy with renal pelvic sympathetic denervation, radiofrequency ablation, retrograde ureteral approach, including insertion of guide wire, selective placement of ureteral sheath(s) and multiple conformable electrodes, contrast injection(s), and fluoroscopy, bilateral	Investigational
0936T	Photobiomodulation therapy of retina, single session	Investigational
0937T	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; including recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	Investigational
0938T	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; recording (including connection and initial recording)	Investigational
0939T	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; scanning analysis with report	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0940T	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional	Investigational
0941T	Cystourethroscopy, flexible; with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization	Investigational
0942T	Cystourethroscopy, flexible; with removal and replacement of prostatic urethral scaffold	Investigational
0943T	Cystourethroscopy, flexible; with removal of prostatic urethral scaffold	Investigational
0944T	3D contour simulation of target liver lesion(s) and margin(s) for image-guided percutaneous microwave ablation	Investigational
0945T	Intraoperative assessment for abnormal (tumor) tissue, in-vivo, following partial mastectomy (eg, lumpectomy) using computer- aided fluorescence imaging (List separately in addition to code for primary procedure)	Investigational
0946T	Orthopedic implant movement analysis using paired computed tomography (CT) examination of the target structure, including data acquisition, data preparation and transmission, interpretation and report (including CT scan of the joint or extremity performed with paired views)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0947T	Magnetic resonance image guided	Investigational
	low intensity focused ultrasound	
	(MRgFUS), stereotactic blood-	
	brain barrier disruption using	
	microbubble resonators to	
	increase the concentration of	
	blood-based biomarkers of target,	
	intracranial, including	
	stereotactic navigation and frame	
00.40 T	placement, when performed	
0948T	"Interrogation device evaluation	Investigational
	(remote), up to 90 days, cardiac	
	contractility modulation system	
	with interim analysis, review and	
	report(s) by a physician or	
	other qualified health care	
0949T	professional"	Investigational
09491	"Interrogation device evaluation	Investigational
	(remote), up to 90 days, cardiac	
	contractility modulation system,	
	remote data acquisition(s), receipt of transmissions,	
	technician	
	review, technical support, and	
	distribution of results"	
0950T	Ablation of benign prostate tissue,	Investigational
	transrectal, with high intensity-	
	focused ultrasound (HIFU),	
	including ultrasound guidance	
	► (For ablation of malignant	
	prostate tissue, transrectal, with	
	high intensity-focused ultrasound	
	[HIFU], including ultrasound	
	guidance, use 55880)	
0951T	Totally implantable active middle	Investigational
	ear hearing implant; initial	
	placement, including	
	mastoidectomy, placement of and	
	attachment to sound processor	
0952T	Totally implantable active middle	Investigational
	ear hearing implant; revision or	
	replacement, with mastoidectomy	
	and replacement of sound	
	processor	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0953T	Totally implantable active middle ear hearing implant; revision or replacement, without mastoidectomy and replacement of sound processor	Investigational
0954T	Totally implantable active middle ear hearing implant; replacement of sound processor only, with attachment to existing transducers	Investigational
0955T	Totally implantable active middle ear hearing implant; removal, including removal of sound processor and all implant components	Investigational
0956T	"Partial craniectomy, channel creation, and tunneling of electrode for sub-scalp implantation of an electrode array, receiver, and telemetry unit for continuous bilateral electroencephalography monitoring system, including imaging guidance"	Investigational
0957T	Revision of sub-scalp implanted electrode array, receiver, and telemetry unit for electrode, when required, including imaging guidance ► (Do not report 0957T in conjunction with 0958T, 0960T)	Investigational
0958T	Removal of sub-scalp implanted electrode array, receiver, and telemetry unit for continuous bilateral electroencephalography monitoring system, including imaging guidance ► (Do not report 0958T in conjunction with 0957T, 0960T)	Investigational
0959T	Removal or replacement of magnet from coil assembly that is connected to continuous bilateral electroencephalography monitoring system, including imaging guidance	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0960T	"Replacement of sub-scalp	Investigational
	implanted electrode array,	
	receiver, and telemetry unit with	
	tunneling of electrode for	
	continuous bilateral	
	electroencephalography	
	monitoring system, including	
	imaging guidance	
	(Do not report 0960T in	
	conjunction with 0957T, 0958T)"	
0961T	"Shortwave infrared radiation	Investigational
	imaging, surgical pathology	
	specimen, to assist gross	
	examination for lymph node	
	localization in fibroadipose tissue,	
	per specimen (List separately in	
	addition to code for primary	
	procedure)	
	► (Use 0961T in conjunction with	
	88307, 88309)	
	► (Do not report more than 1 unit	
00/07	of 0961T for each specimen)"	
0962T	Assistive algorithmic analysis of	Investigational
	acoustic and electrocardiogram	
	recording for detection of cardiac	
	dysfunction (eg, reduced ejection	
	fraction, cardiac murmurs, atrial	
	fibrillation), with review and	
	interpretation by a physician or	
	other qualified health care professional	
0963T	Anoscopy with directed	Investigational
07051	submucosal injection of bulking	Investigationat
	agent into anal canal	
	► (Do not report 0963T in	
	conjunction with 46600)	
0964T	Impression and custom	Investigational
	preparation of jaw expansion oral	intestigationat
	prosthesis for obstructive sleep	
	apnea, including initial	
	adjustment; single arch, without	
	mandibular advancement	
	mechanism	
	meenamism	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0965T	Impression and custom	Investigational
	preparation of jaw expansion oral	
	prosthesis for obstructive sleep	
	apnea, including initial	
	adjustment; dual arch, with	
	additional mandibular	
	advancement, non-fixed hinge mechanism	
0966T	Impression and custom	Investigational
07001	preparation of jaw expansion oral	Investigationat
	prosthesis for obstructive sleep	
	apnea, including initial	
	adjustment; dual arch, with	
	additional mandibular	
	advancement, fixed hinge	
	mechanism	
0967T	Transanal insertion of	Investigational
	endoluminal temporary colorectal	
	anastomosis protection device,	
	including vacuum anchoring	
	component and flexible sheath	
	connected to external vacuum	
	source and monitoring system	
0968T	"Insertion or replacement of	Investigational
	epicranial neurostimulator	
	system, including electrode array	
	and pulse generator, with	
	connection to electrode array ► (For insertion of cranial	
	neurostimulator pulse generator	
	or receiver other than	
	skull mounted, see 61885, 61886)	
	► (For revision of cranial	
	neurostimulator pulse generator	
	or receiver other than	
	skull mounted, use 61888)	
	(For insertion of skull-mounted)	
	cranial neurostimulator pulse	
	generator or	
	receiver, use 61889)"	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0969T	"Removal of epicranial	Investigational
	neurostimulator system	
	(For removal of cranial)	
	neurostimulator pulse generator	
	or receiver other than	
	skull mounted, use 61888)	
	(For removal of skull-mounted)	
	cranial neurostimulator pulse	
	generator or	
	receiver, use 61892)"	
0970T	"Ablation, benign breast tumor	Investigational
	(eg, fibroadenoma),	
	percutaneous, laser, including	
	imaging guidance when	
	performed, each tumor	
	(Do not report 0970T in	
	conjunction with 76641, 76642,	
	76940, 76942)	
	(Report 0970T only once per	
	tumor)	
	 (For cryosurgical ablation of 	
	fibroadenoma, use 19105)	
	 (For cryoablation of malignant 	
	breast tumor[s], use 0581T)	
	 (For laser ablation of malignant 	
	breast tumor[s], use 0971T)"	
0971T	"Ablation, malignant breast	Investigational
	tumor(s), percutaneous, laser,	
	including imaging guidance when	
	performed, unilateral	
	(Do not report 0971T in	
	conjunction with 76641, 76642,	
	76940, 76942)	
	(Report 0971T only once per	
	breast)	
	 (For cryoablation of breast 	
	fibroadenoma[s], use 19105)	
	 (For cryosurgical ablation of 	
	malignant breast tumor[s], use	
	0581T)	
	 (For laser ablation of benign 	
	breast tumor, use 0970T)"	

0972T "Assistive algorithmic classification of burn healing (ie, healing or nonhealing) by noninvasive multispectral imaging, including system set-up and acquisition, selection, and transmission of images, with automated generation of report" Investigational 0973T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure)	CPT [®] /HCPCS Code		Instructions
 healing or nonhealing) by noninvasive multispectral imaging, including system set-up and acquisition, selection, and transmission of images, with automated generation of report" 0973T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm" 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the 	0972T		Investigational
noninvasive multispectral imaging, including system set-up and acquisition, selection, and transmission of images, with automated generation of report"0973T"Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm"Investigational0974T"Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm"Investigational0974T"Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) b (Use 0974T in conjunction with 0973T) b (Do not report 0973T, 0974T in conjunction with 1042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the		5 ()	
imaging, including system set-up and acquisition, selection, and transmission of images, with automated generation of report" Investigational 0973T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ▶ (Use 0974T in conjunction with 0973T) Investigational 0974T "Selective orgymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including Investigational 0973T "Selective orgymatic debridement of the Investigational			
and acquisition, selection, and transmission of images, with automated generation of report"Investigational0973T"Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm"Investigational0974T"Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) 		•	
selection, and transmission of images, with automated generation of report" Investigational 0973T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) Investigational • (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the Investigational			
images, with automated generation of report" 0973T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) Investigational (Use 0974T) • (Do not report 0973T, 0974T in conjunction with 0973T) ● (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the			
generation of report" 0973T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ▶ (Use 0974T in conjunction with 0973T) Investigational 0 (bo not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the Investigational			
0973T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ►(Use 0974T in conjunction with 0973T) ►(Use 0974T in conjunction with 0973T) ►(Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the		•	
debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ▶ (Use 0974T in conjunction with 0973T) Investigational (Use 0974T in conjunction with 0973T) (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the	0072T		Investigational
and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ▶ (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the	09/31	-	Investigationat
requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the Each additional 100 sq cm		· · · · · · · · · · · · · · · · · · ·	
anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm" Investigational 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the			
including patient monitoring, trunk, arms, legs; first 100 sq cm" 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ▶ (Use 0974T in conjunction with 0973T) ▶ (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the			
patient monitoring, trunk, arms, legs; first 100 sq cm"Investigational0974T"Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) 			
legs; first 100 sq cm"0974T"Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the			
 0974T "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ▶ (Use 0974T in conjunction with 0973T) ▶ (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the 			
debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the	0974T		Investigational
requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the		-	-
<pre>anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the</pre>		and/or full-thickness burn eschar,	
<pre>including patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the</pre>		requiring anesthesia (ie, general	
<pre>patient monitoring, trunk, arms, legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the</pre>			
 legs; each additional 100 sq cm (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the 		5	
 (List separately in addition to code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the 		•	
 code for primary procedure) ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the 			
 ► (Use 0974T in conjunction with 0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the 			
0973T) ► (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the		,	
 ▶ (Do not report 0973T, 0974T in conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the 			
conjunction with 11042, 11043, 11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the			
11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic debridement of the			
97597, 97598, for selective enzymatic debridement of the		· · · ·	
enzymatic debridement of the			
		same wound during the same	
session)		-	
► (For nonselective enzymatic			
debridement, use 97602)"			

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0975T	"Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, scalp, neck, hands, feet, and/or multiple digits; first 100 sq cm" "Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation),	Investigational
	<pre>including patient monitoring, scalp, neck, hands, feet, and/or multiple digits; each additional 100 sq cm (List separately in addition to code for primary procedure)</pre>	
0977T	"Upper gastrointestinal blood detection, sensor capsule, with interpretation and report"	Investigational
0978T	Submucosal cryolysis therapy; soft palate, base of tongue, and lingual tonsil	Investigational
0979T	Submucosal cryolysis therapy; soft palate only	Investigational
0980T	Submucosal cryolysis therapy; base of tongue, and lingual tonsil only ► (Do not report 0979T, 0980T in conjunction with 0978T)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0981T	"Transcatheter implantation of	Investigational
	wireless inferior vena cava sensor	
	for long-term hemodynamic	
	monitoring, including deployment	
	of the sensor, radiological	
	supervision and interpretation,	
	right heart catheterization, and inferior vena cava venography,	
	when performed	
	► (Do not report 0981T in	
	conjunction with 36010, 36013,	
	37252, 37253, 75825, 76000,	
	93451, 93453, 93456, 93460,	
	93461, 93566, 93593, 93594,	
	93596, 93597)	
	 (For implantation of wireless) 	
	pulmonary artery sensor, use	
	33289)	
	(For remote monitoring of an	
	implantable inferior vena cava	
	pressure sensor,	
0982T	use 0982T)"	Investigational
07021	"Remote monitoring of implantable inferior vena cava	Investigationat
	pressure sensor, physiologic	
	parameter(s) (eg, weight, blood	
	pressure, pulse oximetry,	
	respiratory flow rate),	
	initial set-up and patient	
	education on use of equipment	
	(Do not report 0982T more than	
	once per episode of care)	
	► (Do not report 0982T for	
00027	monitoring of less than 16 days)"	Investigational
0983T	"Remote monitoring of an implanted inferior vena cava	Investigational
	sensor for up to 30 days, including	
	at least weekly downloads of	
	inferior vena cava area	
	recordings,	
	interpretation(s), trend analysis,	
	and report(s) by a physician or	
	other qualified health care	
	professional ► (Report 0983T only	
	once per 30 days)"	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
0984T	"Intravascular imaging of extracranial cerebral vessels using optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention, including all associated radiological supervision, interpretation, and report; initial vessel (List separately in addition to code for primary procedure) ► (Use 0984T in conjunction with 36221, 36222, 36225, 36226, 37215, 37216) ► (Report 0984T once per session)"	Investigational
0985T	"Intravascular imaging of extracranial cerebral vessels using optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention, including all associated radiological supervision, interpretation, and report; each additional vessel (List separately in addition to code for primary procedure) ► (Use 0985T in conjunction with 0984T)"	Investigational
0986T	"Intravascular imaging of intracranial cerebral vessels using optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention, including all associated radiological supervision, interpretation, and report; initial vessel (List separately in addition to code for primary procedure) ► (Use 0986T in conjunction with 36223, 36224, 36225, 36226, 61624, 61630, 61635, 61640, 61645, 61650) ► (Report 0986T once per session)"	Investigational

CPT®/HCPCS Code		Instructions
0987T	"Intravascular imaging of	Investigational
	intracranial cerebral vessels using	
	optical coherence tomography	
	(OCT) during diagnostic evaluation	
	and/or therapeutic intervention,	
	including all associated	
	radiological supervision,	
	interpretation, and report; each	
	additional vessel (List separately	
	in addition to code for primary	
	procedure ► (Use 0987T in	
	conjunction with 0986T)"	
15011	Harvest of skin for autograft; first	Investigational
15012	Harvest of skin for autograft; each	Investigational
	additional 25 sq cm	
15013	Preparation of skin autograft,	Investigational
	requiring enzymatic processing,;	
	first 25 sq cm or less	
15014	Preparation of skin autograft,	Investigational
	requiring enzymatic processing,;	
	each additional 25 sq cm	
15015	Application of skin autograft; first	Investigational
	480 sq cm or less	
15016	Application of skin autograft;	Investigational
	each additional 480 sq cm	
15017	Application of skin autograft; first	Investigational
(== / =	480 sq cm or less	
15018	Application of skin autograft;	Investigational
	each additional 480 sq cm	
20560	Needle insertion(s) without	Investigational
	injection(s); 1 or 2 muscle(s)	
20561	Needle insertion(s) without	Investigational
	injection(s); 3 or more muscles	
22526	Percutaneous intradiscal	Investigational
	electrothermal annuloplasty,	
	unilateral or bilateral including	
	fluoroscopic guidance; single level	
22527	Percutaneous intradiscal	Investigational
	electrothermal annuloplasty,	
	unilateral or bilateral including	
	fluoroscopic guidance; 1 or more	
	additional levels (List separately in	
	addition to code for primary	
22824	procedure)	Investigational
22836	Vertebral body tethering; up to 7	Investigational
	vertebral segments	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
22837	Vertebral body tethering; 8 or more	Investigational
	vertebral segments	
22838	Revision, replacement, or removal	Investigational
	of vertebral body	
22857	tethering	Investigational
22037	Total disc arthroplasty (artificial disc), anterior approach, including	Investigational
	discectomy to prepare interspace	
	(other than for decompression),	
	single interspace, lumbar	
22860	Total disc arthroplasty, anterior	Investigational
	approach, including discectomy;	_
	second lumbar interspace	
22862	Revision including replacement of	Investigational
	total disc arthroplasty (artificial	
	disc), anterior approach, single	
22867	interspace; lumbar Insertion of interlaminar/interspinous	Investigational
22007	process stabilization/distraction	Investigationat
	device, without fusion, including	
	image guidance when performed,	
	with open decompression, lumbar;	
	single level	
22868	Insertion of	Investigational
	interlaminar/interspinous process	
	stabilization/distraction device,	
	without fusion, including image guidance when performed, with	
	open decompression, lumbar;	
	second level (List separately in	
	addition to code for primary	
	procedure)	
22869	Insertion of	Investigational
	interlaminar/interspinous process	
	stabilization/distraction device,	
	without open decompression or	
	fusion, including image guidance when performed, lumbar; single	
	level	
22870	Insertion of interlaminar/interspinous	Investigational
	process stabilization/distraction	-
	device, without open decompression	
	or fusion, including image guidance	
	when performed, lumbar; second	
	level (List separately in addition to	
	code for primary procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
27278	Arthrodesis, sacroiliac joint,	Investigational
	percutaneous, with image guidance,	
	including placement of intra-articular	
	implant(s) (eg, bone allograft[s],	
	synthetic device[s]), without	
28890	placement of transfixation device	Investigational
20090	Extracorporeal shock wave, high energy, performed by a physician or	Investigational
	other qualified health care	
	professional, requiring anesthesia	
	other than local, including ultrasound	
	guidance, involving the plantar fascia	
30468	Repair of nasal valve collapse	Investigational
	with subcutaneous/submucosal	-
	lateral wall implant(s)	
30469	Nasal valve collapse repair using	Investigational
	low energy, temperature-	
	controlled remodeling	
31242	Surgical nasal/sinus endoscopy;	Investigational
	radiofrequency ablation, posterior	
	nasal nerve	
31243	Surgical nasal/sinus endoscopy;	Investigational
	cryoablation, posterior nasal	
31647	nerve	la continentie e e l
31647	Bronchoscopy, rigid or flexible,	Investigational
	including fluoroscopic guidance, when performed; with balloon	
	occlusion, when performed,	
	assessment of air leak, airway sizing,	
	and insertion of bronchial valve(s),	
	initial lobe	
31648	Bronchoscopy, rigid or flexible,	Investigational
	including fluoroscopic guidance,	_
	when performed; with removal of	
	bronchial valve(s), initial lobe	
31649	Bronchoscopy, rigid or flexible,	Investigational
	including fluoroscopic guidance,	
	when performed; with removal of	
	bronchial valve(s), each additional	
	lobe (List separately in addition to	
	code for primary procedure)	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
31651	Bronchoscopy, rigid or flexible,	Investigational
	including fluoroscopic guidance,	
	when performed; with balloon	
	occlusion, when performed,	
	assessment of air leak, airway sizing,	
	and insertion of bronchial valve(s),	
	each additional lobe (List separately	
	in addition to code for primary	
31660	procedure[s])	Investigational
31000	Bronchoscopy, rigid or flexible, including fluoroscopic guidance,	Investigational
	when performed; with bronchial	
	thermoplasty, 1 lobe	
31661	Bronchoscopy, rigid or flexible,	Investigational
51001	including fluoroscopic guidance,	Investigationat
	when performed; with bronchial	
	thermoplasty, 2 or more lobes	
33275	Transcatheter removal of permanent	Investigational
	leadless pacemaker, right	
	ventricular, including imaging	
	guidance (eg, fluoroscopy, venous	
	ultrasound, ventriculography,	
	femoral venography), when	
	performed	
33276	Phrenic nerve stimulator system	Investigational
	placement, initial analysis with	
	diagnostic mode activation, when	
	performed	
33277	Phrenic nerve stimulator transvenous	Investigational
	lead placement (List separately in	
	addition to code for primary	
22270	procedure)	Investigational
33278	Phrenic nerve stimulator removal	Investigational
33279	Phrenic nerve stimulator removal;	Investigational
55277	transvenous stimulation or sensing	investigationat
	lead(s) only	
33280	Phrenic nerve stimulator removal;	Investigational
	pulse generator only	
33281	Phrenic nerve stimulator transvenous	Investigational
	lead repositioning	-
33287	Phrenic nerve stimulator, removal	Investigational
	and replacement; pulse generator	
33288	Phrenic nerve stimulator removal and	Investigational
	replacement; transvenous stimulation	
	or sensing lead	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
33289	Transcatheter implantation of	Investigational
	wireless pulmonary artery pressure	
	sensor for long-term hemodynamic	
	monitoring, including deployment	
	and calibration of the sensor, right	
	heart catheterization, selective	
	pulmonary catheterization,	
	radiological supervision and interpretation, and pulmonary artery	
	angiography, when performed	
33370	Transcatheter placement and	Investigational
	subsequent removal of cerebral	in congacionat
	embolic protection device(s),	
	including arterial access,	
	catheterization, imaging, and	
	radiological supervision and	
	interpretation, percutaneous (List	
	separately in addition to code for	
	primary procedure)	
33548	Surgical ventricular restoration	Investigational
	procedure, includes prosthetic	
	patch, when performed (eg,	
	ventricular remodeling, SVR, SAVER,	
24472	Dor procedures)	
36473	Endovenous ablation therapy of	Investigational
	incompetent vein, extremity, inclusive of all imaging guidance	
	and monitoring, percutaneous,	
	mechanochemical; first vein treated	
36474	Subsequent vein(s) treated in a	Investigational
	single extremity, each through	
	separate access sites (List	
	separately in addition to code for	
	primary procedure)	
36836	Upper extremity, single access	Investigational
	percutaneous arteriovenous	
	fistula creation	
36837	Upper extremity, separate access	Investigational
	percutaneous arteriovenous	
41512	fistula creation	Investigational
41312	Tongue base suspension,	Investigational
43206	permanent suture technique	Investigational
75200	Esophagoscopy, flexible, transoral; with optical	Investigational
	endomicroscopy	
	епцоппстозсору	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
43252	Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy	Investigational
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed	Investigational
43285	Removal of esophageal sphincter augmentation device	Investigational
43290	Esophagogastroduodenoscopy, with deployment of balloon	Investigational
43291	Esophagogastroduodenoscopy, with removal of balloon	Investigational
43497	Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])	Investigational
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum	Investigational
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum	Investigational
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open	Investigational
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open	Investigational
46707	Repair of anorectal fistula with plug (eg, porcine small intestine submucosa [SIS])	Investigational
47371	Laparoscopy, surgical, ablation of 1 or more liver tumor(s); cryosurgical	Investigational
47381	Ablation, open, of 1 or more liver tumor(s); cryosurgical	Investigational
47383	Ablation, 1 or more liver tumor(s), percutaneous, cryoablation	Investigational
51721	Transurethral ablation transducer insertion for delivery of thermal ultrasound for prostate	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
52284	Cystourethroscopy, with urethral mechanical dilation and drug delivery by drug-coated balloon catheter	Investigational
53451	Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance	Investigational
53452	Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance	Investigational
53453	Periurethral transperineal adjustable balloon continence device; removal, each balloon	Investigational
53454	Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume	Investigational
53865	Insertion of temporary device with cystourethroscopy for ischemic remodeling of bladder neck and prostate	Investigational
53866	Catheterization with removal of temporary device for ischemic remodeling of bladder neck and prostate	Investigational
55706	Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance	Investigational
55880	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance	Investigational
55881	Transurethral ablation of prostate tissue, using thermal ultrasound	Investigational
55882	Transurethral ablation of prostate tissue, using thermal ultrasound; with insertion of ultrasound transducer	Investigational
60660	Percutaneous ablation of 1 or more thyroid nodule(s)	Investigational
60661	Percutaneous ablation of additional lobe of thyroid nodule(s)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
61715	MRI guided focused ultrasound high intensity stereotactic intracranial ablation	Investigational
61736	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion	Investigational
61737	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or complex lesion(s)	Investigational
62263	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days	Investigational
62264	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day	Investigational
62287	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
62380	Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar	Investigational
64454	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed	Investigational
64505	Injection, anesthetic agent; sphenopalatine ganglion	Investigational
64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)	Investigational
64624	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed	Investigational
64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)	Investigational
64628	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral	Investigational
64629	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)	Investigational
66683	Iris prosthesis Implantation	Investigational
76120	Cineradiography/videoradiography, except where specifically included	Investigational
76125	Cineradiography/videoradiography to complement routine examination (List separately in addition to code for primary procedure)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
77085	Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture assessment	Investigational
77086	Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA)	Investigational
77089	Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual X- ray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-risk	Investigational
77090	Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical preparation and transmission of data for analysis to be performed elsewhere	Investigational
77091	Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical calculation only	Investigational
77092	Trabecular bone score (TBS), structural condition of the bone microarchitecture; interpretation and report on fracture-risk only by other qualified health care professional	Investigational
78835	Radiopharmaceutical quantification measurement(s) single area (List separately in addition to code for primary procedure)	Investigational
81195	Cytogenomic analysis, optical genome mapping	Investigational
81277	Cytogenomic neoplasia (genome- wide) microarray analysis, interrogation of genomic regions for copy number and loss-of- heterozygosity variants for chromosomal abnormalities	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
81418	Drug metabolism genomic sequence panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplications and deletions	Investigational
81449	Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes RNA analysis	Investigational
81451	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	Investigational
81456	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	Investigational
81515	Infectious disease, bacterial vaginosis and vaginitis, realtime PCR amplification	Investigational
81539	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score	Investigational
81558	Transplantation medicine (allograft rejection, kidney), mRNA, gene expression profiling	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
81560	Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third party-induced CD154+T- cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score	Investigational
82107	Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio)	Investigational
82172	Apolipoprotein, each	Investigational
82233	Beta-amyloid; 1-40	Investigational
82234	Beta-amyloid; 1-42	Investigational
82523	Collagen cross links, any method	Investigational
82610	Cystatin C	Investigational
82664	Electrophoretic technique, not elsewhere specified	Investigational
83006	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)	Investigational
83695	Lipoprotein (a)	Investigational
83722	Lipoprotein, direct measurement; small dense LDL cholesterol	Investigational
83884	Neurofilament light chain (NfL)	Investigational
84393	Tau, phosphorylated	Investigational
84394	Tau, total	Investigational
83937	Osteocalcin (bone g1a protein)	Investigational
83987	pH; exhaled breath condensate	Investigational
84080	Phosphatase, alkaline; isoenzymes	Investigational
86305	Human epididymis protein 4 (HE4)	Investigational
88375	Optical endomicroscopic image(s), interpretation and report, real- time or referred, each endoscopic session	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
90382	Respiratory syncytial virus,	Investigational
	monoclonal antibody, seasonal dose,	
90584	0.7 mL, for intramuscular use	lavatinational
90584	Dengue vaccine, quadrivalent, live,	Investigational
	2 dose schedule, for subcutaneous use	
90612	Influenza virus vaccine, trivalent,	Investigational
,0012	and severe acute respiratory	investigationat
	syndrome coronavirus 2 (SARS-	
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	31.7 mcg/0.32 mL dosage, for	
	intramuscular use	
90613	Influenza virus vaccine,	Investigational
	quadrivalent, and severe acute	
	respiratory syndrome coronavirus	
	2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine,	
	mRNA-LNP, 40 mcg/0.4 mL	
	dosage, for intramuscular use	
90624	Meningococcal pentavalent	Investigational
	vaccine, Men B-4C recombinant	
	proteins and outer membrane	
	vesicle and conjugated Men A, C,	
	W, Y-diphtheria toxoid carrier, for	
	intramuscular use	
90631	Influenza virus vaccine (IIV), H5,	Investigational
	pandemic formulation, split virus,	
91111	adjuvanted, for intramuscular use	Investigational
71111	Gastrointestinal tract imaging, intraluminal (eg, capsule	Investigational
	endoscopy), esophagus with	
	interpretation and report	
91300	Severe acute respiratory	Investigational COVID-19
	syndrome coronavirus 2 (SARS-	Effective:(04/18/2023)
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	spike protein, preservative free,	
	30 mcg/0.3mL dosage, diluent	
	reconstituted, for intramuscular	
	use	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
91301	Severe acute respiratory	Investigational COVID-19
	syndrome coronavirus 2 (SARS-	Effective:(04/18/2023)
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	spike protein, preservative free,	
	100 mcg/0.5mL dosage, for	
0.4.9.0.9	intramuscular use	
91303	Severe acute respiratory	Investigational COVID-19
	syndrome coronavirus 2 (SARS-	Effective:(05/07/2023)
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, DNA, spike	
	protein, adenovirus type 26	
	(Ad26) vector, preservative free, 5x1010 viral particles/0.5mL	
	dosage, for intramuscular use	
91305	Severe acute respiratory	Investigational COVID-19
71000	syndrome coronavirus 2 (SARS-	Effective:(04/18/2023)
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	spike protein, preservative free,	
	30 mcg/0.3 mL dosage, tris-	
	sucrose formulation, for	
	intramuscular use	
91306	Severe acute respiratory	Investigational COVID-19
	syndrome coronavirus 2 (SARS-	Effective:(04/18/2023)
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	spike protein, preservative free,	
	50 mcg/0.25 mL dosage, for	
	intramuscular use	
91307	Severe acute respiratory	Investigational COVID-19
	syndrome coronavirus 2 (SARS-	Effective:(04/18/2023)
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	spike protein, preservative free,	
	10 mcg/0.2 mL dosage, diluent	
	reconstituted, tris-sucrose	
91308	formulation, for intramuscular use Severe acute respiratory	Investigational COVID-19
71500	syndrome coronavirus 2 (SARS-	Effective:(04/18/2023)
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	spike protein, preservative free, 3	
	mcg/0.2 mL dosage, diluent	
	reconstituted, tris-sucrose	
	formulation, for intramuscular use	

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
91309	Severe acute respiratory	Investigational COVID-19
	syndrome coronavirus 2 (SARS-	Effective:(04/18/2023)
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	spike protein, preservative free,	
	50 mcg/0.5 mL dosage, for	
	intramuscular use	
91311	Severe acute respiratory	Investigational COVID-19
	syndrome coronavirus 2 (SARS-	Effective:(04/18/2023)
	CoV-2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	spike protein, preservative free,	
	25 mcg/0.25 mL dosage, for	
	intramuscular use	
91323	Severe acute respiratory	Investigational
	syndrome coronavirus 2 (SARS-	
	CoV2) (coronavirus disease	
	[COVID-19]) vaccine, mRNA-LNP,	
	10 mcg/0.2 mL dosage, for	
02445	intramuscular use	lave stige tions l
92145	Corneal hysteresis determination,	Investigational
	by air impulse stimulation,	
	unilateral or bilateral, with	
92548	interpretation and report	Investigational
92348	Computerized dynamic	Investigational
	posturography sensory	
	organization test (CDP-SOT), 6	
	conditions (ie, eyes open, eyes closed, visual sway, platform	
	sway, eyes closed platform sway,	
	platform and visual sway),	
	including interpretation and	
	report;	
92549	Computerized dynamic	Investigational
72317	posturography sensory	investigationat
	organization test (CDP-SOT), 6	
	conditions (ie, eyes open, eyes	
	closed, visual sway, platform	
	sway, eyes closed platform sway,	
	platform and visual sway),	
	including interpretation and	
	report; with motor control test	
	(MCT) and adaptation test (ADT)	
92572	Staggered spondaic word test	Investigational
92576	Synthetic sentence identification	Investigational
	test	

CPT®/HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
92972	Coronary transluminal lithotripsy	Investigational
93050	Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive	Investigational
93150	Therapy activation of phrenic nerve stimulator system	Investigational
93151	Interrogation and programming of phrenic nerve stimulator system	Investigational
93152	Interrogation and programming of phrenic nerve stimulator system done at the same time as a polysomnography	Investigational
93153	Interrogation without programming of phrenic nerve stimulator system	Investigational
93264	Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional	Investigational
93356	Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)	Investigational
93701	Bioimpedance-derived physiologic cardiovascular analysis	Investigational
95012	Nitric oxide expired gas determination	Investigational
95803	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
95905	Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when	Investigational
	performed, with interpretation and report	
95957	Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis)	Investigational
96000	Comprehensive computer-based motion analysis by videotaping and 3D kinematics;	Investigational
96001	Comprehensive computer-based motion analysis by videotaping and 3D kinematics; with dynamic plantar pressure measurements during walking	Investigational
96002	Dynamic surface electromyography, during walking or other functional activities, 1-12 muscles	Investigational
96004	Review and interpretation by physician or other qualified health care professional of comprehensive computer-based motion analysis, dynamic plantar pressure measurements, dynamic surface electromyography during walking or other functional activities, and dynamic fine wire electromyography, with written report	Investigational
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes	Investigational
97533	Sensory integrative techniques to enhance sensory processing and promote adaptive responses to environmental demands, direct (one-on-one) patient contact, each 15 minutes	Investigational
97610	Low frequency, non-contact, non- thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day	Investigational

CPT [®] /HCPCS Code	CPT [®] /HCPCS Code Description	Instructions
97799	Unlisted physical medicine/rehabilitation service or procedure	Investigational
98978	Remote therapeutic monitoring; device supply, recording, transmission to monitor cognitive behavioral therapy, each 30 days	Investigational